2,5-Dioxopiperazine lipids with inserted ester, thioester, disulfide and anhydride moieties
The lipid-based nanoparticles prepared by the novel cyclic amino acid lipid compound solve the problems of low nucleic acid delivery efficiency and great toxicity in the prior art, and achieve efficient and low toxicity nucleic acid delivery effects.
Patent Information
- Application Number
- CN201980088233.2
- Authority / Receiving Office
- CN · China
- Patent Type
- Patents(China)
- Current Assignee / Owner
- Priority Date
- 2019-07-08
- Filing Date
- 2019-11-07
- Publication Date
- 2024-11-08
- Estimated Expiration
- 2039-11-07
AI Technical Summary
The prior art is difficult to effectively deliver macromolecular nucleic acids such as mRNA to various cell types and tissues, and there are toxicity problems.
A novel biodegradable cyclic amino acid lipid compound has been developed as cationic lipids for the preparation of lipid-based nanoparticles that combine non-cationic lipids and PEG-modified lipids to form nucleic acids for encapsulation and delivery of nucleic acids liposomes.
It improves the transfection efficiency and intracellular release ability of nucleic acids, has excellent pharmacokinetic characteristics and biodistribution efficiency that reduces toxicity.
Smart Images

Figure CN113272282B_ABST
Abstract
Description
[0001] CROSS-REFERENCE TO RELATED APPLICATIONS
[0002] This application claims the benefit of U.S. Provisional Application No. 62 / 758,179, filed November 9, 2018, and U.S. Provisional Application No. 62 / 871,510, filed July 8, 2019, each of which is incorporated herein by reference in its entirety. Background Art
[0003] The delivery of nucleic acids has been widely explored as a potential treatment option for certain disease states. In particular, messenger RNA (mRNA) therapy has become an increasingly important option for treating a variety of diseases, including those associated with the deficiency of one or more proteins. Summary of the Invention
[0004] The present invention particularly provides a novel class of cyclic amino acid lipid compounds for improving the in vivo delivery of therapeutic agents such as nucleic acids. In particular, the compounds provided by the present invention are biodegradable in nature and are particularly suitable for delivering mRNA and other nucleic acids for therapeutic use. It is expected that the compounds provided herein can be highly effectively delivered in vivo while maintaining favorable toxicity characteristics due to their biodegradable properties.
[0005] In one aspect, the invention features a cationic lipid having a structure according to (A'),
[0006]
[0007] or a pharmaceutically acceptable salt thereof, wherein
[0008] Each R 1 and R 2 are independently H or a C1-C6 aliphatic group;
[0009] Each M is independently an integer having a value from 1 to 4;
[0010] Each A is independently a covalent bond or an arylene group;
[0011] Each L 1 are independently ester, thioester, disulfide or anhydride groups;
[0012] Each L 2 Independently C2-C 10 aliphatic groups;
[0013] Each B site is -CHX 1 - or -CH2CO2-;
[0014] Each X 1 are independently H or OH; and
[0015] Each R 3 Independently C6-C 30 Aliphatic group.
[0016] In some embodiments of Formula (A'), each R 3 Independently C6-C 20 Aliphatic group.
[0017] In embodiments, provided herein are cationic lipids having a structure according to Formula (A),
[0018]
[0019] or a pharmaceutically acceptable salt thereof, wherein
[0020] Each R 1 and R 2 are independently H or a C1-C6 aliphatic group;
[0021] Each m is independently an integer having a value from 1 to 4;
[0022] Each A is independently a covalent bond or an arylene group;
[0023] Each L 1 are independently ester, thioester, disulfide or anhydride groups;
[0024] Each L 2 Independently C2-C 10 aliphatic groups;
[0025] Each X 1 are independently H or OH; and
[0026] Each R 3 Independently C6-C 30 Aliphatic group.
[0027] In some embodiments of Formula (A), each R 3 Independently c6-c 30 In some embodiments of Formula (A), each R 3 Independently c6-c 20 Aliphatic group.
[0028] In an embodiment, the cationic lipid has a structure according to Formula (A), wherein each A is independently a covalent bond or a phenylene group.
[0029] In embodiments, the cationic lipid has a structure according to formula (I),
[0030]
[0031] or a pharmaceutically acceptable salt thereof.
[0032] In some embodiments of Formula (I), each R 3 Independently C6-C 30 In some embodiments of Formula (I), each R 3 Independently C6-C 20 Aliphatic group.
[0033] In embodiments, the cationic lipid has a structure according to Formula (A'), (A), or (I), wherein each R 1 For H.
[0034] In embodiments, the cationic lipid has a structure according to Formula (A'), (A), or (I), wherein each R 2 are independently H or C1-C6 alkyl.
[0035] In embodiments, the cationic lipid has a structure according to Formula (A'), (A), or (I), wherein each L 2 Independently C2-C 10 Alkylene.
[0036] In embodiments, the cationic lipid has a structure according to Formula (A'), (A), or (I), wherein each R 3 Independently C6-C 20 Alkyl, C6-C 20 Alkenyl or C6-C 20 Alkynyl.
[0037] In embodiments, the cationic lipid has a structure according to Formula (A'), (A), or (I), wherein each X 1 For OH.
[0038] In embodiments, the cationic lipid has a structure according to Formula (A'), (A), or (I), wherein each m is 1.
[0039] In an embodiment, the cationic lipid has a structure according to Formula (A'), (A), or (I), wherein each m is 2.
[0040] In an embodiment, the cationic lipid has a structure according to Formula (A'), (A), or (I), wherein each m is 3.
[0041] In an embodiment, the cationic lipid has a structure according to Formula (A'), (A), or (I), wherein each m is 4.
[0042] In embodiments, the cationic lipid has a structure according to Formula (Ia),
[0043]
[0044] or a pharmaceutically acceptable salt thereof, wherein each n is independently an integer having a value from 1 to 9.
[0045] In some embodiments of Formula (Ia), each R 3 Independently C6-C 30 In some embodiments of Formula (Ia), each R 3 Independently C6-C 20 Aliphatic group.
[0046] In embodiments, the cationic lipid has a structure according to Formula (I-a'),
[0047]
[0048] or a pharmaceutically acceptable salt thereof.
[0049] In some embodiments of Formula (I-a'), each R 3 Independently C6-C 30 In some embodiments of Formula (I-a'), each R 3 Independently C6-C 20 Aliphatic group.
[0050] In embodiments, the cationic lipid has a structure according to Formula (Ia) or (I-a'), wherein each n is 1. In embodiments, the cationic lipid has a structure according to Formula (Ia) or (I-a'), wherein each n is 2. In embodiments, the cationic lipid has a structure according to Formula (Ia) or (I-a'), wherein each n is 3.
[0051] In embodiments, the cationic lipid has a structure according to Formula (Ib),
[0052]
[0053] or a pharmaceutically acceptable salt thereof, wherein each n is an integer having a value from 1 to 9.
[0054] In some embodiments of Formula (Ib), each R 3 Independently C6-C 30 In some embodiments of Formula (Ib), each R 3 Independently C6-C 20 Aliphatic group.
[0055] In embodiments, the cationic lipid has a structure according to formula (I-b'),
[0056]
[0057] or a pharmaceutically acceptable salt thereof.
[0058] In some embodiments of Formula (I-b'), each R 3 Independently C6-C 30 In some embodiments of Formula (I-b'), each R 3 Independently C6-C 20 Aliphatic group.
[0059] In embodiments, the cationic lipid has a structure according to Formula (Ib) or (I-b'), wherein each n is 1. In embodiments, the cationic lipid has a structure according to Formula (Ib) or (I-b'), wherein each n is 2. In embodiments, the cationic lipid has a structure according to Formula (Ib) or (I-b'), wherein each n is 3.
[0060] In embodiments, the cationic lipid has a structure according to Formula (Ic),
[0061]
[0062] or a pharmaceutically acceptable salt thereof, wherein each
[0063] n is an integer having a value from 1 to 9; and
[0064] Each R 2 are independently H or CH3.
[0065] In some embodiments of Formula (Ic), each R 3 Independently C6-C 30 In some embodiments of Formula (Ic), each R 3 Independently C6-C 20 Aliphatic group.
[0066] In embodiments, the cationic lipid has a structure according to formula (I-c'),
[0067]
[0068] or a pharmaceutically acceptable salt thereof.
[0069] In some embodiments of Formula (I-c'), each R 3 Independently C6-C 30 In some embodiments of Formula (I-c'), each R 3 Independently C6-C 20 Aliphatic group.
[0070] In embodiments, the cationic lipid has a structure according to formula (Ic) or (I-c'), wherein each n is 1. In embodiments, the cationic lipid has a structure according to formula (Ic) or (I-c'), wherein each n is 2. In embodiments, the cationic lipid has a structure according to formula (Ic) or (I-c'), wherein each n is 3.
[0071] In an embodiment, the cationic lipid has a structure according to Formula (Ic) or (I-c'), wherein each R 2 For H.
[0072] In embodiments, the cationic lipid has a structure according to formula (Ic-1),
[0073]
[0074] or a pharmaceutically acceptable salt thereof.
[0075] In some embodiments of Formula (Ic-1), each R 3 Independently C6-C 30 In some embodiments of Formula (Ic-1), each R 3 Independently C6-C 20 Aliphatic group.
[0076] In embodiments, the cationic lipid has a structure according to formula (I-c'-1),
[0077]
[0078] or a pharmaceutically acceptable salt thereof.
[0079] In some embodiments of Formula (I-c'-1), each R 3 Independently C6-C 30 In some embodiments of Formula (I-c'-1), each R 3 Independently C6-C 20 Aliphatic group.
[0080] In embodiments, the cationic lipid has a structure according to formula (Ic-1) or (I-c'-1), wherein each n is 1. In embodiments, the cationic lipid has a structure according to formula (Ic-1) or (I-c'-1), wherein each n is 2. In embodiments, the cationic lipid has a structure according to formula (Ic-1) or (I-c'-1), wherein each n is 3.
[0081] In an embodiment, the cationic lipid has a structure according to Formula (Ic) or (I-c'), wherein each R 2 For CH3.
[0082] In embodiments, the cationic lipid has a structure according to formula (Ic-2),
[0083]
[0084] or a pharmaceutically acceptable salt thereof.
[0085] In some embodiments of Formula (Ic-2), each R 3 Independently C6-C 30 In some embodiments of Formula (Ic-2), each R 3 Independently C6-C 20 Aliphatic group.
[0086] In embodiments, the cationic lipid has a structure according to formula (I-c'-2),
[0087]
[0088] or a pharmaceutically acceptable salt thereof.
[0089] In some embodiments of Formula (I-c'-2), each R 3 Independently C6-C 30 In some embodiments of Formula (I-c'-2), each R 3 Independently C6-C 20 Aliphatic group.
[0090] In embodiments, the cationic lipid has a structure according to formula (Ic-2) or (I-c'-2), wherein each n is 1. In embodiments, the cationic lipid has a structure according to formula (Ic-2) or (I-c'-2), wherein each n is 2. In embodiments, the cationic lipid has a structure according to formula (Ic-2) or (I-c'-2), wherein each n is 3.
[0091] In embodiments, the cationic lipid has a structure according to Formula (Id),
[0092]
[0093] or a pharmaceutically acceptable salt thereof, wherein
[0094] Each n is independently an integer having a value from 1 to 9; and
[0095] Each X 2 are independently O or S.
[0096] In some embodiments of Formula (Id), each R 3 Independently C6-C30 In some embodiments of Formula (Id), each R 3 Independently C6-C 20 Aliphatic group.
[0097] In embodiments, the cationic lipid has a structure according to formula (I-d'),
[0098]
[0099] or a pharmaceutically acceptable salt thereof
[0100] In some embodiments of Formula (I-d'), each R 3 Independently C6-C 30 In some embodiments of Formula (I-d'), each R 3 Independently C6-C 20 Aliphatic group.
[0101] In embodiments, the cationic lipid has a structure according to formula (Id) or (I-d'), wherein each n is 1. In embodiments, the cationic lipid has a structure according to formula (Id) or (I-d'), wherein each n is 2. In embodiments, the cationic lipid has a structure according to formula (Id) or (I-d'), wherein each n is 3.
[0102] In an embodiment, the cationic lipid has a structure according to Formula (Id) or (I-d'), wherein each X 2 For S.
[0103] In embodiments, the cationic lipid has a structure according to Formula (Id-1),
[0104]
[0105] or a pharmaceutically acceptable salt thereof.
[0106] In some embodiments of Formula (Id-1), each R 3 Independently C6-C 30 In some embodiments of Formula (Id-1), each R 3 Independently C6-C 20 Aliphatic group.
[0107] In an embodiment, the cationic lipid has a structure according to Formula (Id) or (I-d'), wherein each X 2 It is O.
[0108] In embodiments, the cationic lipid has a structure according to formula (Id-2),
[0109]
[0110] or a pharmaceutically acceptable salt thereof.
[0111] In some embodiments of Formula (Id-2), each R 3 Independently C6-C 30 In some embodiments of Formula (Id-2), each R 3 Independently C6-C 20 Aliphatic group.
[0112] In embodiments, the cationic lipid has a structure according to Formula (Id) or (I-d′) (eg, a compound of Formula (Id-1) or (Id-2)), wherein each n is 1.
[0113] In embodiments, the cationic lipid has a structure according to Formula (Id) or (I-d′) (eg, a compound of Formula (Id-1) or (Id-2)), wherein each n is 2.
[0114] In embodiments, the cationic lipid has a structure according to Formula (Id) or (I-d′) (eg, a compound of Formula (Id-1) or (Id-2)), wherein each n is 3.
[0115] In embodiments, the cationic lipid has a structure according to Formula (Ie),
[0116]
[0117] or a pharmaceutically acceptable salt thereof, wherein
[0118] Each n is independently an integer having a value from 2 to 10; and
[0119] Each X 2 are independently O or S.
[0120] In some embodiments of Formula (Ie), each R 3 Independently C6-C 30 In some embodiments of Formula (Ie), each R 3 Independently C6-C 20 Aliphatic group.
[0121] In embodiments, the cationic lipid has a structure according to Formula (I-e'),
[0122]
[0123] or a pharmaceutically acceptable salt thereof.
[0124] In some embodiments of Formula (I-e'), each R 3 Independently C6-C 30 In some embodiments of Formula (I-e'), each R 3 Independently C6-C 20 Aliphatic group.
[0125] In an embodiment, the cationic lipid has a structure according to Formula (Ie) or (I-e'), wherein each X 2 For S.
[0126] In embodiments, the cationic lipid has a structure according to Formula (Ie-1),
[0127]
[0128] or a pharmaceutically acceptable salt thereof.
[0129] In some embodiments of Formula (Ie-1), each R 3 Independently C6-C 30 In some embodiments of Formula (Ie-1), each R 3 Independently C6-C 20 Aliphatic group.
[0130] In an embodiment, the cationic lipid has a structure according to Formula (Ie) or (I-e'), wherein each X 2 It is O.
[0131] In embodiments, the cationic lipid has a structure according to Formula (Ie-2),
[0132]
[0133] or a pharmaceutically acceptable salt thereof.
[0134] In some embodiments of Formula (Ie-2), each R 3 Independently C6-C 30 In some embodiments of Formula (Ie-2), each R 3 Independently C6-C 20 Aliphatic group.
[0135] In embodiments, the cationic lipid has a structure according to Formula (Ie) or (I-e′) (eg, a compound of Formula (Ie-1) or (Ie-2)), wherein each n is 2.
[0136] In embodiments, the cationic lipid has a structure according to Formula (Ie) or (I-e′) (eg, a compound of Formula (Ie-1) or (Ie-2)), wherein each n is 3.
[0137] In embodiments, the cationic lipid has a structure according to Formula (Ie) or (I-e′) (eg, a compound of Formula (Ie-1) or (Ie-2)), wherein each n is 4.
[0138] In embodiments, the cationic lipid has a structure according to Formula (If),
[0139]
[0140] or a pharmaceutically acceptable salt thereof, wherein
[0141] Each n is independently an integer having a value from 2 to 10.
[0142] In some embodiments of Formula (If), each R 3 Independently C6-C 30 In some embodiments of Formula (If), each R 3 Independently C6-C 20 Aliphatic group.
[0143] In embodiments, the cationic lipid has a structure according to formula (I-f'),
[0144]
[0145] or a pharmaceutically acceptable salt thereof.
[0146] In some embodiments of Formula (I-f'), each R 3 Independently C6-C 30 In some embodiments of Formula (I-f'), each R 3 Independently C6-C 20 Aliphatic group.
[0147] In an embodiment, the cationic lipid has a structure according to Formula (If) or (If′), wherein each n is 2.
[0148] In an embodiment, the cationic lipid has a structure according to Formula (If) or (If′), wherein each n is 3.
[0149] In an embodiment, the cationic lipid has a structure according to Formula (If) or (If′), wherein each n is 4.
[0150] In an embodiment, the cationic lipid is any one of Compounds 1-552, or a pharmaceutically acceptable salt thereof.
[0151] In embodiments, the cationic lipid has a structure according to formula (II),
[0152]
[0153] or a pharmaceutically acceptable salt thereof, wherein
[0154] Each R 1 are independently H or a C1-C6 aliphatic group;
[0155] Each L 1 are independently ester, thioester, disulfide or anhydride groups;
[0156] Each L 2 Independently C2-C 10 aliphatic groups;
[0157] Each X 1 are independently H or OH; and
[0158] Each R 3 Independently C6-C 30 Aliphatic group.
[0159] In some embodiments of Formula (II), each R 3 Independently C6-C 20 In some embodiments of Formula (II), each R 3 Independently C8-C 20 Aliphatic group.
[0160] In an embodiment, the cationic lipid has a structure according to Formula (II), wherein each R 1 are independently H or C1-C6 alkyl.
[0161] In an embodiment, the cationic lipid has a structure according to Formula (II), wherein each R 1 For H.
[0162] In an embodiment, the cationic lipid has a structure according to Formula (II), wherein each X 1 For OH.
[0163] In embodiments, the cationic lipid has a structure according to formula (II-a),
[0164]
[0165] or a pharmaceutically acceptable salt thereof, wherein each n is an integer having a value from 1 to 9.
[0166] In some embodiments of Formula (II-a), each R 3 Independently C6-C 30 In some embodiments of Formula (II-a), each R 3 Independently C6-C 20 In some embodiments of Formula (II-a), each R 3 Independently C8-C 20 Aliphatic group.
[0167] In embodiments, the cationic lipid has a structure according to formula (II-a'),
[0168]
[0169] or a pharmaceutically acceptable salt thereof.
[0170] In some embodiments of Formula (II-a'), each R 3 Independently C6-C 30 In some embodiments of Formula (II-a'), each R 3 Independently C6-C 20 In some embodiments of Formula (II-a'), each R 3 Independently C8-C 20 Aliphatic group.
[0171] In embodiments, the cationic lipid has a structure according to formula (II-a) or (II-a'), wherein each n is 1. In embodiments, the cationic lipid has a structure according to formula (II-a) or (II-a'), wherein each n is 2. In embodiments, the cationic lipid has a structure according to formula (II-a) or (II-a'), wherein each n is 3.
[0172] In an embodiment, the cationic lipid of formula (A') has a structure according to formula (III):
[0173]
[0174] or a pharmaceutically acceptable salt thereof, wherein
[0175] Each R 1 and R 2 are independently H or a C1-C6 aliphatic group;
[0176] Each M is independently an integer having a value from 1 to 4;
[0177] Each A is independently a covalent bond or an arylene group;
[0178] Each L1 are independently ester, thioester, disulfide or anhydride groups;
[0179] Each L 2 Independently C2-C 10 aliphatic groups;
[0180] Each R 3 Independently C6-C 30 Aliphatic group.
[0181] In some embodiments of Formula (III), each R 3 Independently C6-C 20 Aliphatic group.
[0182] In embodiments of formula (III), each A is independently a covalent bond or a phenylene group.
[0183] In an embodiment, the cationic lipid of formula (III) has the structure,
[0184]
[0185] or a pharmaceutically acceptable salt thereof.
[0186] In some embodiments of Formula (III'), each R 3 Independently C6-C 30 In some embodiments of Formula (III'), each R 3 Independently C6-C 20 Aliphatic group.
[0187] In the embodiments of formula (III) or formula (III'), each R 1 For H.
[0188] In the embodiments of formula (III) or formula (III'), each R 2 are independently H or C1-C6 alkyl.
[0189] In the embodiments of formula (III) or formula (III'), each L 2 Independently C2-C 10 Alkylene.
[0190] In the embodiments of formula (III) or formula (III'), each R 3 Independently C6-C 20 Alkyl, C6-C 20 Alkenyl or C6-C 20 In the embodiment of formula (III) or formula (III'), R 3Containing a substituent group -OC(O)R' or -C(O)-OR', wherein R' is C1-C 16 alkyl.
[0191] In an embodiment of formula (III) or (III'), each m is 1. In an embodiment of formula (III) or (III'), each m is 2. In an embodiment of formula (III) or (III'), each m is 3. In an embodiment of formula (III) or (III'), each m is 4.
[0192] In an embodiment, the cationic lipid of formula (III) has the following structure:
[0193] or a pharmaceutically acceptable salt thereof, wherein each n is independently an integer having a value from 1 to 9.
[0194] In some embodiments of Formula (III-a), each R 3 Independently C6-C 30 In some embodiments of Formula (III-a), each R 3 Independently C6-C 20 Aliphatic group.
[0195] In an embodiment, the cationic lipid of formula (III) or (III-a) has the following structure:
[0196] or a pharmaceutically acceptable salt thereof.
[0197] In some embodiments of Formula (III-a'), each R 3 Independently C6-C 30 In some embodiments of Formula (III-a'), each R 3 Independently C6-C 20 Aliphatic group.
[0198] In embodiments, the cationic lipid has a structure according to formula (III-a) or (III-a'), wherein each n is 1. In embodiments, the cationic lipid has a structure according to formula (III-a) or (III-a'), wherein each n is 2. In embodiments, the cationic lipid has a structure according to formula (III-a) or (III-a'), wherein each n is 3.
[0199] In an embodiment, the cationic lipid of formula (III) has the following structure:
[0200] or a pharmaceutically acceptable salt thereof, wherein each n is an integer having a value from 1 to 9.
[0201] In some embodiments of Formula (III-b), each R 3 Independently C6-C 30 In some embodiments of Formula (III-b), each R 3 Independently C6-C 20 Aliphatic group.
[0202] In an embodiment, the cationic lipid of formula (III) or (III-b) has the following structure:
[0203] or a pharmaceutically acceptable salt thereof.
[0204] In some embodiments of Formula (III-b'), each R 3 Independently C6-C 30 In some embodiments of Formula (III-b'), each R 3 Independently C6-C 20 Aliphatic group.
[0205] In embodiments, the cationic lipid has a structure according to formula (III-b) or (III-b'), wherein each n is 1. In embodiments, the cationic lipid has a structure according to formula (III-b) or (III-b'), wherein each n is 2. In embodiments, the cationic lipid has a structure according to formula (III-b) or (III-b'), wherein each n is 3.
[0206] In an embodiment, the cationic lipid of formula (III) has the following structure:
[0207] or a pharmaceutically acceptable salt thereof, wherein each N is an integer having a value from 1 to 9; and each R 2 are independently H or CH3.
[0208] In some embodiments of Formula (III-c), each R 3 Independently C6-C 30 In some embodiments of Formula (III-c), each R 3 Independently C6-C 20 Aliphatic group.
[0209] In an embodiment, the cationic lipid of Formula (III) or Formula (III-c) has the following structure:
[0210]
[0211] or a pharmaceutically acceptable salt thereof.
[0212] In some embodiments of Formula (III-c'), each R 3 Independently C6-C 30 In some embodiments of Formula (III-c'), each R 3 Independently C6-C 20 Aliphatic group.
[0213] In the embodiments of formula (III-c) or formula (III-c'), each R 2 For H.
[0214] In an embodiment, the cationic lipid of Formula (III) or Formula (III-c) has the following structure:
[0215] or a pharmaceutically acceptable salt thereof.
[0216] In some embodiments of Formula (III-c-1), each R 3 Independently C6-C 30 In some embodiments of Formula (III-c-1), each R 3 Independently C6-C 20 Aliphatic group.
[0217] In embodiments, the cationic lipid of Formula (III), Formula (III-c), Formula (III-c') or Formula (III-c-1) has the following structure:
[0218] or a pharmaceutically acceptable salt thereof.
[0219] In some embodiments of Formula (III-c'-1), each R 3 Independently C6-C 30 In some embodiments of Formula (III-c'-1), each R 3 Independently C6-C 20 Aliphatic group.
[0220] In the embodiments of formula (III-c) or formula (III-c'), each R 2 For CH3.
[0221] In an embodiment, the cationic lipid of Formula (III) or Formula (III-c) has the following structure:
[0222] or a pharmaceutically acceptable salt thereof.
[0223] In some embodiments of Formula (III-c-2), each R 3 Independently C6-C30 In some embodiments of Formula (III-c-2), each R 3 Independently C6-C 20 Aliphatic group.
[0224] In embodiments, the cationic lipid of Formula (III), Formula (III-c), Formula (III-c') or Formula (III-c-2) has the following structure:
[0225] or a pharmaceutically acceptable salt thereof.
[0226] In some embodiments of Formula (III-c'-2), each R 3 Independently C6-C 30 In some embodiments of Formula (III-c'-2), each R 3 Independently C6-C 20 Aliphatic group.
[0227] In embodiments, the cationic lipid has a structure according to Formula (III-c), (III-c'), (III-c-1), (III-c'-1), (III-c-2), or (III-c'-2), wherein each n is 1. In embodiments, the cationic lipid has a structure according to Formula (III-c), (III-c'), (III-c-1), (III-c'-1), (III-c-2), or (III-c'-2), wherein each n is 2. In embodiments, the cationic lipid has a structure according to Formula (III-c), (III-c'), (III-c-1), (III-c'-1), (III-c-2), or (III-c'-2), wherein each n is 3.
[0228] In an embodiment, the cationic lipid of formula (III) has the following structure:
[0229] or its medicine
[0230] a pharmaceutically acceptable salt, wherein each n is independently an integer having a value from 1 to 9; and
[0231] And each X 2 are independently O or S.
[0232] In some embodiments of Formula (III-d), each R 3 Independently C6-C 30 In some embodiments of Formula (III-d), each R 3 Independently C6-C 20 Aliphatic group.
[0233] In embodiments, the cationic lipid of Formula (III) or Formula (III-d) has the following structure:
[0234]
[0235] or a pharmaceutically acceptable salt thereof.
[0236] In some embodiments of Formula (III-d'), each R 3 Independently C6-C 30 In some embodiments of Formula (III-d'), each R 3 Independently C6-C 20 Aliphatic group.
[0237] In embodiments, the cationic lipid has a structure according to formula (III-d) or (III-d'), wherein each n is 1. In embodiments, the cationic lipid has a structure according to formula (III-d) or (III-d'), wherein each n is 2. In embodiments, the cationic lipid has a structure according to formula (III-d) or (III-d'), wherein each n is 3.
[0238] In the embodiments of Formula (III-d) or Formula (III-d'), each X 2 For S.
[0239] In embodiments, the cationic lipid of Formula (III) or Formula (III-d) has the following structure:
[0240] or a pharmaceutically acceptable salt thereof.
[0241] In some embodiments of Formula (III-d-1), each R 3 Independently C6-C 30 In some embodiments of Formula (III-d-1), each R 3 Independently C6-C 20 Aliphatic group.
[0242] In the embodiments of Formula (III-d) or Formula (III-d'), each X 2 It is O.
[0243] In embodiments, the cationic lipid of Formula (III) or Formula (III-d) has the following structure:
[0244] or a pharmaceutically acceptable salt thereof.
[0245] In some embodiments of Formula (III-d-2), each R3 Independently C6-C 30 In some embodiments of Formula (III-d-2), each R 3 Independently C6-C 20 Aliphatic group.
[0246] In embodiments, the cationic lipid has a structure according to formula (III-d-1) or (III-d-2), wherein each n is 1. In embodiments, the cationic lipid has a structure according to formula (III-d-1) or (III-d-2), wherein each n is 2. In embodiments, the cationic lipid has a structure according to formula (III-d-1) or (III-d-2), wherein each n is 3.
[0247] In an embodiment, the cationic lipid of formula (III) has the following structure:
[0248] or a pharmaceutically acceptable salt thereof, wherein each n is independently an integer having a value from 2 to 10; and each X 2 are independently O or S.
[0249] In some embodiments of Formula (III-e), each R 3 Independently C6-C 30 In some embodiments of Formula (III-e), each R 3 Independently C6-C 20 Aliphatic group.
[0250] In embodiments, the cationic lipid of Formula (III) or Formula (III-e) has the following structure:
[0251] or a pharmaceutically acceptable salt thereof.
[0252] In some embodiments of Formula (III-e'), each R 3 Independently C6-C 30 In some embodiments of Formula (III-e'), each R 3 Independently C6-C 20 Aliphatic group.
[0253] In an embodiment of formula (III-e) or formula (III-e'), each n is 2. In an embodiment of formula (III-e) or formula (III-e'), each n is 3. In an embodiment of formula (III-e) or formula (III-e'), each n is 4.
[0254] In the embodiments of Formula (III-e) or Formula (III-e'), each X2 For S.
[0255] In embodiments, the cationic lipid of Formula (III) or Formula (III-e) has the following structure:
[0256] or a pharmaceutically acceptable salt thereof.
[0257] In some embodiments of Formula (III-e-1), each R 3 Independently C6-C 30 In some embodiments of Formula (III-e-1), each R 3 Independently C6-C 20 Aliphatic group.
[0258] In the embodiments of Formula (III-e) or Formula (III-e'), each X 2 It is O.
[0259] In embodiments, the cationic lipid of Formula (III) or Formula (III-e) has the following structure:
[0260] or a pharmaceutically acceptable salt thereof.
[0261] In some embodiments of Formula (III-e-2), each R 3 Independently C6-C 30 In some embodiments of Formula (III-e-2), each R 3 Independently C6-C 20 Aliphatic group.
[0262] In embodiments, the cationic lipid has a structure according to formula (III-e-1) or (III-e-2), wherein each n is 2. In embodiments, the cationic lipid has a structure according to formula (III-e-1) or (III-e-2), wherein each n is 3. In embodiments, the cationic lipid has a structure according to formula (III-e-1) or (III-e-2), wherein each n is 4.
[0263] In an embodiment, the cationic lipid of formula (III) has the following structure:
[0264] or a pharmaceutically acceptable salt thereof, wherein each n is independently an integer having a value from 2 to 10.
[0265] In some embodiments of Formula (III-f), each R 3 Independently C6-C 30In some embodiments of Formula (III-f), each R 3 Independently C6-C 20 Aliphatic group.
[0266] In an embodiment, the cationic lipid of Formula (III) or Formula (III-f) has the following structure:
[0267] or a pharmaceutically acceptable salt thereof.
[0268] In some embodiments of Formula (III-f'), each R 3 Independently C6-C 30 In some embodiments of Formula (III-f'), each R 3 Independently C6-C 20 Aliphatic group.
[0269] In an embodiment of formula (III-f) or formula (III-f'), each n is 2. In an embodiment of formula (III-f) or formula (III-f'), each n is 3. In an embodiment of formula (III-f) or formula (III-f'), each n is 4.
[0270] In an embodiment, the cationic lipid of formula (A') has the following structure:
[0271]
[0272] or a pharmaceutically acceptable salt thereof, wherein
[0273] Each R 1 are independently H or a C1-C6 aliphatic group;
[0274] Each L 1 are independently ester, thioester, disulfide or anhydride groups;
[0275] Each L 2 Independently C2-C 10 aliphatic groups;
[0276] Each R 3 Independently C6-C 30 Aliphatic group.
[0277] In some embodiments of Formula (IV), each R 3 Independently C6-C 20 In some embodiments of Formula (IV), each R 3 Independently C8-C 20 Aliphatic group.
[0278] In an embodiment of formula (IV), each R 1 are independently H or C1-C6 alkyl. In the embodiment of formula (IV), each R 1 For H.
[0279] In an embodiment, the cationic lipid of formula (IV) has the following structure:
[0280] or a pharmaceutically acceptable salt thereof, wherein each n is an integer having a value from 1 to 9.
[0281] In some embodiments of Formula (IV-a), each R 3 Independently C6-C 30 In some embodiments of Formula (IV-a), each R 3 Independently C6-C 20 In some embodiments of Formula (IV-a), each R 3 Independently C8-C 20 Aliphatic group.
[0282] In embodiments, the cationic lipid of Formula (IV) or Formula (IV-a) has the following structure:
[0283]
[0284] a'), or a pharmaceutically acceptable salt thereof.
[0285] In some embodiments of Formula (IV-a'), each R 3 Independently C6-C 30 In some embodiments of Formula (IV-a'), each R 3 Independently C6-C 20 In some embodiments of Formula (IV-a'), each R 3 Independently C8-C 20 Aliphatic group.
[0286] In embodiments, the cationic lipid has a structure according to formula (IV-a) or (IV-a'), wherein each n is 1. In embodiments, the cationic lipid has a structure according to formula (IV-a) or (IV-a'), wherein each n is 2. In embodiments, the cationic lipid has a structure according to formula (IV-a) or (IV-a'), wherein each n is 3.
[0287] In any of the formulas described herein (e.g., Formula (A'), (A), (I), (Ia), (I-a'), (Ib), (I-b'), (Ic), (I-c'), (Ic-1), (I-c'-1), (Ic-2), (I-c'-2), (Id), (I-d'), (Id-1), (Id-2), (Ie), (I-e'), (Ie-1), (Ie-2), (If), (I-f'), (II), (II-a), (II-a'), (III), (III'), (III-a), (III- a'), (III-b), (III-b'), (III-c), (III-c-1), (III-c'-1), (III-c-2), (III-c'-2), (III-c'), (III-d), (III-d'), (III-d-1), (III-d-2), (III-e), (III-e'), (III-e-1), (III-e-2), (III-f), (III-f'), (IV), (IV-a), or (IV-a'), each R 3 For unsubstituted C6-C 20 Alkyl groups (e.g., each R 3 C6H 13 、C8H 17 、C 10 H 21 、C 12 H 25 、C 14 H 29 、C 16 H 33 or C 18 H 37 ). In an embodiment, each R 3 C 10 H 21 .
[0288] In any of the formulas described herein (e.g., Formula (A'), (A), (I), (Ia), (I-a'), (Ib), (I-b'), (Ic), (I-c'), (Ic-1), (I-c'-1), (Ic-2), (I-c'-2), (Id), (I-d'), (Id-1), (Id-2), (Ie), (I-e'), (Ie-1), (Ie-2), (If), (I-f'), (II), (II-a), (II-a'), (III), (III'), (III-a), (III- a'), (III-b), (III-b'), (III-c), (III-c-1), (III-c'-1), (III-c-2), (III-c'-2), (III-c'), (III-d), (III-d'), (III-d-1), (III-d-2), (III-e), (III-e'), (III-e-1), (III-e-2), (III-f), (III-f'), (IV), (IV-a), or (IV-a'), each R 3 For the replacement of C6-C 20 In an embodiment, R 3 Contains a substituent that is -OC(O)R' or -C(O)-OR', wherein R' is C1-C 16 In an embodiment, R 3 -OC(O)C7H 15 or -C(O)-O-(CH2)2CH(C5H 11 )2 substituted C6-C 10 In an embodiment, each R 3 -(CH2)9-OC(O)C7H 15 or -(CH2)8C(O)-O-(CH2)2CH(C5H 11 )2.
[0289] In any of the formulas described herein (e.g., Formula (A'), (A), (I), (Ia), (I-a'), (Ib), (I-b'), (Ic), (I-c'), (Ic-1), (I-c'-1), (Ic-2), (I-c'-2), (Id), (I-d'), (Id-1), (Id-2), (Ie), (I-e'), (Ie-1), (Ie-2), (If), (I-f'), (II), (II-a), (II-a'), (III), (III'), (III-a), (III- a'), (III-b), (III-b'), (III-c), (III-c-1), (III-c'-1), (III-c-2), (III-c'-2), (III-c'), (III-d), (III-d'), (III-d-1), (III-d-2), (III-e), (III-e'), (III-e-1), (III-e-2), (III-f), (III-f'), (IV), (IV-a), or (IV-a'), each R 3 For unsubstituted C6-C 20 Alkenyl (e.g., each R 3 C 16 H 31 or C 16 H 29 ). In an embodiment, each R 3 is an unsubstituted monoalkenyl, an unsubstituted dienyl, or an unsubstituted trialkenyl. 3 -(CH2) o R', wherein o is 6, 7, 8, 9 or 10, and R' is In an embodiment, o is 6. In an embodiment, o is 7. In an embodiment, o is 8. In an embodiment, o is 9. In an embodiment, o is 10. In an embodiment, R' is In an embodiment, R' is In an embodiment, R' is
[0290] In any of the formulas described herein (e.g., Formula (A'), (A), (I), (Ia), (I-a'), (Ib), (I-b'), (Ic), (I-c'), (Ic-1), (I-c'-1), (Ic-2), (I-c'-2), (Id), (I-d'), (Id-1), (Id-2), (Ie), (I-e'), (Ie-1), (Ie-2), (If), (I-f'), (II), (II-a), (II-a'), (III), (III'), (III-a), (III- a'), (III-b), (III-b'), (III-c), (III-c-1), (III-c'-1), (III-c-2), (III-c'-2), (III-c'), (III-d), (III-d'), (III-d-1), (III-d-2), (III-e), (III-e'), (III-e-1), (III-e-2), (III-f), (III-f'), (IV), (IV-a), or (IV-a'), each R 3 For unsubstituted C6-C 20 Alkynyl.
[0291] In an embodiment, the cationic lipid is any one of Compounds 1-552, or a pharmaceutically acceptable salt thereof.
[0292] In another aspect, the invention features a composition including any of the liposomes described herein (eg, liposomes that encapsulate mRNA encoding a protein).
[0293] In an embodiment, the mRNA encodes the cystic fibrosis transmembrane conductance regulator (CFTR) protein.
[0294] In embodiments, the mRNA encodes an ornithine transcarbamylase (OTC) protein.
[0295] In another aspect, the invention features a composition including a nucleic acid encapsulated within a liposome as described herein.
[0296] In an embodiment, the composition further comprises one or more lipids selected from the group consisting of: one or more cationic lipids, one or more non-cationic lipids, and one or more PEG-modified lipids. In an embodiment, the composition comprises a helper lipid that is dioleoylphosphatidylethanolamine (DOPE). In an embodiment, the composition comprises a helper lipid that is 1,2-dierucoyl-sn-glycero-3-phosphoethanolamine (DEPE).
[0297] In an embodiment, the nucleic acid is an mRNA encoding a peptide or protein.
[0298] In embodiments, the mRNA encodes a peptide or protein for delivery to or treatment of the lungs or lung cells of a subject.
[0299] In an embodiment, the mRNA encodes the cystic fibrosis transmembrane conductance regulator (CFTR) protein.
[0300] In embodiments, the mRNA encodes a peptide or protein for delivery to or treatment of the liver or hepatocytes of a subject.
[0301] In embodiments, the mRNA encodes an ornithine transcarbamylase (OTC) protein.
[0302] In an embodiment, the mRNA encodes a peptide or protein for use in a vaccine.
[0303] In embodiments, the mRNA encodes an antigen.
[0304] In some aspects, the present invention provides methods of treating a disease in a subject, the methods comprising administering to the subject a composition as described herein. BRIEF DESCRIPTION OF THE DRAWINGS
[0305] Figure 1 Concerning intravenous (IV) administration of lipid nanoparticle formulations comprising exemplary cyclic amino acid cationic lipids described herein and ornithine transcarbamylase (hOTC) mRNA. These exemplary compositions were used to deliver mRNA in vivo and resulted in expression of hOTC in CD1 mice.
[0306] Figure 2 Concerning intratracheal aerosol administration of lipid nanoparticle formulations comprising exemplary cyclic amino acid cationic lipids described herein and firefly luciferase (FFL) mRNA. These exemplary compositions are implemented for delivery of mRNA to the lungs based on positive luciferase activity. DETAILED DESCRIPTION
[0307] definition
[0308] To make the present invention more easily understood, certain terms are first defined below. Additional definitions of the following and other terms are set forth throughout this specification. The publications and other reference materials cited herein to describe the background technology of the present invention and to provide additional details about its implementation are incorporated herein by reference.
[0309] Amino Acids As used herein, the term "amino acid" in its broadest sense refers to any compound and / or substance that can be incorporated into a polypeptide chain. In some embodiments, an amino acid has the general structure H2N–C(H)(R)–COOH. In some embodiments, the amino acid is a naturally occurring amino acid. In some embodiments, the amino acid is a non-standard amino acid. In some embodiments, the amino acid is a synthetic amino acid; in some embodiments, the amino acid is a d-amino acid; and in some embodiments, the amino acid is an l-amino acid. "Standard amino acid" refers to any of the twenty standard l-amino acids commonly found in naturally occurring peptides. "Non-standard amino acid" refers to any amino acid other than the standard amino acids, whether synthetically prepared or obtained from a natural source. As used herein, "synthetic amino acid" encompasses chemically modified amino acids, including but not limited to salts, amino acid derivatives (e.g., amides), and / or substitutions. Amino acids, including the carboxyl and / or amino terminal amino acids in peptides, can be modified by methylation, amidation, acetylation, protecting groups, and / or substitution with other chemical groups that can alter the circulating half-life of the peptide without adversely affecting its activity. Amino acids can participate in disulfide bonds. An amino acid may comprise one or more post-translational modifications, for example, conjugation to one or more chemical entities (e.g., a methyl group, an acetate group, an acetyl group, a phosphate group, a formyl moiety, an isoprenoid group, a sulfate group, a polyethylene glycol moiety, a lipid moiety, a carbohydrate moiety, and a biotin moiety, etc.). The term "amino acid" is used interchangeably with "amino acid residue" and may refer to a free amino acid and / or an amino acid residue of a peptide. Whether the term refers to a free amino acid or a residue of a peptide will be apparent from the context in which the term is used.
[0310] Animal: As used herein, the term "animal" refers to any member of the animal kingdom. In some embodiments, "animal" refers to a human at any stage of development. In some embodiments, "animal" refers to a non-human animal at any stage of development. In certain embodiments, the non-human animal is a mammal (e.g., a rodent, mouse, rat, rabbit, monkey, dog, cat, sheep, cow, primate, and / or pig). In some embodiments, animals include, but are not limited to, mammals, birds, reptiles, amphibians, fish, insects, and / or worms. In some embodiments, animals can be transgenic animals, genetically engineered animals, and / or clones.
[0311] Approximately or approximately: As used herein, when applied to one or more target values, the term "approximately" or "approximately" refers to a value similar to the reference value. In certain embodiments, the term "approximately" or "approximately" refers to a range of values that fall within 25%, 20%, 19%, 18%, 17%, 16%, 15%, 14%, 13%, 12%, 11%, 10%, 9%, 8%, 7%, 6%, 5%, 4%, 3%, 2%, 1% or less of either direction (greater than or less than) of the value, unless otherwise stated or otherwise apparent from the context (unless the number exceeds 100% of the possible value).
[0312] Bioactive: As used herein, the term "bioactive" refers to the characteristic of any agent that is active in a biological system, particularly an organism. For example, an agent that has a biological effect on an organism when administered to that organism is considered bioactive.
[0313] Delivery: As used herein, the term "delivery" encompasses both local and systemic delivery. For example, delivery of mRNA encompasses situations where the mRNA is delivered to the target tissue and the encoded protein is expressed and retained in the target tissue (also referred to as "local distribution" or "local delivery"), as well as situations where the mRNA is delivered to the target tissue and the encoded protein is expressed and secreted into the patient's circulatory system (e.g., serum) and then distributed systemically and taken up by other tissues (also referred to as "systemic distribution" or "systemic delivery").
[0314] Expression: As used herein, "expression" of a nucleic acid sequence refers to the translation of mRNA into polypeptides, the assembly of multiple polypeptides into complete proteins (e.g., enzymes), and / or post-translational modifications of polypeptides or fully assembled proteins (e.g., enzymes). In this application, the terms "expression" and "production" and grammatically equivalent terms are used interchangeably.
[0315] Functional: As used herein, a "functional" biomolecule is a biomolecule in a form that exhibits the properties and / or activities that characterize it.
[0316] Half-life: As used herein, the term "half-life" is the time required for the concentration or activity of an agent, such as an amino acid or protein, to fall to half its value measured at the beginning of a time period.
[0317] Helper lipid: As used herein, the term "helper lipid" refers to any neutral or zwitterionic lipid material including cholesterol. Without wishing to be bound by a particular theory, helper lipids can increase stability, rigidity, and / or fluidity within the lipid bilayer / nanoparticle.
[0318] Improvement, increase, or decrease: As used herein, the terms "improve," "increase," or "decrease," or grammatical equivalents, refer to values relative to a baseline measurement, such as that measured in the same individual before initiation of a treatment described herein, or that measured in a control subject (or control subjects) in the absence of a treatment described herein. A "control subject" is a subject having the same form of disease as the subject being treated and who is about the same age as the subject being treated.
[0319] In vitro: As used herein, the term "in vitro" refers to events that occur in an artificial environment, such as in a test tube or reaction vessel, in cell culture, etc., rather than in a multicellular organism.
[0320] In vivo: As used herein, the term "in vivo" refers to events that occur within multicellular organisms such as humans and non-human animals. In the context of cell-based systems, the term can be used to refer to events that occur within living cells (as opposed to, for example, in vitro systems).
[0321] Isolated: As used herein, the term "isolated" refers to a substance and / or entity that is (1) separated from at least some components with which it was originally associated when produced (whether in nature and / or in an experimental setting), and / or (2) produced, prepared, and / or manufactured by the hand of man. An isolated substance and / or entity can be separated from about 10%, about 20%, about 30%, about 40%, about 50%, about 60%, about 70%, about 80%, about 90%, about 91%, about 92%, about 93%, about 94%, about 95%, about 96%, about 97%, about 98%, about 99%, or more than about 99% of other components with which it was originally associated. In some embodiments, the purity of the isolated agent is about 80%, about 85%, about 90%, about 91%, about 92%, about 93%, about 94%, about 95%, about 96%, about 97%, about 98%, about 99% or more. As used herein, a substance is "pure" if it is substantially free of other components. As used herein, the calculation of the purity percentage of an isolated substance and / or entity should not include excipients (e.g., buffers, solvents, water, etc.).
[0322] Liposome: As used herein, the term "liposome" refers to any lamellar, multilamellar, or solid nanoparticle vesicle. Generally, as used herein, liposomes can be formed by mixing one or more lipids or by mixing one or more lipids and a polymer. In some embodiments, liposomes suitable for the present invention contain one or more cationic lipids and optionally one or more non-cationic lipids, optionally one or more cholesterol-based lipids, and / or optionally one or more PEG-modified lipids.
[0323] Messenger RNA (mRNA): As used herein, the term "messenger RNA (mRNA)" or "mRNA" refers to a polynucleotide that encodes at least one polypeptide. As used herein, mRNA includes modified RNA and unmodified RNA. The term "modified mRNA" relates to an mRNA that comprises at least one chemically modified nucleotide. An mRNA may comprise one or more coding and non-coding regions. An mRNA may be purified from a natural source, produced using a recombinant expression system, and optionally purified, chemically synthesized, and the like. Where appropriate, for example, in the case of a chemically synthesized molecule, the mRNA may comprise nucleoside analogs, such as analogs with chemically modified bases or sugars, backbone modifications, and the like. Unless otherwise indicated, mRNA sequences are presented in a 5' to 3' direction. In some embodiments, the mRNA is or comprises natural nucleosides (e.g., adenosine, guanosine, cytidine, uridine); nucleoside analogs (e.g., 2-aminoadenosine, 2-thiothymidine, inosine, pyrrolopyrimidine, 3-methyladenosine, 5-methylcytidine, C-5 propynylcytidine, C-5 propynyl-uridine, 2-aminoadenosine, C5-bromouridine, C5-fluorouridine, C5-iodouridine, C5-propynyluridine, C5-propynylcytidine, C5-methyl cytidine, 2-aminoadenosine, 7-deazaadenosine, 7-deazaguanosine, 8-oxoadenosine, 8-oxoguanosine, O(6)-methylguanosine, and 2-thiocytidine); chemically modified bases; biologically modified bases (e.g., methylated bases); inserted bases; modified sugars (e.g., 2'-fluororibose, ribose, 2'-deoxyribose, arabinose, and hexose); and / or modified phosphate groups (e.g., phosphorothioate and 5'-N-phosphoramidite linkages).
[0324] Nucleic acid: As used herein, the term "nucleic acid" in its broadest sense refers to any compound and / or substance that can be incorporated into a polynucleotide chain. In some embodiments, a nucleic acid is a compound and / or substance that is incorporated into or can be incorporated into a polynucleotide chain by a phosphodiester bond. In some embodiments, "nucleic acid" refers to a single nucleic acid residue (e.g., nucleotides and / or nucleosides). In some embodiments, "nucleic acid" refers to a polynucleotide chain comprising a single nucleic acid residue. In some embodiments, "nucleic acid" encompasses RNA and single-stranded and / or double-stranded DNA and / or cDNA. In some embodiments, "nucleic acid" encompasses ribonucleic acid (RNA), including but not limited to any one or more of interfering RNA (RNAi), small interfering RNA (siRNA), short hairpin RNA (shRNA), antisense RNA (aRNA), messenger RNA (mRNA), modified messenger RNA (mmRNA), long non-coding RNA (lncRNA), microRNA (miRNA), poly-encoding nucleic acid (MCNA), polymer-encoding nucleic acid (PCNA), guide RNA (gRNA) and CRISPR RNA (crRNA). In some embodiments, "nucleic acid" encompasses deoxyribonucleic acid (DNA), including but not limited to any one or more of single-stranded DNA (ssDNA), double-stranded DNA (dsDNA), and complementary DNA (cDNA). In some embodiments, "nucleic acid" encompasses RNA and DNA. In embodiments, the DNA can be in the form of antisense DNA, plasmid DNA, a portion of a plasmid DNA, pre-condensed DNA, a product of a polymerase chain reaction (PCR), a vector (e.g., P1, PAC, BAC, YAC, artificial chromosome), an expression cassette, a chimeric sequence, chromosomal DNA, or a derivative of these groups.In embodiments, the RNA can be in the form of messenger RNA (mRNA), ribosomal RNA (rRNA), signal recognition particle RNA (7SL RNA or SRP RNA), transfer RNA (tRNA), transfer messenger RNA (tmRNA), small nuclear RNA (snRNA), small nucleolar RNA (snoRNA), SmY RNA, small Cajal body-specific RNA (scaRNA), guide RNA (gRNA), ribonuclease P (RNase P), Y RNA, telomerase RNA component (TERC), splicing leader RNA (SL RNA), antisense RNA (aRNA or asRNA), cis-natural antisense transcript (cis-NAT), CRISPR RNA (crRNA), long noncoding RNA (lncRNA), microRNA (miRNA), piwi-interacting RNA (piRNA), small interfering RNA (siRNA), transactional siRNA (tasiRNA), repeat-associated siRNA (rasiRNA), 73K RNA, retrotransposon, viral genome, viroid, satellite RNA, or derivatives of these groups. In some embodiments, the nucleic acid is an mRNA encoding a protein such as an enzyme.
[0325] Patient: As used herein, the term "patient" or "subject" refers to any organism to which a provided composition can be administered, for example, for experimental, diagnostic, prophylactic, cosmetic, and / or therapeutic purposes. Typical patients include animals (e.g., mammals such as mice, rats, rabbits, non-human primates, and / or humans). In some embodiments, the patient is a human. This includes both prenatal and postnatal humans.
[0326] Pharmaceutically acceptable: As used herein, the term "pharmaceutically acceptable" refers to substances that are suitable for use in contact with the tissues of humans and animals without excessive toxicity, irritation, allergic response, or other problem or complication, commensurate with a reasonable benefit / risk ratio, within the scope of sound medical judgment.
[0327] Pharmaceutically acceptable salts: Pharmaceutically acceptable salts are well known in the art. For example, SM Berge et al. describe pharmaceutically acceptable salts in detail in J. Pharmaceutical Sciences (1977) 66: 1-19. Pharmaceutically acceptable salts of the compounds of the present invention include those derived from suitable inorganic and organic acids and bases. Examples of pharmaceutically acceptable non-toxic acid addition salts are salts of amino groups formed with inorganic or organic acids, such as hydrochloric acid, hydrobromic acid, phosphoric acid, sulfuric acid, and perchloric acid, organic acids such as acetic acid, oxalic acid, maleic acid, tartaric acid, citric acid, succinic acid, or malonic acid, or by using other methods used in the art, such as ion exchange. Other pharmaceutically acceptable salts include adipate, alginate, ascorbate, aspartate, benzenesulfonate, benzoate, bisulfate, borate, butyrate, camphorate, camphorsulfonate, citrate, cyclopentanepropionate, digluconate, dodecylsulfate, ethanesulfonate, formate, fumarate, gluconoheptate, glycerophosphate, gluconate, hemisulfate, heptanoate, hexanoate, hydroiodide, 2-hydroxyethanesulfonate, lactobionate, lactate, laurate, lauryl sulfate, malate, maleate, malonate, methanesulfonate, 2-naphthalenesulfonate, nicotinate, nitrate, oleate, oxalate, palmitate, pamoate, pectinate, persulfate, 3-phenylpropionate, phosphate, picrate, pivalate, propionate, stearate, succinate, sulfate, tartrate, thiocyanate, p-toluenesulfonate, undecanoate, valerate, and the like. Salts derived from appropriate bases include alkali metal salts, alkaline earth metal salts, ammonium salts and N + (C 1-4 alkyl) salts. Representative alkali metal salts or alkaline earth metal salts include sodium salts, lithium salts, potassium salts, calcium salts, magnesium salts, and the like. Other pharmaceutically acceptable salts include non-toxic ammonium, quaternary ammonium, and amine cations formed when appropriate using counterions such as halides, hydroxides, carboxylates, sulfates, phosphates, nitrates, sulfonates, and arylsulfonates. Additional pharmaceutically acceptable salts include salts formed by quaternization of amines using appropriate electrophiles (e.g., alkyl halides) to form quaternized alkylated amino salts.
[0328] Systemic distribution or delivery: As used herein, the terms "systemic distribution," "systemic delivery," or grammatical equivalents refer to a delivery or distribution mechanism or method that affects the entire body or entire organism. Typically, systemic distribution or delivery is accomplished via the body's circulatory system (e.g., blood). This is in contrast to the definition of "local distribution or delivery."
[0329] Subject: As used herein, the term "subject" refers to a human or any non-human animal (e.g., mouse, rat, rabbit, dog, cat, cow, pig, sheep, horse, or primate). Humans include prenatal and postnatal. In many embodiments, the subject is a human. The subject can be a patient, which refers to a person who presents to a medical provider for disease diagnosis or treatment. The term "subject" can be used interchangeably with "individual" or "patient" herein. A subject can have a disease or disorder or be susceptible to a disease or disorder, but may or may not show symptoms of the disease or disorder.
[0330] Substantially: As used herein, the term "substantially" refers to the qualitative condition of exhibiting a characteristic or property of interest in full or nearly full extent or degree. One of ordinary skill in the biological arts will understand that biological and chemical phenomena rarely, if ever, go to completion and / or proceed to completion or achieve or avoid an absolute result. Thus, the term "substantially" is used herein to capture the potential lack of completeness inherent in many biological and chemical phenomena.
[0331] Target tissue: As used herein, the term "target tissue" refers to any tissue affected by the disease to be treated. In some embodiments, target tissues include those tissues that exhibit disease-associated pathology, symptoms, or characteristics.
[0332] Therapeutically effective amount: As used herein, the term "therapeutically effective amount" of a therapeutic agent refers to an amount that, when administered to a subject suffering from or susceptible to a disease, disorder, and / or condition, is sufficient to treat, diagnose, prevent, and / or delay the onset of symptoms of the disease, disorder, and / or condition. One of ordinary skill in the art will recognize that a therapeutically effective amount is typically administered via a dosing regimen comprising at least one unit dose.
[0333] Treatment: As used herein, the term "treatment" refers to any method used to partially or completely alleviate, ameliorate, alleviate, inhibit, prevent, delay the onset of, reduce the severity of, and / or reduce the incidence of one or more symptoms or features of a particular disease, disorder, and / or condition. Treatment can be administered to subjects who do not exhibit signs of disease and / or who exhibit only early signs of disease in order to reduce the risk of developing pathology associated with the disease.
[0334] Aliphatic: As used herein, the term aliphatic refers to C1-C 40 Hydrocarbons, and include saturated hydrocarbons and unsaturated hydrocarbons. Aliphatic groups can be straight chain, branched chain or cyclic. For example, C1-C 20 Aliphatic groups may include C1-C 20 Alkyl (e.g., straight or branched C1-C 20 saturated alkyl), C2-C 20 Alkenyl (e.g., straight or branched C4-C 20Dienyl, linear or branched C6-C 20 triene, etc.) and C2-C 20 Alkynyl (e.g., straight-chain or branched C2-C 20 C1-C 20 Aliphatic groups may include C3-C 20 Cyclic aliphatic groups (e.g., C3-C 20 Cycloalkyl, C4-C 20 Cycloalkenyl or C8-C 20 In some embodiments, the aliphatic group may comprise one or more cyclic aliphatic groups and / or one or more heteroatoms such as oxygen, nitrogen, or sulfur, and may be optionally substituted with one or more substituents such as alkyl, halogen, alkoxy, hydroxy, amino, aryl, ether, ester, or amide. The aliphatic group is unsubstituted or substituted with one or more substituents as described herein. For example, the aliphatic group may be substituted with one or more (e.g., 1, 2, 3, 4, 5, or 6 independently selected substituents) of halogen, -COR', -C0H, -C0R', -CN, -OH, -OR', -OCOR', -OC0R', -NH2, -NHR', -N(R')2, -SR', or -S0R', wherein each instance of R' is independently C1-C 20 Aliphatic groups (e.g., C1-C 20 Alkyl, C1-C 15 Alkyl, C1-C 10 In an embodiment, R' is independently unsubstituted alkyl (e.g., unsubstituted C1-C3 alkyl). 20 Alkyl, C1-C 15 Alkyl, C1-C 10 In one embodiment, R' is independently an unsubstituted C1-C3 alkyl. In one embodiment, the aliphatic group is unsubstituted. In one embodiment, the aliphatic group does not include any heteroatoms.
[0335] Alkyl: As used herein, the term "alkyl" refers to acyclic straight-chain and branched hydrocarbon groups, for example, "C1-C 20"Alkyl" refers to an alkyl group having 1 to 20 carbons. The alkyl group can be straight or branched. Examples of alkyl groups include, but are not limited to, methyl, ethyl, n-propyl, isopropyl, butyl, isobutyl, sec-butyl, tert-butyl, pentyl, isopentyl, tert-pentyl, hexyl, isohexyl, and the like. Other alkyl groups will be apparent to those skilled in the art given the benefit of this disclosure. The alkyl group can be unsubstituted or substituted with one or more substituents as described herein. For example, the alkyl group can be substituted with one or more (e.g., 1, 2, 3, 4, 5, or 6 independently selected substituents) of halogen, -COR', -C0H, -C0R', -CN, -OH, -OR', -OCOR', -OC0R', -NH2, -NHR', -N(R')2, -SR', or -S0R', wherein each instance of R' is independently a C1-C20 aliphatic group (e.g., C1-C20 20 Alkyl, C1-C 15 Alkyl, C1-C 10 In an embodiment, R' is independently unsubstituted alkyl (e.g., unsubstituted C1-C3 alkyl). 20 Alkyl, C1-C 15 Alkyl, C1-C 10 In some embodiments, R' is independently unsubstituted C1-C3 alkyl. In some embodiments, the alkyl group is substituted (e.g., with 1, 2, 3, 4, 5, or 6 substituent groups as described herein). In some embodiments, the alkyl group is substituted with an -OH group and may also be referred to herein as a "hydroxyalkyl," where the prefix indicates an -OH group and "alkyl" is as described herein.
[0336] Attaching the suffix "-ene" to a group indicates that the group is a divalent moiety, for example, arylene is a divalent moiety of aryl, and heteroarylene is a divalent moiety of heteroaryl.
[0337] Alkylene: As used herein, the term "alkylene" refers to a saturated divalent straight or branched hydrocarbon radical, and is exemplified by methylene, ethylene, isopropylene, and the like. Similarly, as used herein, the term "alkenylene" refers to an unsaturated divalent straight or branched hydrocarbon radical having one or more unsaturated carbon-carbon double bonds, which may be present at any stable point along the chain, and the term "alkynylene" refers herein to an unsaturated divalent straight or branched hydrocarbon radical having one or more unsaturated carbon-carbon triple bonds, which may be present at any stable point along the chain. In certain embodiments, an alkylene, alkenylene, or alkynylene radical may contain one or more cyclic aliphatic groups and / or one or more heteroatoms such as oxygen, nitrogen, or sulfur, and may be optionally substituted with one or more substituents such as alkyl, halogen, alkoxy, hydroxy, amino, aryl, ether, ester, or amide. For example, the alkylene, alkenylene, or alkynylene group may be substituted with one or more (e.g., 1, 2, 3, 4, 5, or 6 independently selected substituents) of halogen, -COR', -CO2H, -CO2R', -CN, -OH, -OR', -OCOR', -OCOR', -NH2, -NHR', -N(R')2, -SR', or -SO2R', wherein each instance of R' is independently C1-C 20 Aliphatic groups (e.g., C1-C 20 Alkyl, C1-C 15 Alkyl, C1-C 10 In an embodiment, R' is independently unsubstituted alkyl (e.g., unsubstituted C1-C3 alkyl). 20 Alkyl, C1-C 15 Alkyl, C1-C 10 In some embodiments, R′ is independently unsubstituted C1-C3 alkyl. In some embodiments, the alkylene, alkenylene, or alkynylene group is unsubstituted. In some embodiments, the alkylene, alkenylene, or alkynylene group does not include any heteroatoms.
[0338] Alkenyl: As used herein, "alkenyl" means any straight or branched hydrocarbon chain having one or more unsaturated carbon-carbon double bonds, which may be present at any stable point along the chain, for example, "C2-C 20"Alkenyl" refers to an alkenyl group having from 2 to 20 carbons. For example, alkenyl includes prop-2-enyl, but-2-enyl, but-3-enyl, 2-methylprop-2-enyl, hex-2-enyl, hex-5-enyl, 2,3-dimethylbut-2-enyl, and the like. In embodiments, the alkenyl contains 1, 2, or 3 carbon-carbon double bonds. In embodiments, the alkenyl contains a single carbon-carbon double bond. In embodiments, multiple double bonds (e.g., 2 or 3) are conjugated. The alkenyl group may be unsubstituted. The present invention also provides a plurality of substituted or substituted alkenyl groups, wherein each instance of R' is independently C1-C2, C0-1, C1- ... 20 Aliphatic groups (e.g., C1-C 20 Alkyl, C1-C 15 Alkyl, C1-C 10 In an embodiment, R' is independently unsubstituted alkyl (e.g., unsubstituted C1-C3 alkyl). 20 Alkyl, C1-C 15 Alkyl, C1-C 10 In some embodiments, R′ is independently unsubstituted C1-C3 alkyl. In some embodiments, alkenyl is unsubstituted. In some embodiments, alkenyl is substituted (e.g., with 1, 2, 3, 4, 5, or 6 substituent groups as described herein). In some embodiments, alkenyl groups are substituted with an —OH group and may also be referred to herein as “hydroxyalkenyl,” where the prefix represents an —OH group and “alkenyl” is as described herein.
[0339] Alkynyl: As used herein, "alkynyl" means any hydrocarbon chain in a straight or branched configuration having one or more carbon-carbon triple bonds at any stable point along the chain, for example, "C2-C 20"Alkynyl" refers to an alkynyl group having from 2 to 20 carbons. Examples of alkynyl groups include prop-2-ynyl, but-2-ynyl, but-3-ynyl, pent-2-ynyl, 3-methylpent-4-ynyl, hex-2-ynyl, hex-5-ynyl, and the like. In embodiments, the alkynyl group contains one carbon-carbon triple bond. The alkynyl group can be unsubstituted or substituted with one or more substituents as described herein. For example, the alkynyl group can be substituted with one or more (e.g., 1, 2, 3, 4, 5, or 6 independently selected substituents) of halogen, -COR', -C0H, -C0R', -CN, -OH, -OR', -OCOR', -OC0R', -NH2, -NHR', -N(R')2, -SR', or -S0R', wherein each instance of R' is independently a C1-C20 aliphatic group (e.g., C1-C20 aliphatic group). 20 Alkyl, C1-C 15 Alkyl, C1-C 10 In an embodiment, R' is independently unsubstituted alkyl (e.g., unsubstituted C1-C3 alkyl). 20 Alkyl, C1-C 15 Alkyl, C1-C 10 In one embodiment, R' is independently unsubstituted C1-C3 alkyl. In one embodiment, alkynyl is unsubstituted. In one embodiment, alkynyl is substituted (e.g., with 1, 2, 3, 4, 5, or 6 substituent groups as described herein).
[0340] Aryl: The term "aryl" used alone or as part of a larger moiety as in "aralkyl" refers to a monocyclic, bicyclic, or tricyclic carbocyclic ring system having a total of six to fourteen ring members, wherein the ring system has a single point of attachment to the rest of the molecule, at least one ring in the system is aromatic, and wherein each ring in the system contains 4 to 7 ring members. In an embodiment, an aryl group has 6 ring carbon atoms ("C6 aryl"; e.g., phenyl). In some embodiments, an aryl group has 10 ring carbon atoms ("C 10 In some embodiments, an aryl group has 14 ring carbon atoms ("C 14 "Aryl" also includes ring systems in which an aromatic ring, as defined above, is fused to one or more carbocyclic or heterocyclic groups, wherein the radical or point of attachment is on the aromatic ring, and in such cases, the number of carbon atoms continues to refer to the number of carbon atoms in the aromatic ring system. Exemplary aryl groups include phenyl, naphthyl, and anthracene.
[0341] Arylene: As used herein, the term "arylene" refers to a divalent aromatic group (ie, having two points of attachment to the molecule). Exemplary arylene groups include phenylene (eg, unsubstituted phenylene or substituted phenylene).
[0342] Halogen: As used herein, the term "halogen" refers to fluorine, chlorine, bromine, or iodine.
[0343] Assorted alkyl: the term "assorted alkyl" means a side chain or unbranched alkyl, alkenyl or alkynyl group having from 1 to 14 carbon atoms in addition to 1, 2, 3 or 4 heteroatoms independently selected from the group consisting of N, O, S and P. Assorted alkyl includes tertiary amines, secondary amines, ethers, thioethers, amides, thioamides, carbamates, thiocarbamates, hydrazones, imines, phosphodiester, phosphoramidates, sulfonamides and disulfides. Assorted alkyl groups can optionally include monocycles, dicycles or tricycles, wherein each ring ideally has three to six members. Examples of assorted alkyl include polyethers, such as methoxymethyl and ethoxyethyl.
[0344] Heteroalkylene: As used herein, the term "heteroalkylene" refers to a divalent form of a heteroalkyl group as described herein.
[0345] Compounds of the present invention
[0346] Liposome-based vehicles are considered to be attractive carriers of therapeutic agents, and still need continuous development efforts. Although the vehicles based on liposomes comprising some lipid components have demonstrated encouraging results aspect encapsulation, stability and site location, there is still a great need to improve the delivery system based on liposomes. For example, the significant shortcoming of liposome delivery systems relates to the structure of liposomes with enough cell cultures or in vivo stability to reach desired target cells and / or intracellular compartments, and the ability of such liposome delivery systems to effectively release the material encapsulated therein to such target cells.
[0347] In particular, there remains a need for improved lipid compounds that exhibit improved pharmacokinetic properties and are capable of delivering macromolecules such as nucleic acids to a variety of cell types and tissues with increased efficiency. Importantly, there remains a particular need for novel lipid compounds characterized by reduced toxicity and capable of effectively delivering encapsulated nucleic acids and polynucleotides to target cells, tissues, and organs.
[0348] A novel class of cyclic amino acid lipid compounds for improving the in vivo delivery of therapeutic agents such as nucleic acids is described herein. Specifically, the biodegradable compounds described herein can be used as cationic lipids, along with other non-cationic lipids, to formulate lipid-based nanoparticles (e.g., liposomes) for encapsulating therapeutic agents, such as nucleic acids (e.g., DNA, siRNA, mRNA, microRNA) for therapeutic use.
[0349] In embodiments, compounds as described herein can provide one or more desired features or characteristics. That is, in certain embodiments, the feature of compounds as described herein can be to have one or more characteristics, and these characteristics provide the advantages of such compounds relative to other similarly classified lipids. For example, compounds disclosed herein can allow control and customization of the characteristics of the liposome compositions (e.g., lipid nanoparticles) of which they are components. Specifically, the feature of compounds disclosed herein can be enhanced transfection efficiency and the ability thereof to cause specific biological results. Such results can include, for example, enhanced cellular uptake, endosome / lysosome destruction ability and / or promote the release of intracellularly encapsulated materials (e.g., polynucleotides). In addition, compounds disclosed herein have favorable pharmacokinetic properties, biodistribution and efficiency (e.g., due to the different dissociation rates of the polymer groups used).
[0350] Compounds of formula (A')
[0351] Provided herein are compounds that are cationic lipids.
[0352] In one aspect, the invention features a cationic lipid having a structure according to (A'),
[0353]
[0354] or a pharmaceutically acceptable salt thereof, wherein
[0355] Each R 1 and R 2 are independently H or a C1-C6 aliphatic group;
[0356] Each M is independently an integer having a value from 1 to 4;
[0357] Each A is independently a covalent bond or an arylene group;
[0358] Each L 1 are independently ester, thioester, disulfide or anhydride groups;
[0359] Each L 2 Independently C2-C 10 aliphatic groups;
[0360] Each B site is -CHX 1 - or -CH2CO2-;
[0361] Each X 1 are independently H or OH; and
[0362] Each R 3 Independently C6-C 30 Aliphatic group.
[0363] In some embodiments of Formula (A'), each R 3 Independently C6-C 20 Aliphatic group.
[0364] Compounds of formula (A)
[0365] In embodiments, cationic lipids of the present invention include compounds having a structure according to Formula (A),
[0366]
[0367] or a pharmaceutically acceptable salt thereof, wherein
[0368] Each R 1 and R 2 are independently H or a C1-C6 aliphatic group;
[0369] Each M is independently an integer having a value from 1 to 4;
[0370] Each A is independently a covalent bond or an arylene group;
[0371] Each L 1 are independently ester, thioester, disulfide or anhydride groups;
[0372] Each L 2 Independently C2-C 10 aliphatic groups;
[0373] Each X 1 are independently H or OH; and
[0374] Each R 3 Independently C6-C 30 Aliphatic group.
[0375] In some embodiments of Formula (A), each R 3 Independently c6-c 30 In some embodiments of Formula (A), each R 3 Independently c6-c 20 Aliphatic group.
[0376] In formula (A') or an embodiment of formula (A), R 1 is independently H. In an embodiment, R 1 is independently a C1-C6 aliphatic group (eg, methyl).
[0377] In formula (A') or an embodiment of formula (A), R 2 is independently H. In an embodiment, R 2 is independently a C1-C6 aliphatic group (eg, methyl).
[0378] In Formula (A') or embodiments of Formula (A), m is 1. In embodiments, m is 2. In embodiments, m is 3. In embodiments, m is 4. In embodiments, each m is 1. In embodiments, each m is 2. In embodiments, each m is 3. In embodiments, each m is 4.
[0379] In formula (A') or embodiments of formula (A), each A is a covalent bond. In embodiments, each A is an arylene group.
[0380] In formula (A') or an embodiment of formula (A), L 1 are independently esters. In an embodiment, L 1 are independently thioesters. In an embodiment, L 1 are independently disulfides. In an embodiment, L 1 are independently anhydride groups. In an embodiment, each L 1 In an embodiment, each L 1 is a thioester. In an embodiment, each L 1 is a disulfide. In an embodiment, each L 1 It is an anhydride group.
[0381] In formula (A') or embodiments of formula (A), each L 2 is a C2 aliphatic group (e.g., a C2 alkylene group). In an embodiment, each L 2 is a C3 aliphatic group (e.g., a C3 alkylene group). In an embodiment, each L 2 is a C4 aliphatic group (e.g., a C4 alkylene group). In an embodiment, each L 2 is a C5 aliphatic group (e.g., a C5 alkylene group). 2 is a C6 aliphatic group (e.g., a C6 alkylene group). In an embodiment, each L 2 is a C7 aliphatic group (e.g., a C7 alkylene group). In an embodiment, each L 2 is a C8 aliphatic group (e.g., a C8 alkylene group). In an embodiment, each L 2 is a C9 aliphatic group (e.g., a C9 alkylene group). In an embodiment, each L 2 C 10 Aliphatic groups (e.g., C 10 alkylene).
[0382] In formula (A') or an embodiment of formula (A), X 1 is independently H. In an embodiment, X 1 is independently OH. In an embodiment, each X 1is H. In an embodiment, each X 1 For OH.
[0383] In formula (A') or embodiments of formula (A), each R 3 is a C6 aliphatic group (e.g., a C6 alkyl group or a C6 alkenyl group). 3 is a C7 aliphatic group (e.g., a C7 alkyl group or a C7 alkenyl group). 3 is a C8 aliphatic group (e.g., a C8 alkyl group or a C8 alkenyl group). 3 is a C9 aliphatic group (e.g., a C9 alkyl group or a C9 alkenyl group). 3 C 10 Aliphatic groups (e.g., C 10 Alkyl or C 10 In an embodiment, each R 3 C 11 Aliphatic groups (e.g., C 11 Alkyl or C 11 In an embodiment, each R 3 C 12 Aliphatic groups (e.g., C 12 Alkyl or C 12 In an embodiment, each R 3 C 13 Aliphatic groups (e.g., C 13 Alkyl or C 13 In an embodiment, each R 3 C 14 Aliphatic groups (e.g., C 14 Alkyl or C 14 In an embodiment, each R 3 C 15 Aliphatic groups (e.g., C 15 Alkyl or C 15 In an embodiment, each R 3 C 16 Aliphatic groups (e.g., C 16 Alkyl or C 16 In an embodiment, each R 3 C 17 Aliphatic groups (e.g., C 17 Alkyl or C 17 In an embodiment, each R 3 C 18 Aliphatic groups (e.g., C 18 Alkyl or C 18 In an embodiment, each R 3 C 19Aliphatic groups (e.g., C 19 Alkyl or C 19 In an embodiment, each R 3 C 20 Aliphatic groups (e.g., C 20 Alkyl or C 20 In an embodiment, R 3 Is unsubstituted.
[0384] In formula (A') or embodiments of formula (A), each R 3 C 21 Aliphatic groups (e.g., C 21 Alkyl or C 21 In an embodiment, each R 3 C 22 Aliphatic groups (e.g., C 22 Alkyl or C 22 In an embodiment, each R 3 C 23 Aliphatic groups (e.g., C 23 Alkyl or C 23 In an embodiment, each R 3 C 24 Aliphatic groups (e.g., C 24 Alkyl or C 24 In an embodiment, each R 3 C 25 Aliphatic groups (e.g., C 25 Alkyl or C 25 In an embodiment, each R 3 C 26 Aliphatic groups (e.g., C 26 Alkyl or C 26 In an embodiment, each R 3 C 27 Aliphatic groups (e.g., C 27 Alkyl or C 27 In an embodiment, each R 3 C 28 Aliphatic groups (e.g., C 28 Alkyl or C 28 In an embodiment, each R 3 C 29 Aliphatic groups (e.g., C 29 Alkyl or C 29 In an embodiment, each R 3 C 30 Aliphatic groups (e.g., C 30 Alkyl or C 30 alkenyl).
[0385] Compounds of formula (I)
[0386] In an embodiment, the cationic lipid of formula (A) has a structure according to formula (I),
[0387]
[0388] or a pharmaceutically acceptable salt thereof.
[0389] In some embodiments of Formula (I), each R 3 Independently C6-C 30 In some embodiments of Formula (I), each R 3 Independently C6-C 20 Aliphatic group.
[0390] In formula (I), R 1 、R 2 、R 3 、X 1 , L 1 , L 2 and m can be any permissible group or value as described herein for Formula (A') or Formula (A). In some embodiments of Formula (I), R 1 、R 2 、R 3 、X 1 , L 1 , L 2 and m can be any permissible group or value as described herein for Formula (A).
[0391] In embodiments, the cationic lipid has a structure according to Formula (A'), (A), or (I), wherein each R 1 For H.
[0392] In embodiments, the cationic lipid has a structure according to Formula (A'), (A), or (I), wherein each R 2 are independently H or C1-C6 alkyl.
[0393] In embodiments, the cationic lipid has a structure according to Formula (A'), (A), or (I), wherein each L 2 Independently C2-C 10 Alkylene.
[0394] In embodiments, the cationic lipid has a structure according to Formula (A'), (A), or (I), wherein each R 3 Independently C6-C 20 Alkyl, C6-C 20 Alkenyl or C6-C 20 Alkynyl.
[0395] In embodiments, the cationic lipid has a structure according to Formula (A'), (A), or (I), wherein each X 1 For OH.
[0396] In embodiments, the cationic lipid has a structure according to Formula (A'), (A), or (I), wherein each m is 1.
[0397] In an embodiment, the cationic lipid has a structure according to Formula (A'), (A), or (I), wherein each m is 2.
[0398] In an embodiment, the cationic lipid has a structure according to Formula (A'), (A), or (I), wherein each m is 3.
[0399] In an embodiment, the cationic lipid has a structure according to Formula (A'), (A), or (I), wherein each m is 4.
[0400] Compounds of formula (Ia)
[0401] In an embodiment, the cationic lipid of formula (I) has a structure according to formula (Ia),
[0402] or a pharmaceutically acceptable salt thereof, wherein each n is independently an integer having a value of 1 to 9.
[0403] In some embodiments of Formula (Ia), each R 3 Independently C6-C 30 In some embodiments of Formula (Ia), each R 3 Independently C6-C 20 Aliphatic group.
[0404] In an embodiment, the cationic lipid of formula (Ia) has a structure according to formula (I-a'),
[0405] or a pharmaceutically acceptable salt thereof.
[0406] In some embodiments of Formula (I-a'), each R 3 Independently C6-C 30 In some embodiments of Formula (I-a'), each R 3 Independently C6-C 20 Aliphatic group.
[0407] In formulas (Ia) and (I-a'), R 3and R is any permissible group as described herein (e.g., as described for Formula (A'), Formula (A), or Formula (I)). In some embodiments of Formulas (Ia) and (Ia'), R 3 Any permissible group may be as described for Formula (A) or Formula (I).
[0408] In embodiments, the cationic lipid has a structure according to Formula (Ia) or (I-a'), wherein each n is 3. In embodiments, each n is 1. In embodiments, each n is 2. In embodiments, each n is 4. In embodiments, each n is 5. In embodiments, each n is 6. In embodiments, each n is 7. In embodiments, each n is 8. In embodiments, each n is 9.
[0409] Compounds of formula (Ib)
[0410] In an embodiment, the cationic lipid of formula (I) has a structure according to formula (Ib),
[0411] or a pharmaceutically acceptable salt thereof, wherein each n is an integer having a value from 1 to 9.
[0412] In some embodiments of Formula (Ib), each R 3 Independently C6-C 30 In some embodiments of Formula (Ib), each R 3 Independently C6-C 20 Aliphatic group.
[0413] In an embodiment, the cationic lipid of formula (Ib) has a structure according to formula (I-b'),
[0414] or a pharmaceutically acceptable salt thereof.
[0415] In some embodiments of Formula (I-b'), each R 3 Independently C6-C 30 In some embodiments of Formula (I-b'), each R 3 Independently C6-C 20 Aliphatic group.
[0416] In formulas (Ib) and (I-b'), R 3 can be any permissible group as described herein (e.g., as described for Formula (A'), Formula (A), or Formula (I)). In some embodiments of Formulas (Ib) and (I-b'), R 3 Any permissible group may be as described for Formula (A) or Formula (I).
[0417] In embodiments, the cationic lipid has a structure according to Formula (Ib) or (I-b'), wherein each n is 2. In embodiments, each n is 1. In embodiments, each n is 3. In embodiments, each n is 4. In embodiments, each n is 5. In embodiments, each n is 6. In embodiments, each n is 7. In embodiments, each n is 8. In embodiments, each n is 9.
[0418] Compounds of formula (Ic)
[0419] In an embodiment, the cationic lipid of formula (I) has a structure according to formula (Ic),
[0420]
[0421] or a pharmaceutically acceptable salt thereof, wherein each
[0422] n is an integer having a value from 1 to 9; and
[0423] Each R 2 are independently H or CH3.
[0424] In some embodiments of Formula (Ic), each R 3 Independently C6-C 30 In some embodiments of Formula (Ic), each R 3 Independently C6-C 20 Aliphatic group.
[0425] In an embodiment, the cationic lipid of formula (Ic) has a structure according to formula (I-c'),
[0426]
[0427] or a pharmaceutically acceptable salt thereof
[0428] In some embodiments of Formula (I-c'), each R 3 Independently C6-C 30 In some embodiments of Formula (I-c'), each R 3 Independently C6-C 20 Aliphatic group.
[0429] In formulas (Ic) and (I-c'), R 2 and R 3 Each of can be according to any permissible group described herein (e.g., as described for Formula (A'), Formula (A), or Formula (I)). In some embodiments of Formulas (Ic) and (I-c'), R2 and R 3 Each of can be any permissible groups as described for Formula (A) or Formula (I).
[0430] In embodiments, the cationic lipid has a structure according to formula (Ic-1),
[0431]
[0432] or a pharmaceutically acceptable salt thereof.
[0433] In some embodiments of Formula (Ic-1), each R 3 Independently C6-C 30 In some embodiments of Formula (Ic-1), each R 3 Independently C6-C 20 Aliphatic group.
[0434] In formula (Ic-1), each R 3 can independently be any permissible group as described herein (e.g., as described for Formula (A'), Formula (A), or Formula (I)). In some embodiments of Formula (Ic-1), each R 3 and R is any permissible group as described herein for Formula (A) or Formula (I).
[0435] In embodiments, the cationic lipid has a structure according to formula (I-c'-1),
[0436]
[0437] or a pharmaceutically acceptable salt thereof.
[0438] In some embodiments of Formula (I-c'-1), each R 3 Independently C6-C 30 In some embodiments of Formula (I-c'-1), each R 3 Independently C6-C 20 Aliphatic group.
[0439] In formula (I-c'-1), each R 3 can independently be any permissible group as described herein (e.g., as described for Formula (A'), Formula (A), or Formula (I)). In some embodiments of Formula (I-c'-1), each R 3 and R is any permissible group as described herein for Formula (A) or Formula (I).
[0440] In an embodiment, the cationic lipid has a structure according to Formula (Ic) or (I-c'), wherein each R2 For CH3.
[0441] In embodiments, the cationic lipid has a structure according to formula (Ic-2),
[0442]
[0443] or a pharmaceutically acceptable salt thereof.
[0444] In some embodiments of Formula (Ic-2), each R 3 Independently C6-C 30 In some embodiments of Formula (Ic-2), each R 3 Independently C6-C 20 Aliphatic group.
[0445] In formula (Ic-2), each R 3 can independently be any permissible group as described herein (e.g., as described for Formula (A'), Formula (A), or Formula (I)). In some embodiments of Formula (Ic-2), each R 3 and R is any permissible group as described herein for Formula (A) or Formula (I).
[0446] In embodiments, the cationic lipid has a structure according to formula (I-c'-2),
[0447]
[0448] or a pharmaceutically acceptable salt thereof.
[0449] In some embodiments of Formula (I-c'-2), each R 3 Independently C6-C 30 In some embodiments of Formula (I-c'-2), each R 3 Independently C6-C 20 Aliphatic group.
[0450] In formula (I-c'-2), each R 3 can independently be any permissible group as described herein (e.g., as described for Formula (A'), Formula (A), or Formula (I)). In some embodiments of Formula (I-c'-2), each R 3 and R is any permissible group as described herein for Formula (A) or Formula (I).
[0451] In embodiments, the cationic lipid has a structure according to Formula (Ic) or (I-c') (e.g., according to Formula (Ic-1), (I-c'-1), (Ic-2), or (I-c'-2)), wherein each n is 2. In embodiments, each n is 1. In embodiments, each n is 3. In embodiments, each n is 4. In embodiments, each n is 5. In embodiments, each n is 6. In embodiments, each n is 7. In embodiments, each n is 8. In embodiments, each n is 9.
[0452] In embodiments, the cationic lipid has a structure according to Formula (Ic) or (I-c') (e.g., according to Formula (Ic-1), (I-c'-1), (Ic-2), or (I-c'-2)), wherein each R 2 For H.
[0453] Compounds of formula (Id)
[0454] In an embodiment, the cationic lipid of formula (I) has a structure according to formula (Id),
[0455]
[0456] or a pharmaceutically acceptable salt thereof, wherein
[0457] Each n is independently an integer having a value from 1 to 9; and
[0458] Each X 2 are independently O or S.
[0459] In some embodiments of Formula (Id), each R 3 Independently C6-C 30 In some embodiments of Formula (Id), each R 3 Independently C6-C 20 Aliphatic group.
[0460] In an embodiment, the cationic lipid of formula (Id) has a structure according to formula (I-d'),
[0461]
[0462] or a pharmaceutically acceptable salt thereof
[0463] In some embodiments of Formula (I-d'), each R 3 Independently C6-C 30 In some embodiments of Formula (I-d'), each R 3 Independently C6-C 20 Aliphatic group.
[0464] In an embodiment, the cationic lipid has a structure according to Formula (Id) or (I-d'), wherein each X 2 For S.
[0465] In embodiments, the cationic lipid has a structure according to Formula (Id-1),
[0466]
[0467] or a pharmaceutically acceptable salt thereof.
[0468] In some embodiments of Formula (Id-1), each R 3 Independently C6-C 30 In some embodiments of Formula (Id-1), each R 3 Independently C6-C 20 Aliphatic group.
[0469] In an embodiment, the cationic lipid has a structure according to Formula (Id) or (I-d'), wherein each X 2 It is O.
[0470] In embodiments, the cationic lipid has a structure according to formula (Id-2),
[0471]
[0472] or a pharmaceutically acceptable salt thereof.
[0473] In some embodiments of Formula (Id-2), each R 3 Independently C6-C 30 In some embodiments of Formula (Id-2), each R 3 Independently C6-C 20 Aliphatic group.
[0474] In any of formulae (Id), (I-d'), (Id-1) and (Id-2), R 3 and (Id-2) are any permissible groups as described herein (e.g., as described for Formula (A'), Formula (A), or Formula (I)). 3 and R is any permissible group as described herein for Formula (A) or Formula (I).
[0475] In embodiments, the cationic lipid has a structure according to any one of Formulas (Id), (Id), (Id-1), and (Id-2), wherein each n is 3. In embodiments, each n is 1. In embodiments, each n is 2. In embodiments, each n is 4. In embodiments, each n is 5. In embodiments, each n is 6. In embodiments, each n is 7. In embodiments, each n is 8. In embodiments, each n is 9.
[0476] Compounds of formula (Ie)
[0477] In an embodiment, the cationic lipid of formula (I) has a structure according to formula (Ie),
[0478]
[0479] or a pharmaceutically acceptable salt thereof, wherein
[0480] Each n is independently an integer having a value from 2 to 10; and
[0481] Each X 2 are independently O or S.
[0482] In some embodiments of Formula (Ie), each R 3 Independently C6-C 30 In some embodiments of Formula (Ie), each R 3 Independently C6-C 20 Aliphatic group.
[0483] In an embodiment, the cationic lipid of formula (Ie) has a structure according to formula (I-e'),
[0484]
[0485] or a pharmaceutically acceptable salt thereof.
[0486] In some embodiments of Formula (I-e'), each R 3 Independently C6-C 30 In some embodiments of Formula (I-e'), each R 3 Independently C6-C 20 Aliphatic group.
[0487] In an embodiment, the cationic lipid has a structure according to Formula (Ie) or (I-e'), wherein each X 2 For S.
[0488] In embodiments, the cationic lipid has a structure according to Formula (Ie-1),
[0489]
[0490] or a pharmaceutically acceptable salt thereof.
[0491] In some embodiments of Formula (Ie-1), each R 3 Independently C6-C 30 In some embodiments of Formula (Ie-1), each R 3 Independently C6-C 20 Aliphatic group.
[0492] In an embodiment, the cationic lipid has a structure according to Formula (Ie) or (I-e'), wherein each X 2 It is O.
[0493] In embodiments, the cationic lipid has a structure according to Formula (Ie-2),
[0494]
[0495] or a pharmaceutically acceptable salt thereof.
[0496] In some embodiments of Formula (Ie-2), each R 3 Independently C6-C 30 In some embodiments of Formula (Ie-2), each R 3 Independently C6-C 20 Aliphatic group.
[0497] In any of formulae (Ie), (I-e'), (Ie-1) and (Ie-2), R 3 and (Ie-2) are any permissible groups as described herein (e.g., as described for Formula (A'), Formula (A), or Formula (I)). 3 and R is any permissible group as described herein for Formula (A) or Formula (I).
[0498] In embodiments, the cationic lipid has a structure according to any one of Formulas (Ie), (Ie), (Ie-1), and (Ie-2), wherein each n is 4. In embodiments, each n is 2. In embodiments, each n is 3. In embodiments, each n is 5. In embodiments, each n is 6. In embodiments, each n is 7. In embodiments, each n is 8. In embodiments, each n is 9. In embodiments, each n is 10.
[0499] Compounds of formula (If)
[0500] In embodiments, the cationic lipid has a structure according to Formula (If),
[0501]
[0502] or a pharmaceutically acceptable salt thereof, wherein
[0503] Each n is independently an integer having a value from 2 to 10.
[0504] In some embodiments of Formula (If), each R 3 Independently C6-C 30 In some embodiments of Formula (If), each R 3 Independently C6-C 20 Aliphatic group.
[0505] In embodiments, the cationic lipid has a structure according to formula (I-f'),
[0506]
[0507] or a pharmaceutically acceptable salt thereof.
[0508] In some embodiments of Formula (I-f'), each R 3 Independently C6-C 30 In some embodiments of Formula (I-f'), each R 3 Independently C6-C 20 Aliphatic group.
[0509] In formulas (If) and (I-f'), R 3 and (I-f') are any permissible groups as described herein (e.g., as described for Formula (A'), Formula (A), or Formula (I)). In some embodiments of Formulas (If) and (I-f'), R 3 and R is any permissible group as described herein for Formula (A) or Formula (I).
[0510] In embodiments, the cationic lipid has a structure according to Formula (If) or (If'), wherein each n is 3. In embodiments, each n is 2. In embodiments, each n is 4. In embodiments, each n is 5. In embodiments, each n is 6. In embodiments, each n is 7. In embodiments, each n is 8. In embodiments, each n is 9. In embodiments, each n is 10.
[0511] Compound of formula (II)
[0512] In an embodiment, the cationic lipid of formula (A) has a structure according to formula (II),
[0513]
[0514] or a pharmaceutically acceptable salt thereof, wherein
[0515] Each R 1 are independently H or a C1-C6 aliphatic group;
[0516] Each L 1 are independently ester, thioester, disulfide or anhydride groups;
[0517] Each L 2 Independently C2-C 10 aliphatic groups;
[0518] Each X 1 are independently H or OH; and
[0519] Each R 3 Independently C6-C 30 Aliphatic group.
[0520] In some embodiments of Formula (II), each R 3 Independently C6-C 20 In some embodiments of Formula (II), each R 3 Independently C8-C 20 Aliphatic group.
[0521] In an embodiment, the cationic lipid has a structure according to formula (II), wherein R 1 are independently H. In an embodiment, the cationic lipid has a structure according to formula (II), wherein R 1 is independently a C1-C6 aliphatic group (e.g., methyl). In an embodiment, the cationic lipid has a structure according to formula (II), wherein each R 1 In an embodiment, the cationic lipid has a structure according to formula (II), wherein each R 1 For H.
[0522] In an embodiment, the cationic lipid has a structure according to formula (II), wherein L 1 In an embodiment, the cationic lipid has a structure according to formula (II), wherein L 1 In an embodiment, the cationic lipid has a structure according to formula (II), wherein L 1 In an embodiment, the cationic lipid has a structure according to formula (II), wherein L 1In an embodiment, the cationic lipid has a structure according to formula (II), wherein each L 1 In an embodiment, each L 1 In an embodiment, the cationic lipid has a structure according to formula (II), wherein each L 1 In an embodiment, the cationic lipid has a structure according to formula (II), wherein each L 1 It is an anhydride group.
[0523] In an embodiment, the cationic lipid has a structure according to Formula (II), wherein each L 2 L is a C2 aliphatic group (e.g., a C2 alkylene group). In an embodiment, the cationic lipid has a structure according to formula (II), wherein each L 2 L is a C3 aliphatic group (e.g., a C3 alkylene group). In an embodiment, the cationic lipid has a structure according to formula (II), wherein each L 2 L is a C4 aliphatic group (e.g., a C4 alkylene group). In an embodiment, the cationic lipid has a structure according to formula (II), wherein each L 2 L is a C5 aliphatic group (e.g., a C5 alkylene group). In an embodiment, the cationic lipid has a structure according to formula (II), wherein each L 2 L is a C6 aliphatic group (e.g., a C6 alkylene group). In an embodiment, the cationic lipid has a structure according to formula (II), wherein each L 2 L is a C7 aliphatic group (e.g., a C7 alkylene group). In an embodiment, the cationic lipid has a structure according to formula (II), wherein each L 2 L is a C8 aliphatic group (e.g., C8 alkylene). In an embodiment, the cationic lipid has a structure according to formula (II), wherein each L 2 is a C9 aliphatic group (e.g., a C9 alkylene group). In an embodiment, each L 2 C 10 Aliphatic groups (e.g., C 10 alkylene).
[0524] In an embodiment, the cationic lipid has a structure according to Formula (II), wherein X 1 are independently H. In an embodiment, the cationic lipid has a structure according to formula (II), wherein X 1 In an embodiment, the cationic lipid has a structure according to formula (II), wherein each X 1 is H. In an embodiment, the cationic lipid has a structure according to formula (II), wherein each X 1 For OH.
[0525] In an embodiment, the cationic lipid has a structure according to Formula (II), wherein each R 3 is a C8 aliphatic group (e.g., a C8 alkyl group or a C8 alkenyl group). In an embodiment, the cationic lipid has a structure according to formula (II), wherein each R 3 is a C9 aliphatic group (e.g., a C9 alkyl group or a C9 alkenyl group). In an embodiment, the cationic lipid has a structure according to formula (II), wherein each R 3 C 10 Aliphatic groups (e.g., C 10 Alkyl or C 10 In an embodiment, the cationic lipid has a structure according to formula (II), wherein each R 3 C 11 Aliphatic groups (e.g., C 11 Alkyl or C 11 In an embodiment, the cationic lipid has a structure according to formula (II), wherein each R 3 C 12 Aliphatic groups (e.g., C 12 Alkyl or C 12 In an embodiment, the cationic lipid has a structure according to formula (II), wherein each R 3 C 13 Aliphatic groups (e.g., C 13 Alkyl or C 13 In an embodiment, the cationic lipid has a structure according to formula (II), wherein each R 3 C 14 Aliphatic groups (e.g., C 14 Alkyl or C 14 In an embodiment, the cationic lipid has a structure according to formula (II), wherein each R 3 C 15 Aliphatic groups (e.g., C 15 Alkyl or C 15 In an embodiment, the cationic lipid has a structure according to formula (II), wherein each R 3 C 16 Aliphatic groups (e.g., C 16 Alkyl or C 16 In an embodiment, the cationic lipid has a structure according to formula (II), wherein each R 3 C 17 Aliphatic groups (e.g., C 17 Alkyl or C 17 In an embodiment, the cationic lipid has a structure according to formula (II), wherein each R 3 C 18 Aliphatic groups (e.g., C18 Alkyl or C 18 In an embodiment, the cationic lipid has a structure according to formula (II), wherein each R 3 C 19 Aliphatic groups (e.g., C 19 Alkyl or C 19 In an embodiment, the cationic lipid has a structure according to formula (II), wherein each R 3 C 20 Aliphatic groups (e.g., C 20 Alkyl or C 20 In an embodiment, the cationic lipid has a structure according to formula (II), wherein R 3 Is unsubstituted.
[0526] In an embodiment of formula (II), each R 3 C 21 Aliphatic groups (e.g., C 21 Alkyl or C 21 In an embodiment, each R 3 C 22 Aliphatic groups (e.g., C 22 Alkyl or C 22 In an embodiment, each R 3 C 23 Aliphatic groups (e.g., C 23 Alkyl or C 23 In an embodiment, each R 3 C 24 Aliphatic groups (e.g., C 24 Alkyl or C 24 In an embodiment, each R 3 C 25 Aliphatic groups (e.g., C 25 Alkyl or C 25 In an embodiment, each R 3 C 26 Aliphatic groups (e.g., C 26 Alkyl or C 26 In an embodiment, each R 3 C 27 Aliphatic groups (e.g., C 27 Alkyl or C 27 In an embodiment, each R 3 C 28 Aliphatic groups (e.g., C 28 Alkyl or C 28 In an embodiment, each R 3 C 29 Aliphatic groups (e.g., C29 Alkyl or C 29 In an embodiment, each R 3 C 30 Aliphatic groups (e.g., C 30 Alkyl or C 30 alkenyl).
[0527] Compound of formula (II-a)
[0528] In an embodiment, the cationic lipid of formula (II) has a structure according to formula (II-a),
[0529]
[0530] or a pharmaceutically acceptable salt thereof, wherein each n is an integer having a value from 1 to 9.
[0531] In some embodiments of Formula (II-a), each R 3 Independently C6-C 30 In some embodiments of Formula (II-a), each R 3 Independently C6-C 20 In some embodiments of Formula (II-a), each R 3 Independently C8-C 20 Aliphatic group.
[0532] In an embodiment, the cationic lipid of formula (II-a) has a structure according to formula (II-a'),
[0533]
[0534] or a pharmaceutically acceptable salt thereof.
[0535] In some embodiments of Formula (II-a'), each R 3 Independently C6-C 30 In some embodiments of Formula (II-a'), each R 3 Independently C6-C 20 In some embodiments of Formula (II-a'), each R 3 Independently C8-C 20 Aliphatic group.
[0536] In formulas (II-a) and (II-a'), R 3 can be any permissible group as described herein for Formula (A'), Formula (A), or Formula (II). In some embodiments of Formulas (II-a) and (II-a'), R 3and R is any permissible group as described herein for Formula (A) or Formula (I).
[0537] In embodiments, the cationic lipid has a structure according to Formula (II-a) or (II-a), wherein each n is 2. In embodiments, each n is 1. In embodiments, each n is 3. In embodiments, each n is 4. In embodiments, each n is 5. In embodiments, each n is 6. In embodiments, each n is 7. In embodiments, each n is 8. In embodiments, each n is 9.
[0538] Compounds of formula (III) and (III')
[0539] In an embodiment, the cationic lipid of formula (A') has a structure according to formula (III),
[0540]
[0541] or a pharmaceutically acceptable salt thereof, wherein
[0542] Each R 1 and R 2 are independently H or a C1-C6 aliphatic group;
[0543] Each M is independently an integer having a value from 1 to 4;
[0544] Each A is independently a covalent bond or an arylene group;
[0545] Each L 1 are independently ester, thioester, disulfide or anhydride groups;
[0546] Each L 2 Independently C2-C 10 aliphatic groups;
[0547] Each R 3 Independently C6-C 30 Aliphatic group.
[0548] In some embodiments of Formula (III), each R 3 Independently C6-C 20 Aliphatic group.
[0549] In formula (III), each R 1 、R 2 ,m,A,L 1 , L 2 and R 3 and (I) may independently be any permissible groups listed according to any aspect or embodiment described herein (eg, as described for Formula (A'), (A), or (I)).
[0550] In an embodiment, each A is independently a covalent bond or a phenylene group.
[0551] In an embodiment, the cationic lipid of formula (III) has the structure,
[0552]
[0553] or a pharmaceutically acceptable salt thereof.
[0554] In some embodiments of Formula (III'), each R 3 Independently C6-C 30 In some embodiments of Formula (III'), each R 3 Independently C6-C 20 Aliphatic group.
[0555] In formula (III'), each R 1 、R 2 , m, L 1 , L 2 and R 3 and (III) may independently be any permissible groups listed according to any aspect or embodiment described herein (eg, as described for Formula (A'), (A), or (III)).
[0556] In the embodiments of formula (III) or (III'), each R 1 For H.
[0557] In the embodiments of formula (III) or (III'), each R 2 are independently H or C1-C6 alkyl.
[0558] In the embodiments of formula (III) or (III'), each L 2 Independently C2-C 10 Alkylene.
[0559] In the embodiments of formula (III) or (III'), each R 3 Independently C6-C 20 Alkyl, C6-C 20 Alkenyl or C6-C 20 In one embodiment, R 3 Contains a substituent that is -OC(O)R' or -C(O)-OR', wherein R' is C1-C 16 alkyl.
[0560] In an embodiment of formula (III) or (III'), each m is 1. In an embodiment, each m is 2. In an embodiment, each m is 3. In an embodiment, each m is 4.
[0561] Compound of formula (III-a)
[0562] In an embodiment, the cationic lipid of formula (III) has the following structure:
[0563] or a pharmaceutically acceptable salt thereof, wherein each n is independently an integer having a value from 1 to 9.
[0564] In some embodiments of Formula (III-a), each R 3 Independently C6-C 30 In some embodiments of Formula (III-a), each R 3 Independently C6-C 20 Aliphatic group.
[0565] In an embodiment, the cationic lipid of formula (III) or (III-a) has the following structure:
[0566] or a pharmaceutically acceptable salt thereof.
[0567] In some embodiments of Formula (III-a'), each R 3 Independently C6-C 30 In some embodiments of Formula (III-a'), each R 3 Independently C6-C 20 Aliphatic group.
[0568] In formula (III-a) or (III-a'), each R 3 and R and R are independently any permissible groups as described herein (eg, as described for Formula (A'), Formula (A), or Formula (III)).
[0569] In an embodiment of formula (III-a) or (III-a'), each n is 3. In an embodiment, each n is 1. In an embodiment, each n is 2. In an embodiment, each n is 4. In an embodiment, each n is 5. In an embodiment, each n is 6. In an embodiment, each n is 7. In an embodiment, each n is 8. In an embodiment, each n is 9.
[0570] Compound of formula (III-b)
[0571] In an embodiment, the cationic lipid of formula (III) has the following structure:
[0572] or a pharmaceutically acceptable salt thereof, wherein each n is an integer having a value from 1 to 9.
[0573] In some embodiments of Formula (III-b), each R 3 Independently C6-C 30 In some embodiments of Formula (III-b), each R 3 Independently C6-C 20 Aliphatic group.
[0574] In an embodiment, the cationic lipid of formula (III) or (III-b) has the following structure:
[0575] or a pharmaceutically acceptable salt thereof.
[0576] In some embodiments of Formula (III-b'), each R 3 Independently C6-C 30 In some embodiments of Formula (III-b'), each R 3 Independently C6-C 20 Aliphatic group.
[0577] In formula (III-b) or (III-b'), each R 3 and R and R are independently any permissible groups as described herein (eg, as described for Formula (A'), Formula (A), or Formula (III)).
[0578] In formula (III-b) or an embodiment of (III-b), each n is 2. In an embodiment, each n is 1. In an embodiment, each n is 3. In an embodiment, each n is 4. In an embodiment, each n is 5. In an embodiment, each n is 6. In an embodiment, each n is 7. In an embodiment, each n is 8. In an embodiment, each n is 9.
[0579] Compound of formula (III-c)
[0580] In an embodiment, the cationic lipid of formula (III) has the following structure:
[0581] or a pharmaceutically acceptable salt thereof, wherein each n is an integer having a value from 1 to 9; and each R 2 are independently H or CH3.
[0582] In some embodiments of Formula (III-c), each R 3 Independently C6-C 30 In some embodiments of Formula (III-c), each R 3 Independently C6-C 20 Aliphatic group.
[0583] In an embodiment, the cationic lipid of Formula (III) or Formula (III-c) has the following structure:
[0584]
[0585] or a pharmaceutically acceptable salt thereof.
[0586] In some embodiments of Formula (III-c'), each R 3 Independently C6-C 30 In some embodiments of Formula (III-c'), each R 3 Independently C6-C 20 Aliphatic group.
[0587] In the embodiments of formula (III-c) or formula (III-c'), each R 2 For H.
[0588] In an embodiment, the cationic lipid of Formula (III) or Formula (III-c) has the following structure:
[0589] or a pharmaceutically acceptable salt thereof.
[0590] In some embodiments of Formula (III-c-1), each R 3 Independently C6-C 30 In some embodiments of Formula (III-c-1), each R 3 Independently C6-C 20 Aliphatic group.
[0591] In embodiments, the cationic lipid of Formula (III), Formula (III-c), Formula (III-c') or Formula (III-c-1) has the following structure:
[0592] or a pharmaceutically acceptable salt thereof.
[0593] In some embodiments of Formula (III-c'-1), each R 3 Independently C6-C 30 In some embodiments of Formula (III-c'-1), each R 3 Independently C6-C 20 Aliphatic group.
[0594] In the embodiments of formula (III-c) or formula (III-c'), each R 2 For CH3.
[0595] In an embodiment, the cationic lipid of Formula (III) or Formula (III-c) has the following structure:
[0596] or a pharmaceutically acceptable salt thereof.
[0597] In some embodiments of Formula (III-c-2), each R 3 Independently C6-C 30 In some embodiments of Formula (III-c-2), each R 3 Independently C6-C 20 Aliphatic group.
[0598] In embodiments, the cationic lipid of Formula (III), Formula (III-c), Formula (III-c') or Formula (III-c-2) has the following structure:
[0599] or a pharmaceutically acceptable salt thereof.
[0600] In some embodiments of Formula (III-c'-2), each R 3 Independently C6-C 30 In some embodiments of Formula (III-c'-2), each R 3 Independently C6-C 20 Aliphatic group.
[0601] In embodiments, the cationic lipid has a structure according to Formula (III-c), (III-c'), (III-c-1), (III-c'-1), (III-c-2), or (III-c'-2), wherein each n is 1. In embodiments, the cationic lipid has a structure according to Formula (III-c), (III-c'), (III-c-1), (III-c'-1), (III-c-2), or (III-c'-2), wherein each n is 2. In embodiments, the cationic lipid has a structure according to Formula (III-c), (III-c'), (III-c-1), (III-c'-1), (III-c-2), or (III-c'-2), wherein each n is 3.
[0602] In formula (III-c), (III-c'), (III-c-1), (III-c'-1), (III-c-2) or (III-c'-2), each R 3 and R and R are independently any permissible groups as described herein (eg, as described for Formula (A'), Formula (A), or Formula (III)).
[0603] In embodiments of Formula (III-c), (III-c'), (III-c-1), (III-c'-1), (III-c-2), or (III-c'-2), each n is 1. In embodiments, each n is 2. In embodiments, each n is 3. In embodiments, each n is 4. In embodiments, each n is 5. In embodiments, each n is 6. In embodiments, each n is 7. In embodiments, each n is 8. In embodiments, each n is 9.
[0604] Compound of formula (III-d)
[0605] In an embodiment, the cationic lipid of formula (III) has the following structure:
[0606] or its medicine
[0607] a pharmaceutically acceptable salt, wherein each n is independently an integer having a value from 1 to 9; and
[0608] And each X 2 are independently O or S.
[0609] In some embodiments of Formula (III-d), each R 3 Independently C6-C 30 In some embodiments of Formula (III-d), each R 3 Independently C6-C 20 Aliphatic group.
[0610] In embodiments, the cationic lipid of Formula (III) or Formula (III-d) has the following structure:
[0611]
[0612] or a pharmaceutically acceptable salt thereof.
[0613] In some embodiments of Formula (III-d'), each R 3 Independently C6-C 30 In some embodiments of Formula (III-d'), each R 3 Independently C6-C 20 Aliphatic group.
[0614] In embodiments, the cationic lipid has a structure according to formula (III-d) or (III-d'), wherein each n is 1. In embodiments, the cationic lipid has a structure according to formula (III-d) or (III-d'), wherein each n is 2. In embodiments, the cationic lipid has a structure according to formula (III-d) or (III-d'), wherein each n is 3. In embodiments, n is 4. In embodiments, n is 5. In embodiments, n is 6. In embodiments, n is 7. In embodiments, n is 8. In embodiments, n is 9.
[0615] In the embodiments of Formula (III-d) or Formula (III-d'), each X 2 For S.
[0616] In embodiments, the cationic lipid of Formula (III) or Formula (III-d) has the following structure:
[0617] or a pharmaceutically acceptable salt thereof.
[0618] In some embodiments of Formula (III-d-1), each R 3 Independently C6-C 30 In some embodiments of Formula (III-d-1), each R 3 Independently C6-C 20 Aliphatic group.
[0619] In the embodiments of Formula (III-d) or Formula (III-d'), each X 2 It is O.
[0620] In embodiments, the cationic lipid of Formula (III) or Formula (III-d) has the following structure:
[0621] or a pharmaceutically acceptable salt thereof.
[0622] In some embodiments of Formula (III-d-2), each R 3 Independently C6-C 30 In some embodiments of Formula (III-d-2), each R 3 Independently C6-C 20 Aliphatic group.
[0623] In formula (III-d), (III-d'), (III-d-1) or (III-d-2), each R 3 and R and R are independently any permissible groups as described herein (eg, as described for Formula (A'), Formula (A), or Formula (III)).
[0624] In embodiments of Formula (III-d), (III-d'), (III-d-1), or (III-d-2), each n is 1. In embodiments, each n is 2. In embodiments, each n is 3. In embodiments, each n is 4. In embodiments, each n is 5. In embodiments, each n is 6. In embodiments, each n is 7. In embodiments, each n is 8. In embodiments, each n is 9.
[0625] Compound of formula (III-e)
[0626] In an embodiment, the cationic lipid of formula (III) has the following structure:
[0627] or a pharmaceutically acceptable salt thereof, wherein each n is independently an integer having a value from 2 to 10; and each X 2 are independently O or S.
[0628] In some embodiments of Formula (III-e), each R 3 Independently C6-C 30 In some embodiments of Formula (III-e), each R 3 Independently C6-C 20 Aliphatic group.
[0629] In embodiments, the cationic lipid of Formula (III) or Formula (III-e) has the following structure:
[0630] or a pharmaceutically acceptable salt thereof.
[0631] In some embodiments of Formula (III-e'), each R 3 Independently C6-C 30 In some embodiments of Formula (III-e'), each R 3 Independently C6-C 20 Aliphatic group
[0632] In an embodiment of Formula (III-e) or Formula (III-e'), each n is 2. In an embodiment, each n is 3. In an embodiment, each n is 4. In an embodiment, each n is 5. In an embodiment, each n is 6. In an embodiment, each n is 7. In an embodiment, each n is 8. In an embodiment, each n is 9. In an embodiment, each n is 10.
[0633] In the embodiments of Formula (III-e) or Formula (III-e'), each X 2 For S.
[0634] In embodiments, the cationic lipid of Formula (III) or Formula (III-e) has the following structure:
[0635] or a pharmaceutically acceptable salt thereof.
[0636] In some embodiments of Formula (III-e-1), each R 3 Independently C6-C 30 In some embodiments of Formula (III-e-1), each R 3 Independently C6-C 20 Aliphatic group.
[0637] In the embodiments of Formula (III-e) or Formula (III-e'), each X 2 It is O.
[0638] In embodiments, the cationic lipid of Formula (III) or Formula (III-e) has the following structure:
[0639] or a pharmaceutically acceptable salt thereof.
[0640] In some embodiments of Formula (III-e-2), each R 3 Independently C6-C 30 In some embodiments of Formula (III-e-2), each R 3 Independently C6-C 20 Aliphatic group.
[0641] In formula (III-e), (III-e'), (III-e-1) or (III-e-2), each R 3 and R and R are independently any permissible groups as described herein (eg, as described for Formula (A'), Formula (A), or Formula (III)).
[0642] In embodiments of Formula (III-e), (III-e'), (III-e-1), or (III-e-2), each n is 2. In embodiments, each n is 3. In embodiments, each n is 4. In embodiments, each n is 5. In embodiments, each n is 6. In embodiments, each n is 7. In embodiments, each n is 8. In embodiments, each n is 9. In embodiments, each n is 10.
[0643] Compound of formula (III-f)
[0644] In an embodiment, the cationic lipid of formula (III) has the following structure:
[0645] or a pharmaceutically acceptable salt thereof, wherein each n is independently an integer having a value from 2 to 10.
[0646] In some embodiments of Formula (III-f), each R 3 Independently C6-C 30 In some embodiments of Formula (III-f), each R 3 Independently C6-C 20 Aliphatic group.
[0647] In an embodiment, the cationic lipid of Formula (III) or Formula (III-f) has the following structure:
[0648] or a pharmaceutically acceptable salt thereof.
[0649] In some embodiments of Formula (III-f'), each R 3 Independently C6-C 30 In some embodiments of Formula (III-f'), each R 3 Independently C6-C 20 Aliphatic group.
[0650] In an embodiment, each n is 2. In an embodiment, each n is 3. In an embodiment, each n is 4.
[0651] In formula (III-f) or (III-f'), each R 3 and R and R are independently any permissible groups as described herein (eg, as described for Formula (A'), Formula (A), or Formula (III)).
[0652] In an embodiment of formula (III-f) or (III-f'), each n is 3. In an embodiment, each n is 2. In an embodiment, each n is 4. In an embodiment, each n is 5. In an embodiment, each n is 6. In an embodiment, each n is 7. In an embodiment, each n is 8. In an embodiment, each n is 9. In an embodiment, each n is 10.
[0653] Compound of formula (IV)
[0654] In an embodiment, the cationic lipid of formula (A') has the following structure:
[0655]
[0656] or a pharmaceutically acceptable salt thereof, wherein
[0657] Each R 1are independently H or a C1-C6 aliphatic group;
[0658] Each L 1 are independently ester, thioester, disulfide or anhydride groups;
[0659] Each L 2 Independently C2-C 10 aliphatic groups;
[0660] Each R 3 Independently C6-C 30 Aliphatic group.
[0661] In some embodiments of Formula (IV), each R 3 Independently C6-C 20 In some embodiments of Formula (IV), each R 3 Independently C8-C 20 Aliphatic group.
[0662] In formula (IV), each R 1 , L 1 , L 2 and R 3 and (I) may independently be any permissible groups listed according to any aspect or embodiment described herein (eg, as described for Formula (A'), (A), or (I)).
[0663] In an embodiment of formula (IV), each R 1 are independently H or C1-C6 alkyl. In the embodiment of formula (IV), each R 1 For H.
[0664] Compound of formula (IV-a)
[0665] In an embodiment, the cationic lipid of formula (IV) has the following structure:
[0666] or a pharmaceutically acceptable salt thereof, wherein each n is an integer having a value from 1 to 9.
[0667] In some embodiments of Formula (IV-a), each R 3 Independently C6-C 30 In some embodiments of Formula (IV-a), each R 3 Independently C6-C 20 In some embodiments of Formula (IV-a), each R 3 Independently C8-C 20 Aliphatic group.
[0668] In embodiments, the cationic lipid of Formula (IV) or Formula (IV-a) has the following structure:
[0669] or a pharmaceutically acceptable salt thereof.
[0670] In some embodiments of Formula (IV-a'), each R 3 Independently C6-C 30 In some embodiments of Formula (IV-a'), each R 3 Independently C6-C 20 In some embodiments of Formula (IV-a'), each R 3 Independently C8-C 20 Aliphatic group.
[0671] In an embodiment, each n is 2.
[0672] In formula (IV-a) or (IV-a'), each R 3 and R and R are independently any permissible groups as described herein (eg, as described for Formula (A'), Formula (A), or Formula (III)).
[0673] In an embodiment of formula (IV-a) or (IV-a'), each n is 2. In an embodiment, each n is 1. In an embodiment, each n is 3. In an embodiment, each n is 4. In an embodiment, each n is 5. In an embodiment, each n is 6. In an embodiment, each n is 7. In an embodiment, each n is 8. In an embodiment, each n is 9.
[0674] In any of the formulas described herein (e.g., Formula (A'), (A), (I), (Ia), (I-a'), (Ib), (I-b'), (Ic), (I-c'), (Ic-1), (I-c'-1), (Ic-2), (I-c'-2), (Id), (I-d'), (Id-1), (Id-2), (Ie), (I-e'), (Ie-1), (Ie-2), (If), (I-f'), (II), (II-a), (II-a'), (III), (III'), (III-a), (III-a'), (III- In one embodiment of any of (III-a), (III-b), (III-b'), (III-c), (III-c-1), (III-c'-1), (III-c-2), (III-c'-2), (III-c'), (III-d), (III-d'), (III-d-1), (III-d-2), (III-e), (III-e'), (III-e-1), (III-e-2), (III-f), (III-f'), (IV), (IV-a), or (IV-a'), the cationic lipid has a structure according to: 3 For unsubstituted C6-C 20 Alkyl groups (e.g., each R 3 C6H 13 、C8H 17 、C 10 H 21 、C 12 H 25 、C 14 H 29 、C 16 H 33 or C 18 H 37 ). In an embodiment, each R 3 For unsubstituted C8-C 20 In an embodiment, each R 3 C6H 13 In an embodiment, each R 3 C8H 17 In an embodiment, each R 3 C 10 H 21 In an embodiment, each R 3 C 12 H 25 In an embodiment, each R 3 C 14 H 29 In an embodiment, each R 3 C 16H 33 In an embodiment, each R 3 C 18 H 37 .
[0675] In any of the formulas described herein (e.g., Formula (A'), (A), (I), (Ia), (I-a'), (Ib), (I-b'), (Ic), (I-c'), (Ic-1), (I-c'-1), (Ic-2), (I-c'-2), (Id), (I-d'), (Id-1), (Id-2), (Ie), (I-e'), (Ie-1), (Ie-2), (If), (I-f'), (II), (II-a), (II-a'), (III), (III'), (III-a), (III- a'), (III-b), (III-b'), (III-c), (III-c-1), (III-c'-1), (III-c-2), (III-c'-2), (III-c'), (III-d), (III-d'), (III-d-1), (III-d-2), (III-e), (III-e'), (III-e-1), (III-e-2), (III-f), (III-f'), (IV), (IV-a), or (IV-a'), each R 3 For the replacement of C6-C 20 In an embodiment, R 3 Contains a substituent that is -OC(O)R' or -C(O)-OR', wherein R' is C1-C 16 In an embodiment, R 3 -OC(O)C7H 15 or -C(O)-O-(CH2)2CH(C5H 11 )2 substituted C6-C 10 In an embodiment, R 3 is a C6 alkyl substituted by -OC(O)R' or -C(O)-OR', wherein R' is an unsubstituted straight or branched C5-C 16 Alkyl groups, such as -OC(O)C7H 15 or -C(O)-O-(CH2)2CH(C5H 11 )2). In an embodiment, R 3 is a C7 alkyl substituted by -OC(O)R' or -C(O)-OR', wherein R' is an unsubstituted straight or branched C5-C 16 Alkyl groups, such as -OC(O)C7H 15or -C(O)-O-(CH2)2CH(C5H 11 )2). In an embodiment, R 3 is a C8 alkyl substituted by -OC(O)R' or -C(O)-OR', wherein R' is an unsubstituted straight or branched C5-C 16 Alkyl groups, such as -OC(O)C7H 15 or -C(O)-O-(CH2)2CH(C5H 11 )2). In an embodiment, R 3 is a C9 alkyl substituted by -OC(O)R' or -C(O)-OR', wherein R' is an unsubstituted straight or branched C5-C 16 Alkyl groups, such as -OC(O)C7H 15 or -C(O)-O-(CH2)2CH(C5H 11 )2). In an embodiment, R 3 C is substituted by -OC(O)R' or -C(O)-OR' 10 Alkyl, wherein R' is an unsubstituted straight or branched C5-C 16 Alkyl groups, such as -OC(O)C7H 15 or -C(O)-O-(CH2)2CH(C5H 11 )2). In an embodiment, each R 3 -(CH2)9-OC(O)C7H 15 or -(CH2)8C(O)-O-(CH2)2CH(C5H 11 )2.
[0676] In any of the formulas described herein (e.g., Formula (A'), (A), (I), (Ia), (I-a'), (Ib), (I-b'), (Ic), (I-c'), (Ic-1), (I-c'-1), (Ic-2), (I-c'-2), (Id), (I-d'), (Id-1), (Id-2), (Ie), (I-e'), (Ie-1), (Ie-2), (If), (I-f'), (II), (II-a), (II-a'), (III), (III'), (III-a), (III- a'), (III-b), (III-b'), (III-c), (III-c-1), (III-c'-1), (III-c-2), (III-c'-2), (III-c'), (III-d), (III-d'), (III-d-1), (III-d-2), (III-e), (III-e'), (III-e-1), (III-e-2), (III-f), (III-f'), (IV), (IV-a), or (IV-a'), each R 3 For unsubstituted C6-C 20 Alkenyl (e.g., each R 3 C 16 H 31 or C 16 H 29 ). In an embodiment, each R 3 For unsubstituted C8-C 20 In an embodiment, each R 3 For unsubstituted C 10 -C 20 In an embodiment, each R 3 is an unsubstituted monoalkenyl, an unsubstituted dienyl, or an unsubstituted trialkenyl. 3 For unsubstituted C6-C 20 In an embodiment, each R 3 For unsubstituted C6-C 20 In an embodiment, each R 3 For unsubstituted C6-C 20 In an embodiment, each R 3 -(CH2) o R', wherein o is 6, 7, 8, 9 or 10, and R' is In an embodiment, o is 6. In an embodiment, o is 7. In an embodiment, o is 8. In an embodiment, o is 9. In an embodiment, o is 10. In an embodiment, R' is In an embodiment, R' is In an embodiment, R' is In an embodiment, each R 3 C 16 H 31 In an embodiment, each R 3 C 16 H 29 .
[0677] In any of the formulas described herein (e.g., Formula (A'), (A), (I), (Ia), (I-a'), (Ib), (I-b'), (Ic), (I-c'), (Ic-1), (I-c'-1), (Ic-2), (I-c'-2), (Id), (I-d'), (Id-1), (Id-2), (Ie), (I-e'), (Ie-1), (Ie-2), (If), (I-f'), (II), (II-a), (II-a'), (III), (III'), (III-a), (III- a'), (III-b), (III-b'), (III-c), (III-c-1), (III-c'-1), (III-c-2), (III-c'-2), (III-c'), (III-d), (III-d'), (III-d-1), (III-d-2), (III-e), (III-e'), (III-e-1), (III-e-2), (III-f), (III-f'), (IV), (IV-a), or (IV-a'), each R 3 For unsubstituted C6-C 20 In an embodiment, each R 3 For unsubstituted C8-C 20 In an embodiment, each R 3 For unsubstituted C 10 -C 20 Alkynyl.
[0678] In any of the formulas described herein (e.g., Formula (A'), (A), (I), (Ia), (I-a'), (Ib), (I-b'), (Ic), (I-c'), (Ic-1), (I-c'-1), (Ic-2), (I-c'-2), (Id), (I-d'), (Id-1), (Id-2), (Ie), (I-e'), (Ie-1), (Ie-2), (If), (I-f'), (II), (II-a), (II-a'), (III), (III'), (III-a), (III- a'), (III-b), (III-b'), (III-c), (III-c-1), (III-c'-1), (III-c-2), (III-c'-2), (III-c'), (III-d), (III-d'), (III-d-1), (III-d-2), (III-e), (III-e'), (III-e-1), (III-e-2), (III-f), (III-f'), (IV), (IV-a), or (IV-a'), each R 3 For unsubstituted C6-C 30 In an embodiment, each R 3 For unsubstituted C8-C 30 In an embodiment, each R 3 For unsubstituted C 10 -C 30 Alkynyl.
[0679] Exemplary compounds of the present invention
[0680] Exemplary compounds include any of those described in Tables AP.
[0681] In these tables, substructure a = -(CH2)9-OC(O)-C7H 15 , and substructure b=-(CH2)8-C(O)-O-CH2CH2CH(C5H 11 )2.
[0682] Table A. cDD Thioesters
[0683]
[0684]
[0685]
[0686]
[0687]
[0688]
[0689] In embodiments, the cationic lipid is compound 1. In embodiments, the cationic lipid is compound 2. In embodiments, the cationic lipid is compound 3. In embodiments, the cationic lipid is compound 4. In embodiments, the cationic lipid is compound 5. In embodiments, the cationic lipid is compound 6. In embodiments, the cationic lipid is compound 7. In embodiments, the cationic lipid is compound 8. In embodiments, the cationic lipid is compound 9. In embodiments, the cationic lipid is compound 10. In embodiments, the cationic lipid is compound 11. In embodiments, the cationic lipid is compound 12. In embodiments, the cationic lipid is compound 13. In embodiments, the cationic lipid is compound 14. In embodiments, the cationic lipid is compound 15. In embodiments, the cationic lipid is compound 16. In embodiments, the cationic lipid is compound 17. In embodiments, the cationic lipid is compound 18. In embodiments, the cationic lipid is compound 19. In embodiments, the cationic lipid is compound 20. In embodiments, the cationic lipid is compound 21. In embodiments, the cationic lipid is compound 22. In embodiments, the cationic lipid is compound 23. In embodiments, the cationic lipid is compound 24. In embodiments, the cationic lipid is compound 25. In an embodiment, the cationic lipid is compound 26. In an embodiment, the cationic lipid is compound 27. In an embodiment, the cationic lipid is compound 28. In an embodiment, the cationic lipid is compound 29. In an embodiment, the cationic lipid is compound 30.
[0690] Table B. cDD Esters
[0691]
[0692]
[0693]
[0694]
[0695]
[0696]
[0697] In embodiments, the cationic lipid is compound 31. In embodiments, the cationic lipid is compound 32. In embodiments, the cationic lipid is compound 33. In embodiments, the cationic lipid is compound 34. In embodiments, the cationic lipid is compound 35. In embodiments, the cationic lipid is compound 36. In embodiments, the cationic lipid is compound 37. In embodiments, the cationic lipid is compound 38. In embodiments, the cationic lipid is compound 39. In embodiments, the cationic lipid is compound 40. In embodiments, the cationic lipid is compound 41. In embodiments, the cationic lipid is compound 42. In embodiments, the cationic lipid is compound 43. In embodiments, the cationic lipid is compound 44. In embodiments, the cationic lipid is compound 45. In embodiments, the cationic lipid is compound 46. In embodiments, the cationic lipid is compound 47. In embodiments, the cationic lipid is compound 48. In embodiments, the cationic lipid is compound 49. In embodiments, the cationic lipid is compound 50. In embodiments, the cationic lipid is compound 51. In embodiments, the cationic lipid is compound 52. In embodiments, the cationic lipid is compound 53. In embodiments, the cationic lipid is compound 54. In an embodiment, the cationic lipid is compound 55. In an embodiment, the cationic lipid is compound 56. In an embodiment, the cationic lipid is compound 57. In an embodiment, the cationic lipid is compound 58. In an embodiment, the cationic lipid is compound 59. In an embodiment, the cationic lipid is compound 60.
[0698] Table C.cEE Thioesters
[0699]
[0700]
[0701]
[0702]
[0703]
[0704]
[0705]
[0706]
[0707] In embodiments, the cationic lipid is compound 61. In embodiments, the cationic lipid is compound 62. In embodiments, the cationic lipid is compound 63. In embodiments, the cationic lipid is compound 64. In embodiments, the cationic lipid is compound 65. In embodiments, the cationic lipid is compound 66. In embodiments, the cationic lipid is compound 67. In embodiments, the cationic lipid is compound 68. In embodiments, the cationic lipid is compound 69. In embodiments, the cationic lipid is compound 70. In embodiments, the cationic lipid is compound 71. In embodiments, the cationic lipid is compound 72. In embodiments, the cationic lipid is compound 73. In embodiments, the cationic lipid is compound 74. In embodiments, the cationic lipid is compound 75. In embodiments, the cationic lipid is compound 76. In embodiments, the cationic lipid is compound 77. In embodiments, the cationic lipid is compound 78. In embodiments, the cationic lipid is compound 79. In embodiments, the cationic lipid is compound 80. In embodiments, the cationic lipid is compound 81. In embodiments, the cationic lipid is compound 82. In embodiments, the cationic lipid is compound 83. In embodiments, the cationic lipid is compound 84. In an embodiment, the cationic lipid is compound 85. In an embodiment, the cationic lipid is compound 86. In an embodiment, the cationic lipid is compound 87. In an embodiment, the cationic lipid is compound 88. In an embodiment, the cationic lipid is compound 89. In an embodiment, the cationic lipid is compound 90.
[0708] Table D. cEE Esters
[0709]
[0710]
[0711]
[0712]
[0713]
[0714]
[0715]
[0716]
[0717] In embodiments, the cationic lipid is Compound 91. In embodiments, the cationic lipid is Compound 92. In embodiments, the cationic lipid is Compound 93. In embodiments, the cationic lipid is Compound 94. In embodiments, the cationic lipid is Compound 95. In embodiments, the cationic lipid is Compound 96. In embodiments, the cationic lipid is Compound 97. In embodiments, the cationic lipid is Compound 98. In embodiments, the cationic lipid is Compound 99. In embodiments, the cationic lipid is Compound 100. In embodiments, the cationic lipid is Compound 101. In embodiments, the cationic lipid is Compound 102. In embodiments, the cationic lipid is Compound 103. In embodiments, the cationic lipid is Compound 104. In embodiments, the cationic lipid is Compound 105. In embodiments, the cationic lipid is Compound 106. In embodiments, the cationic lipid is Compound 107. In embodiments, the cationic lipid is Compound 108. In embodiments, the cationic lipid is Compound 109. In embodiments, the cationic lipid is Compound 110. In embodiments, the cationic lipid is Compound 111. In embodiments, the cationic lipid is Compound 112. In embodiments, the cationic lipid is Compound 113. In an embodiment, the cationic lipid is Compound 114. In an embodiment, the cationic lipid is Compound 115. In an embodiment, the cationic lipid is Compound 116. In an embodiment, the cationic lipid is Compound 117. In an embodiment, the cationic lipid is Compound 118. In an embodiment, the cationic lipid is Compound 119. In an embodiment, the cationic lipid is Compound 120.
[0718] Table E. Homoserine (cHse) lipids
[0719]
[0720]
[0721]
[0722]
[0723]
[0724]
[0725]
[0726] In embodiments, the cationic lipid is compound 121. In embodiments, the cationic lipid is compound 122. In embodiments, the cationic lipid is compound 123. In embodiments, the cationic lipid is compound 124. In embodiments, the cationic lipid is compound 125. In embodiments, the cationic lipid is compound 126. In embodiments, the cationic lipid is compound 127. In embodiments, the cationic lipid is compound 128. In embodiments, the cationic lipid is compound 129. In embodiments, the cationic lipid is compound 130. In embodiments, the cationic lipid is compound 131. In embodiments, the cationic lipid is compound 132. In embodiments, the cationic lipid is compound 133. In embodiments, the cationic lipid is compound 134. In embodiments, the cationic lipid is compound 135. In embodiments, the cationic lipid is compound 136. In embodiments, the cationic lipid is compound 137. In embodiments, the cationic lipid is compound 138. In embodiments, the cationic lipid is compound 139. In embodiments, the cationic lipid is compound 140. In embodiments, the cationic lipid is compound 141. In embodiments, the cationic lipid is compound 142. In an embodiment, the cationic lipid is Compound 143. In an embodiment, the cationic lipid is Compound 144. In an embodiment, the cationic lipid is Compound 145. In an embodiment, the cationic lipid is Compound 146. In an embodiment, the cationic lipid is Compound 147. In an embodiment, the cationic lipid is Compound 148. In an embodiment, the cationic lipid is Compound 149. In an embodiment, the cationic lipid is Compound 150.
[0727] Table F. cCC disulfides
[0728]
[0729]
[0730]
[0731]
[0732]
[0733] In embodiments, the cationic lipid is Compound 151. In embodiments, the cationic lipid is Compound 152. In embodiments, the cationic lipid is Compound 153. In embodiments, the cationic lipid is Compound 154. In embodiments, the cationic lipid is Compound 155. In embodiments, the cationic lipid is Compound 156. In embodiments, the cationic lipid is Compound 157. In embodiments, the cationic lipid is Compound 158. In embodiments, the cationic lipid is Compound 159. In embodiments, the cationic lipid is Compound 160. In embodiments, the cationic lipid is Compound 161. In embodiments, the cationic lipid is Compound 162. In embodiments, the cationic lipid is Compound 163. In embodiments, the cationic lipid is Compound 164. In embodiments, the cationic lipid is Compound 165. In embodiments, the cationic lipid is Compound 166. In embodiments, the cationic lipid is Compound 167. In embodiments, the cationic lipid is Compound 168. In embodiments, the cationic lipid is Compound 169. In embodiments, the cationic lipid is Compound 170. In embodiments, the cationic lipid is Compound 171. In embodiments, the cationic lipid is Compound 172. In an embodiment, the cationic lipid is Compound 173. In an embodiment, the cationic lipid is Compound 174. In an embodiment, the cationic lipid is Compound 175. In an embodiment, the cationic lipid is Compound 176. In an embodiment, the cationic lipid is Compound 177. In an embodiment, the cationic lipid is Compound 178. In an embodiment, the cationic lipid is Compound 179. In an embodiment, the cationic lipid is Compound 180.
[0734] Table G. cCC Thioesters
[0735]
[0736]
[0737]
[0738]
[0739]
[0740]
[0741] In embodiments, the cationic lipid is compound 181. In embodiments, the cationic lipid is compound 182. In embodiments, the cationic lipid is compound 183. In embodiments, the cationic lipid is compound 184. In embodiments, the cationic lipid is compound 185. In embodiments, the cationic lipid is compound 186. In embodiments, the cationic lipid is compound 187. In embodiments, the cationic lipid is compound 188. In embodiments, the cationic lipid is compound 189. In embodiments, the cationic lipid is compound 190. In embodiments, the cationic lipid is compound 191. In embodiments, the cationic lipid is compound 192. In embodiments, the cationic lipid is compound 193. In embodiments, the cationic lipid is compound 194. In embodiments, the cationic lipid is compound 195. In embodiments, the cationic lipid is compound 196. In embodiments, the cationic lipid is compound 197. In embodiments, the cationic lipid is compound 198. In embodiments, the cationic lipid is compound 199. In embodiments, the cationic lipid is compound 200. In embodiments, the cationic lipid is compound 201. In embodiments, the cationic lipid is compound 202. In an embodiment, the cationic lipid is Compound 203. In an embodiment, the cationic lipid is Compound 204. In an embodiment, the cationic lipid is Compound 205. In an embodiment, the cationic lipid is Compound 206. In an embodiment, the cationic lipid is Compound 207. In an embodiment, the cationic lipid is Compound 208. In an embodiment, the cationic lipid is Compound 209. In an embodiment, the cationic lipid is Compound 210.
[0742] Table H. cSS esters
[0743]
[0744]
[0745]
[0746]
[0747]
[0748]
[0749] In embodiments, the cationic lipid is Compound 211. In embodiments, the cationic lipid is Compound 212. In embodiments, the cationic lipid is Compound 213. In embodiments, the cationic lipid is Compound 214. In embodiments, the cationic lipid is Compound 215. In embodiments, the cationic lipid is Compound 216. In embodiments, the cationic lipid is Compound 217. In embodiments, the cationic lipid is Compound 218. In embodiments, the cationic lipid is Compound 219. In embodiments, the cationic lipid is Compound 220. In embodiments, the cationic lipid is Compound 221. In embodiments, the cationic lipid is Compound 222. In embodiments, the cationic lipid is Compound 223. In embodiments, the cationic lipid is Compound 224. In embodiments, the cationic lipid is Compound 225. In embodiments, the cationic lipid is Compound 226. In embodiments, the cationic lipid is Compound 227. In embodiments, the cationic lipid is Compound 228. In embodiments, the cationic lipid is Compound 229. In embodiments, the cationic lipid is Compound 230. In embodiments, the cationic lipid is Compound 231. In embodiments, the cationic lipid is Compound 232. In an embodiment, the cationic lipid is Compound 233. In an embodiment, the cationic lipid is Compound 234. In an embodiment, the cationic lipid is Compound 235. In an embodiment, the cationic lipid is Compound 236. In an embodiment, the cationic lipid is Compound 237. In an embodiment, the cationic lipid is Compound 238. In an embodiment, the cationic lipid is Compound 239. In an embodiment, the cationic lipid is Compound 240.
[0750] Table I. cDD Thioesters - Biodegradable
[0751]
[0752]
[0753]
[0754]
[0755]
[0756]
[0757]
[0758]
[0759]
[0760] In embodiments, the cationic lipid is Compound 241. In embodiments, the cationic lipid is Compound 242. In embodiments, the cationic lipid is Compound 243. In embodiments, the cationic lipid is Compound 244. In embodiments, the cationic lipid is Compound 245. In embodiments, the cationic lipid is Compound 246. In embodiments, the cationic lipid is Compound 247. In embodiments, the cationic lipid is Compound 248. In embodiments, the cationic lipid is Compound 249. In embodiments, the cationic lipid is Compound 250. In embodiments, the cationic lipid is Compound 251. In embodiments, the cationic lipid is Compound 252. In embodiments, the cationic lipid is Compound 253. In embodiments, the cationic lipid is Compound 254. In embodiments, the cationic lipid is Compound 255. In embodiments, the cationic lipid is Compound 256. In embodiments, the cationic lipid is Compound 257. In embodiments, the cationic lipid is Compound 258. In embodiments, the cationic lipid is Compound 259. In embodiments, the cationic lipid is Compound 260. In embodiments, the cationic lipid is Compound 261. In embodiments, the cationic lipid is Compound 262. In an embodiment, the cationic lipid is compound 263. In an embodiment, the cationic lipid is compound 264. In an embodiment, the cationic lipid is compound 265. In an embodiment, the cationic lipid is compound 266. In an embodiment, the cationic lipid is compound 267. In an embodiment, the cationic lipid is compound 268. In an embodiment, the cationic lipid is compound 269. In an embodiment, the cationic lipid is compound 270. In an embodiment, the cationic lipid is compound 271. In an embodiment, the cationic lipid is compound 272. In an embodiment, the cationic lipid is compound 273. In an embodiment, the cationic lipid is compound 274. In an embodiment, the cationic lipid is compound 275. In an embodiment, the cationic lipid is compound 276. In an embodiment, the cationic lipid is compound 277. In an embodiment, the cationic lipid is compound 278. In an embodiment, the cationic lipid is compound 279.
[0761] Table J. cDD Esters - Biodegradable
[0762]
[0763]
[0764]
[0765]
[0766]
[0767]
[0768]
[0769]
[0770]
[0771]
[0772] In embodiments, the cationic lipid is compound 280. In embodiments, the cationic lipid is compound 281. In embodiments, the cationic lipid is compound 282. In embodiments, the cationic lipid is compound 283. In embodiments, the cationic lipid is compound 284. In embodiments, the cationic lipid is compound 285. In embodiments, the cationic lipid is compound 286. In embodiments, the cationic lipid is compound 287. In embodiments, the cationic lipid is compound 288. In embodiments, the cationic lipid is compound 289. In embodiments, the cationic lipid is compound 290. In embodiments, the cationic lipid is compound 291. In embodiments, the cationic lipid is compound 292. In embodiments, the cationic lipid is compound 293. In embodiments, the cationic lipid is compound 294. In embodiments, the cationic lipid is compound 295. In embodiments, the cationic lipid is compound 296. In embodiments, the cationic lipid is compound 297. In embodiments, the cationic lipid is compound 298. In embodiments, the cationic lipid is compound 299. In embodiments, the cationic lipid is compound 300. In embodiments, the cationic lipid is compound 301. In embodiments, the cationic lipid is compound 302. In embodiments, the cationic lipid is compound 303. In embodiments, the cationic lipid is compound 304. In embodiments, the cationic lipid is compound 305. In embodiments, the cationic lipid is compound 306. In embodiments, the cationic lipid is compound 307. In embodiments, the cationic lipid is compound 308. In embodiments, the cationic lipid is compound 309. In embodiments, the cationic lipid is compound 310. In embodiments, the cationic lipid is compound 311. In embodiments, the cationic lipid is compound 312. In embodiments, the cationic lipid is compound 313. In embodiments, the cationic lipid is compound 314. In embodiments, the cationic lipid is compound 315. In embodiments, the cationic lipid is compound 316. In embodiments, the cationic lipid is compound 317. In embodiments, the cationic lipid is compound 318.
[0773] Table K.cEE Thioesters - Biodegradable
[0774]
[0775]
[0776]
[0777]
[0778]
[0779]
[0780]
[0781]
[0782]
[0783] In embodiments, the cationic lipid is compound 319. In embodiments, the cationic lipid is compound 320. In embodiments, the cationic lipid is compound 321. In embodiments, the cationic lipid is compound 322. In embodiments, the cationic lipid is compound 323. In embodiments, the cationic lipid is compound 324. In embodiments, the cationic lipid is compound 325. In embodiments, the cationic lipid is compound 326. In embodiments, the cationic lipid is compound 327. In embodiments, the cationic lipid is compound 328. In embodiments, the cationic lipid is compound 329. In embodiments, the cationic lipid is compound 330. In embodiments, the cationic lipid is compound 331. In embodiments, the cationic lipid is compound 332. In embodiments, the cationic lipid is compound 333. In embodiments, the cationic lipid is compound 334. In embodiments, the cationic lipid is compound 335. In embodiments, the cationic lipid is compound 336. In embodiments, the cationic lipid is compound 337. In embodiments, the cationic lipid is compound 338. In embodiments, the cationic lipid is compound 339. In embodiments, the cationic lipid is compound 340. In an embodiment, the cationic lipid is compound 341. In an embodiment, the cationic lipid is compound 342. In an embodiment, the cationic lipid is compound 343. In an embodiment, the cationic lipid is compound 344. In an embodiment, the cationic lipid is compound 345. In an embodiment, the cationic lipid is compound 346. In an embodiment, the cationic lipid is compound 347. In an embodiment, the cationic lipid is compound 348. In an embodiment, the cationic lipid is compound 349. In an embodiment, the cationic lipid is compound 350. In an embodiment, the cationic lipid is compound 351. In an embodiment, the cationic lipid is compound 352. In an embodiment, the cationic lipid is compound 353. In an embodiment, the cationic lipid is compound 354. In an embodiment, the cationic lipid is compound 355. In an embodiment, the cationic lipid is compound 356. In an embodiment, the cationic lipid is compound 357.
[0784] Table L.cEE Esters - Biodegradable
[0785]
[0786]
[0787]
[0788]
[0789]
[0790]
[0791]
[0792]
[0793]
[0794]
[0795] In embodiments, the cationic lipid is compound 358. In embodiments, the cationic lipid is compound 359. In embodiments, the cationic lipid is compound 360. In embodiments, the cationic lipid is compound 361. In embodiments, the cationic lipid is compound 362. In embodiments, the cationic lipid is compound 363. In embodiments, the cationic lipid is compound 364. In embodiments, the cationic lipid is compound 365. In embodiments, the cationic lipid is compound 366. In embodiments, the cationic lipid is compound 367. In embodiments, the cationic lipid is compound 368. In embodiments, the cationic lipid is compound 369. In embodiments, the cationic lipid is compound 370. In embodiments, the cationic lipid is compound 371. In embodiments, the cationic lipid is compound 372. In embodiments, the cationic lipid is compound 373. In embodiments, the cationic lipid is compound 374. In embodiments, the cationic lipid is compound 375. In embodiments, the cationic lipid is compound 376. In embodiments, the cationic lipid is compound 377. In embodiments, the cationic lipid is compound 378. In embodiments, the cationic lipid is compound 379. In an embodiment, the cationic lipid is compound 380. In an embodiment, the cationic lipid is compound 381. In an embodiment, the cationic lipid is compound 382. In an embodiment, the cationic lipid is compound 383. In an embodiment, the cationic lipid is compound 384. In an embodiment, the cationic lipid is compound 385. In an embodiment, the cationic lipid is compound 386. In an embodiment, the cationic lipid is compound 387. In an embodiment, the cationic lipid is compound 388. In an embodiment, the cationic lipid is compound 389. In an embodiment, the cationic lipid is compound 390. In an embodiment, the cationic lipid is compound 391. In an embodiment, the cationic lipid is compound 392. In an embodiment, the cationic lipid is compound 393. In an embodiment, the cationic lipid is compound 394. In an embodiment, the cationic lipid is compound 395. In an embodiment, the cationic lipid is compound 396.
[0796] Table M. Homoserine (cHse) Lipids - Biodegradable
[0797]
[0798]
[0799]
[0800]
[0801]
[0802]
[0803]
[0804]
[0805]
[0806] In embodiments, the cationic lipid is compound 397. In embodiments, the cationic lipid is compound 398. In embodiments, the cationic lipid is compound 399. In embodiments, the cationic lipid is compound 400. In embodiments, the cationic lipid is compound 401. In embodiments, the cationic lipid is compound 402. In embodiments, the cationic lipid is compound 403. In embodiments, the cationic lipid is compound 404. In embodiments, the cationic lipid is compound 405. In embodiments, the cationic lipid is compound 406. In embodiments, the cationic lipid is compound 407. In embodiments, the cationic lipid is compound 408. In embodiments, the cationic lipid is compound 409. In embodiments, the cationic lipid is compound 410. In embodiments, the cationic lipid is compound 411. In embodiments, the cationic lipid is compound 412. In embodiments, the cationic lipid is compound 413. In embodiments, the cationic lipid is compound 414. In embodiments, the cationic lipid is compound 415. In embodiments, the cationic lipid is compound 416. In embodiments, the cationic lipid is compound 417. In embodiments, the cationic lipid is compound 418. In embodiments, the cationic lipid is compound 419. In embodiments, the cationic lipid is compound 420. In embodiments, the cationic lipid is compound 421. In embodiments, the cationic lipid is compound 422. In embodiments, the cationic lipid is compound 423. In embodiments, the cationic lipid is compound 424. In embodiments, the cationic lipid is compound 425. In embodiments, the cationic lipid is compound 426. In embodiments, the cationic lipid is compound 427. In embodiments, the cationic lipid is compound 428. In embodiments, the cationic lipid is compound 429. In embodiments, the cationic lipid is compound 430. In embodiments, the cationic lipid is compound 431. In embodiments, the cationic lipid is compound 432. In embodiments, the cationic lipid is compound 433. In embodiments, the cationic lipid is compound 434. In embodiments, the cationic lipid is compound 435.
[0807] Table N. cCC disulfide - biodegradable
[0808]
[0809]
[0810]
[0811]
[0812]
[0813]
[0814]
[0815]
[0816]
[0817] In embodiments, the cationic lipid is compound 436. In embodiments, the cationic lipid is compound 437. In embodiments, the cationic lipid is compound 438. In embodiments, the cationic lipid is compound 439. In embodiments, the cationic lipid is compound 440. In embodiments, the cationic lipid is compound 441. In embodiments, the cationic lipid is compound 442. In embodiments, the cationic lipid is compound 443. In embodiments, the cationic lipid is compound 444. In embodiments, the cationic lipid is compound 445. In embodiments, the cationic lipid is compound 446. In embodiments, the cationic lipid is compound 447. In embodiments, the cationic lipid is compound 448. In embodiments, the cationic lipid is compound 449. In embodiments, the cationic lipid is compound 450. In embodiments, the cationic lipid is compound 451. In embodiments, the cationic lipid is compound 452. In embodiments, the cationic lipid is compound 453. In embodiments, the cationic lipid is compound 454. In embodiments, the cationic lipid is compound 455. In embodiments, the cationic lipid is compound 456. In embodiments, the cationic lipid is compound 457. In an embodiment, the cationic lipid is compound 458. In an embodiment, the cationic lipid is compound 459. In an embodiment, the cationic lipid is compound 460. In an embodiment, the cationic lipid is compound 461. In an embodiment, the cationic lipid is compound 462. In an embodiment, the cationic lipid is compound 463. In an embodiment, the cationic lipid is compound 464. In an embodiment, the cationic lipid is compound 465. In an embodiment, the cationic lipid is compound 466. In an embodiment, the cationic lipid is compound 467. In an embodiment, the cationic lipid is compound 468. In an embodiment, the cationic lipid is compound 469. In an embodiment, the cationic lipid is compound 470. In an embodiment, the cationic lipid is compound 471. In an embodiment, the cationic lipid is compound 472. In an embodiment, the cationic lipid is compound 473. In an embodiment, the cationic lipid is compound 474.
[0818] Table O. cCC Thioesters - Biodegradable
[0819]
[0820]
[0821]
[0822]
[0823]
[0824]
[0825]
[0826]
[0827]
[0828]
[0829] In embodiments, the cationic lipid is compound 475. In embodiments, the cationic lipid is compound 476. In embodiments, the cationic lipid is compound 477. In embodiments, the cationic lipid is compound 478. In embodiments, the cationic lipid is compound 479. In embodiments, the cationic lipid is compound 480. In embodiments, the cationic lipid is compound 481. In embodiments, the cationic lipid is compound 482. In embodiments, the cationic lipid is compound 483. In embodiments, the cationic lipid is compound 484. In embodiments, the cationic lipid is compound 485. In embodiments, the cationic lipid is compound 486. In embodiments, the cationic lipid is compound 487. In embodiments, the cationic lipid is compound 488. In embodiments, the cationic lipid is compound 489. In embodiments, the cationic lipid is compound 490. In embodiments, the cationic lipid is compound 491. In embodiments, the cationic lipid is compound 492. In embodiments, the cationic lipid is compound 493. In embodiments, the cationic lipid is compound 494. In embodiments, the cationic lipid is compound 495. In embodiments, the cationic lipid is compound 496. In embodiments, the cationic lipid is compound 497. In embodiments, the cationic lipid is compound 498. In embodiments, the cationic lipid is compound 499. In embodiments, the cationic lipid is compound 500. In embodiments, the cationic lipid is compound 501. In embodiments, the cationic lipid is compound 502. In embodiments, the cationic lipid is compound 503. In embodiments, the cationic lipid is compound 504. In embodiments, the cationic lipid is compound 505. In embodiments, the cationic lipid is compound 506. In embodiments, the cationic lipid is compound 507. In embodiments, the cationic lipid is compound 508. In embodiments, the cationic lipid is compound 509. In embodiments, the cationic lipid is compound 510. In embodiments, the cationic lipid is compound 511. In embodiments, the cationic lipid is compound 512. In embodiments, the cationic lipid is compound 513.
[0830] Table P.cSS esters - biodegradable
[0831]
[0832]
[0833]
[0834]
[0835]
[0836]
[0837]
[0838]
[0839]
[0840] In embodiments, the cationic lipid is compound 514. In embodiments, the cationic lipid is compound 515. In embodiments, the cationic lipid is compound 516. In embodiments, the cationic lipid is compound 517. In embodiments, the cationic lipid is compound 518. In embodiments, the cationic lipid is compound 519. In embodiments, the cationic lipid is compound 520. In embodiments, the cationic lipid is compound 521. In embodiments, the cationic lipid is compound 522. In embodiments, the cationic lipid is compound 523. In embodiments, the cationic lipid is compound 524. In embodiments, the cationic lipid is compound 525. In embodiments, the cationic lipid is compound 526. In embodiments, the cationic lipid is compound 527. In embodiments, the cationic lipid is compound 528. In embodiments, the cationic lipid is compound 529. In embodiments, the cationic lipid is compound 530. In embodiments, the cationic lipid is compound 531. In embodiments, the cationic lipid is compound 532. In embodiments, the cationic lipid is compound 533. In embodiments, the cationic lipid is compound 534. In embodiments, the cationic lipid is compound 535. In an embodiment, the cationic lipid is compound 536. In an embodiment, the cationic lipid is compound 537. In an embodiment, the cationic lipid is compound 538. In an embodiment, the cationic lipid is compound 539. In an embodiment, the cationic lipid is compound 540. In an embodiment, the cationic lipid is compound 541. In an embodiment, the cationic lipid is compound 542. In an embodiment, the cationic lipid is compound 543. In an embodiment, the cationic lipid is compound 544. In an embodiment, the cationic lipid is compound 545. In an embodiment, the cationic lipid is compound 546. In an embodiment, the cationic lipid is compound 547. In an embodiment, the cationic lipid is compound 548. In an embodiment, the cationic lipid is compound 549. In an embodiment, the cationic lipid is compound 550. In an embodiment, the cationic lipid is compound 551. In an embodiment, the cationic lipid is compound 552.
[0841] Synthesis of the compounds of the present invention
[0842] Compounds described herein (e.g., formulas (A'), (A), (I), (Ia), (I-a'), (Ib), (I-b'), (Ic), (I-c'), (Ic-1), (I-c'-1), (Ic-2), (I-c'-2), (Id), (I-d'), (Id-1 ), (Id-2), (Ie), (I-e'), (Ie-1), (Ie-2), (If), (I-f'), (II), (II-a), (II-a'), (III), (III'), (III-a), (III-a'), (III-b), (III-b Compounds of the invention comprising: (III-a), (III-c), (III-c-1), (III-c'-1), (III-c-2), (III-c'-2), (III-c'), (III-d), (III-d'), (III-d-1), (III-d-2), (III-e), (III-e'), (III-e-1), (III-e-2), (III-f), (III-f'), (IV), (IV-a), or (IV-a'), such as any one of compounds 1-552) can be prepared according to methods known in the art, including the exemplary synthetic scheme 1 provided herein.
[0843] For example, thioester compounds described herein (e.g., compounds described in Table A or Table C) can be prepared as shown in Scheme A, wherein R 3 and n can be any group or value as described herein.For example, cyclic diamino acids such as cyclic di(aspartic acid) (cDD) or cyclic di(glutamic acid) (cEE) with appropriate thiols can provide desired cationic lipids.Exemplary lipids prepared according to Scheme A are described in the Examples herein.
[0844] Scheme A. Exemplary Thioester Synthesis
[0845]
[0846] Another exemplary synthesis of the thioester lipids described herein is shown in Scheme B, where R 3 For example, the starting di(amino acid) cEE can be activated using EDCI to form the succinimidyl ester cEE-OSu, which can then be treated under basic conditions (eg, Hunig's base or DMAP in DMF) to form the desired cationic lipid.
[0847] Scheme B. Exemplary Thioester Synthesis
[0848]
[0849] An exemplary synthesis of an ester lipid described herein (e.g., a compound as described in Table B or Table D) is shown in Scheme C, where R 3 and n can be any group or value as described herein. For example, the starting di(amino acid) cDD or cEE can be treated with a protected alcohol (e.g., a silylated alcohol, such as alcohol A5) to form a protected form of the desired ester cationic lipid. Deprotection (e.g., deprotection of the silyl group) can then yield the desired ester cationic lipid. This protocol can also be used to prepare thioesters as described herein by replacing the protected alcohol with a protected thiol (e.g., a silylated thiol).
[0850] Scheme C. Exemplary Ester Synthesis
[0851]
[0852] Homoserine-based lipids (e.g., compounds of Table E) can be prepared according to Scheme D, where R 3 and n can be any group or value as described herein.For example, cyclic dihomoserine (cHse) can be esterified with protected carboxylic acid to obtain a silylated cHse cationic lipid intermediate.Then, deprotection of the silyl group can obtain the desired cHse cationic lipid.
[0853] Scheme D. Exemplary homoserine lipid synthesis
[0854]
[0855] Nucleic Acids
[0856] Compounds described herein (e.g., formulas (A'), (A), (I), (Ia), (I-a'), (Ib), (I-b'), (Ic), (I-c'), (Ic-1), (I-c'-1), (Ic-2), (I-c'-2), (Id), (I-d'), ( Id-1), (Id-2), (Ie), (I-e'), (Ie-1), (Ie-2), (If), (I-f'), (II), (II-a), (II-a'), (III), (III'), (III-a), (III-a'), (III-b) , (III-b'), (III-c), (III-c-1), (III-c'-1), (III-c-2), (III-c'-2), (III-c'), (III-d), (III-d'), (III-d-1), (III-d-2), (III-e), (III-e'), (III-e-1), (III-e-2), (III-f), (III-f'), (IV), (IV-a) or (IV-a'), such as any one of compounds 1-552) can be used to prepare a composition for delivering nucleic acids.
[0857] Nucleic acid synthesis
[0858] Nucleic acids according to the present invention can be synthesized according to any known method. For example, mRNA according to the present invention can be synthesized by in vitro transcription (IVT). Briefly, IVT is typically performed using a linear or circular DNA template comprising a promoter, a pool of ribonucleotide triphosphates, a buffer system that may include DTT and magnesium ions, and an appropriate RNA polymerase (e.g., T3, T7, a mutant T7 or SP6 RNA polymerase), DNAse I, a pyrophosphatase, and / or an RNAse inhibitor. The exact conditions will vary depending on the specific application.
[0859] In some embodiments, to prepare mRNA according to the present invention, a DNA template is transcribed in vitro. Suitable DNA templates typically have a promoter for in vitro transcription, such as T3, T7, a mutated T7 or SP6 promoter, followed by the desired nucleotide sequence and termination signal of the desired mRNA.
[0860] Can use standard method to measure according to the expectation mRNA sequence of the present invention and mix it in the DNA template.For example, starting from the expected amino acid sequence (for example enzyme sequence), carry out virtual reverse translation based on degenerate genetic code.Then can use optimization algorithm to select suitable codon.Usually, can optimize G / C content on the one hand, to realize G / C content as high as possible, on the other hand, use the frequency of considering tRNA according to codon as far as possible.Can for example set up and display optimized RNA sequence by suitable display device, and compare it with original (wild type) sequence.Can also analyze secondary structure to calculate respectively stable and destabilizing characteristic or the zone of RNA.
[0861] As mentioned above, the term "amino acid" in its broadest sense refers to any compound and / or substance that can be incorporated into a polypeptide chain. The DNA can be in the form of antisense DNA, plasmid DNA, a portion of plasmid DNA, precondensed DNA, a product of the polymerase chain reaction (PCR), a vector (e.g., P1, PAC, BAC, YAC, artificial chromosome), an expression cassette, a chimeric sequence, chromosomal DNA, or a derivative of these groups. The RNA can be in the form of messenger RNA (mRNA), ribosomal RNA (rRNA), signal recognition particle RNA (7SL RNA or SRP RNA), transfer RNA (tRNA), transfer messenger RNA (tmRNA), small nuclear RNA (snRNA), small nucleolar RNA (snoRNA), SmY RNA, small Cajal body-specific RNA (scaRNA), guide RNA (gRNA), ribonuclease P (RNaseP), Y RNA, telomerase RNA component (TERC), splicing leader RNA (SL RNA), antisense RNA (aRNA or asRNA), cis-natural antisense transcript (cis-NAT), CRISPR RNA (crRNA), long noncoding RNA (lncRNA), microRNA (miRNA), piwi-interacting RNA (piRNA), small interfering RNA (siRNA), transactional siRNA (tasiRNA), repeat-associated siRNA (rasiRNA), 73K RNA, retrotransposon, viral genome, viroid, satellite RNA, or derivatives of these groups. In some embodiments, the nucleic acid is an mRNA encoding a protein.
[0862] mRNA synthesis
[0863] mRNA according to the present invention can be synthesized according to any of a variety of known methods. For example, mRNA according to the present invention can be synthesized by in vitro transcription (IVT). Briefly, IVT is typically performed using a linear or circular DNA template comprising a promoter, a pool of ribonucleotide triphosphates, a buffer system that may comprise DTT and magnesium ions, and an appropriate RNA polymerase (e.g., T3, T7, or SP6 RNA polymerase), DNAse I, a pyrophosphatase, and / or an RNAse inhibitor. The exact conditions will vary depending on the specific application. The exact conditions will vary depending on the specific application. According to several embodiments, the presence of these reagents in the final product is undesirable and therefore can be referred to as an impurity, and a preparation containing one or more of these impurities can be referred to as an impure preparation. In some embodiments, in vitro transcription occurs in a single batch.
[0864] In some embodiments, to prepare mRNA according to the present invention, the DNA template is transcribed in vitro. Suitable DNA templates generally have a promoter for in vitro transcription, such as a T3, T7 or SP6 promoter, followed by the desired nucleotide sequence and termination signal of the desired mRNA.
[0865] Can use standard method to measure according to the expectation mRNA sequence of the present invention and mix it in the DNA template.For example, starting from the expected amino acid sequence (for example enzyme sequence), carry out virtual reverse translation based on degenerate genetic code.Then can use optimization algorithm to select suitable codon.Usually, can optimize G / C content on the one hand, to realize G / C content as high as possible, on the other hand, use the frequency of considering tRNA according to codon as far as possible.Can for example set up and display optimized RNA sequence by suitable display device, and compare it with original (wild type) sequence.Can also analyze secondary structure to calculate respectively stable and destabilizing characteristic or the zone of RNA.
[0866] Modified mRNA
[0867] In some embodiments, the mRNA according to the present invention can be synthesized as unmodified mRNA or modified mRNA. In some embodiments, the mRNA according to the present invention includes naturally occurring nucleosides (or unmodified nucleosides; that is, adenosine, guanosine, cytidine and uridine). In other embodiments, the mRNA according to the present invention includes nucleotide modifications in RNA. The modified mRNA according to the present invention may include nucleotide modifications, for example, backbone modifications, sugar modifications or base modifications. In some embodiments, mRNA can be synthesized by the following naturally occurring nucleotides and / or nucleotide analogs (modified nucleotides): including but not limited to purines (adenine (A), guanine (G)) or pyrimidines (thymine (T), cytosine (C), uracil (U)), and modified nucleotide analogs or derivatives of purines and pyrimidines. In some embodiments, the mRNA according to the present invention includes one or more nucleoside analogs (such as adenosine analogs, guanosine analogs, cytidine analogs or uridine analogs). In some embodiments, mRNA includes unmodified and modified nucleosides. In some embodiments, the one or more nucleoside analogs include 1-methyladenine, 2-methyladenine, 2-methylthio-N-6-isopentenyladenine, N6-methyladenine, N6-isopentenyladenine, 2-thiocytosine, 3-methylcytosine, 4-acetylcytosine, 5-methylcytosine, 2,6-diaminopurine, 1-methylguanine, 2-methylguanine, 2,2-dimethylguanine, 7-methylguanine, inosine, 1-methylinosine, pseudouracil (5-uracil), dihydrouracil, 2-thiouracil, 4-thiouracil, 5-carboxymethylaminomethyl-2-thiouracil, 5-(
[00145] The present invention also includes but is not limited to the following: uracil, 5-fluorouracil, 5-bromouracil, 5-carboxymethylaminomethyluracil, 5-methyl-2-thiouracil, 5-methyluracil, N-uracil-5-oxyacetic acid methyl ester, 5-methylaminomethyluracil, 5-methoxyaminomethyl-2-thiouracil, 5'-methoxycarbonylmethyluracil, 5-methoxyuracil, uracil-5-oxyacetic acid methyl ester, uracil-5-oxyacetic acid (v), 1-methylpseudouracil, quercetin, β-D-mannosylquercetin, whibutoxoside and pyrophosphamide, phosphorothioate, peptide nucleotides, methylphosphonate, 7-deazaguanosine, 5-methylcytosine and inosine.The preparation of such analogs is known to those skilled in the art, for example, according to U.S. Patent No. 4,373,071, U.S. Patent No. 4,401,796, U.S. Patent No. 4,415,732, U.S. Patent No. 4,458,066, U.S. Patent No. 4,500,707, U.S. Patent No. 4,668,777, U.S. Patent No. 4,973,679, U.S. Patent No. 5,047,524, U.S. Patent No. 5,132,418, U.S. Patent No. 5,153,319, U.S. Patent No. 5,262,530, and U.S. Patent No. 5,700,642, the disclosures of which are incorporated by reference in their entireties.
[0868] In some embodiments, mRNA can include RNA backbone modifications. Generally, backbone modifications are modifications in which the phosphates of the nucleotide backbones contained in the RNA are chemically modified. Exemplary backbone modifications generally include, but are not limited to, modifications selected from the group consisting of methylphosphonates, methylphosphonamides, phosphoramidates, thiophosphates (e.g., cytidine 5'-O-(1-thiophosphate)), borate phosphates, positively charged guanidinium groups, etc., which means that phosphodiester bonds are replaced by other anionic groups, cationic groups, or neutral groups.
[0869] In some embodiments, mRNA can include sugar modifications. Typical sugar modifications are chemical modifications of the sugars of the nucleotides it includes, including but not limited to sugar modifications selected from the group consisting of: 4'-thioribonucleotides (see, for example, U.S. Patent Application Publication No. US 2016 / 0031928, which is incorporated herein by reference), 2'-deoxy-2'-fluoro-oligoribonucleotides (2'-fluoro-2'-deoxycytidine 5'-triphosphate, 2'-fluoro-2'-deoxyuridine 5'-triphosphate), 2'-deoxy-2'-deamine-oligoribonucleotides (2'-amino-2'-deoxycytidine 5'-triphosphate, 2'-amino-2'-deoxyuridine 5'-triphosphate), 2'-O-alkyl oligoribonucleotides. Nucleotides, 2'-deoxy-2'-C-alkyl oligoribonucleotides (2'-O-methylcytidine 5'-triphosphate, 2'-methyluridine 5'-triphosphate), 2'-C-alkyl oligoribonucleotides and their isomers (2'-arabinocytidine 5'-triphosphate, 2'-arabinouridine 5'-triphosphate) or azidotriphosphates (2'-azido-2'-deoxycytidine 5'-triphosphate, 2'-azido-2'-deoxyuridine 5'-triphosphate).
[0870] In some embodiments, mRNA can include the modification (base modification) of the base of nucleotide. The modified nucleotides comprising base modification are also referred to as base modified nucleotides. The examples of such base modified nucleotides include but are not limited to 2-amino-6-chloropurine riboside, 5'-triphosphate, 2-aminoadenosine 5'-triphosphate, 2-thiocytidine 5'-triphosphate, 2-thiouridine 5'-triphosphate, 4-thiouridine 5'-triphosphate, 5-aminoallylcytidine 5'-triphosphate, 5-aminoallyluridine 5'-triphosphate, 5-bromocytidine 5'-triphosphate, 5-bromouridine 5'-triphosphate, 5-iodine 5'-triphosphate, 5-iodouridine 5'-triphosphate, 5-methylcytidine 5'-triphosphate, 5-methyluridine 5'-triphosphate , 6-azacytidine 5'-triphosphate, 6-azauridine 5'-triphosphate, 6-chloropurine riboside 5'-triphosphate, 7-deazaadenosine 5'-triphosphate, 7-deazaguanosine 5'-triphosphate, 8-azaadenosine 5'-triphosphate, 8-azidoadenosine 5'-triphosphate, benzimidazole nucleoside 5'-triphosphate, N1-methyladenosine 5'-triphosphate, N1-methylguanosine 5'-triphosphate, N6-methyladenosine 5'-triphosphate, O6-methylguanosine 5'-triphosphate, pseudouridine 5'-triphosphate, puromycin 5'-triphosphate or xanthine riboside 5'-triphosphate.
[0871] Typically, mRNA synthesis involves the addition of a "cap" at the N(5') terminus and a "tail" at the C(3') terminus. The presence of the cap is important for providing resistance to nucleases present in most eukaryotic cells. The presence of the "tail" serves to protect the mRNA from degradation by exonucleases.
[0872] Thus, in some embodiments, the mRNA includes a 5' cap structure. The 5' cap is typically added as follows: first, an RNA terminal phosphatase removes one terminal phosphate group from the 5' nucleotide, leaving two terminal phosphates; then, guanosine triphosphate (GTP) is added to the terminal phosphate by a guanylyltransferase, generating a 5'5'5 triphosphate bond; and then, a methyltransferase methylates the 7-nitrogen of guanine. Examples of cap structures include, but are not limited to, m7G(5')ppp(5'(A, G(5')ppp(5')A and G(5')ppp(5')G.
[0873] In some embodiments, mRNA includes 3' poly (A) tail structure.The poly A tail on the 3' end of mRNA typically includes about 10 to 300 adenosine nucleotides (for example, about 10 to 200 adenosine nucleotides, about 10 to 150 adenosine nucleotides, about 10 to 100 adenosine nucleotides, about 20 to 70 adenosine nucleotides, or about 20 to 60 adenosine nucleotides). In some embodiments, mRNA includes 3' poly (C) tail structure.The suitable poly C tail on the 3' end of mRNA typically includes about 10 to 200 cytosine nucleotides (for example, about 10 to 150 cytosine nucleotides, about 10 to 100 cytosine nucleotides, about 20 to 70 cytosine nucleotides, about 20 to 60 cytosine nucleotides, or about 10 to 40 cytosine nucleotides).Poly C tail can be added to poly A tail, or poly A tail can be substituted.
[0874] In some embodiments, the mRNA includes a 5' and / or 3' untranslated region. In some embodiments, the 5' untranslated region includes one or more elements that affect the stability or translation of the mRNA, such as an iron response element. In some embodiments, the length of the 5' untranslated region can be between about 50 and 500 nucleotides.
[0875] In some embodiments, the 3' untranslated region includes one or more polyadenylation signals, protein binding sites that affect the localization and stability of the mRNA in the cell, or one or more miRNA binding sites. In some embodiments, the length of the 3' untranslated region can be between 50 and 500 nucleotides or longer.
[0876] Cap structure
[0877] In some embodiments, the mRNA includes a 5' cap structure. The 5' cap is typically added as follows: first, an RNA terminal phosphatase removes one terminal phosphate group from the 5' nucleotide, leaving two terminal phosphates; then, guanosine triphosphate (GTP) is added to the terminal phosphate by a guanylyltransferase, generating a 5'5'5 triphosphate bond; and then, a methyltransferase methylates the 7-nitrogen of guanine. Examples of cap structures include, but are not limited to, m7G(5')ppp(5'(A, G(5')ppp(5')A and G(5')ppp(5')G.
[0878] The naturally occurring cap structure consists of 7-methylguanosine linked to the 5'-end of the first transcribed nucleotide via a triphosphate bridge, resulting in m 7A dinucleotide cap consisting of G(5')ppp(5')N, where N is any nucleoside. In vivo, the cap is added enzymatically. It is added to the nucleus of the cell and catalyzed by the enzyme guanylyltransferase. The cap is added to the 5' end of the RNA immediately after transcription begins. The terminal nucleoside is typically guanosine and is oriented in the opposite direction to all other nucleotides, i.e., G(5')ppp(5')GpNpNp.
[0879] The common cap for mRNA produced by in vitro transcription is m 7 G(5')ppp(5')G has been used as a dinucleotide cap during in vitro transcription with T7 or SP6 RNA polymerase to obtain RNA with a cap structure at its 5'-end. The main method for synthesizing caPPEd mRNA in vitro is to use preformed mRNA. 7 G(5')ppp(5')G(“m 7 GpppG") dinucleotides serve as transcription initiators.
[0880] To date, the common form of synthetic dinucleotide cap used in in vitro translation experiments is the anti-reverse cap analog ("ARCA") or modified ARCA, which is typically a modified cap analog in which the 2' or 3' OH group is replaced by -OCH3.
[0881] Additional cap analogs include, but are not limited to, chemical structures selected from the group consisting of: m 7 GpppG、m 7 GpppA,m 7 GpppC; unmethylated cap analogs (e.g., GpppG); dimethylated cap analogs (e.g., m 2, 7 GpppG), trimethylated cap analogs (e.g., m 2,2,7 GpppG), dimethylated symmetrical cap analogs (e.g., m 7 Gpppm 7 G) or anti-reverse cap analogs (e.g., ARCA; m 7 , 2'Ome GpppG、m 72'd GpppG、m 7,3'Ome GpppG、m 7,3' d GpppG and their tetraphosphate derivatives) (see, eg, Jemielity, J. et al., “Novel 'anti-reverse' cap analogs with superior translational properties”, RNA, 9: 1108-1122 (2003)).
[0882] In some embodiments, a suitable cap is a 7-methylguanylate ("m-guanylate") linked to the 5'-end of the first transcribed nucleotide via a triphosphate bridge. 7 G”), thus obtaining m 7 G(5')ppp(5')N, wherein N is any nucleoside. 7 The preferred embodiment of the G cap is m 7 G(5')ppp(5')G.
[0883] In some embodiments, the cap is a Cap0 structure. The Cap0 structure lacks the 2'-O-methyl residues attached to the ribose sugars at bases 1 and 2. In some embodiments, the cap is a Cap1 structure. The Cap1 structure has a 2'-O-methyl residue at base 2. In some embodiments, the cap is a Cap2 structure. The Cap2 structure has 2'-O-methyl residues attached to both bases 2 and 3.
[0884] Various m 7 G cap analogs are known in the art, many of which are commercially available. These cap analogs include the m 7 GpppG, and ARCA 3'-OCH3 and 2'-OCH3 cap analogs (Jemielity, J. et al., RNA, 9: 1108-1122 (2003)). Additional cap analogs for use in embodiments of the present invention include N7-benzylated dinucleoside tetraphosphate analogs (described in Grudzien, E. et al., RNA, 10: 1479-1487 (2004)), phosphorothioate cap analogs (described in Grudzien-Nogalska, E. et al., RNA, 13: 1745-1755 (2007)), and cap analogs described in U.S. Pat. Nos. 8,093,367 and 8,304,529 (including biotinylated cap analogs), which are incorporated herein by reference.
[0885] Tail structure
[0886] Typically, the presence of a "tail" is used to protect mRNA from exonuclease degradation. It is believed that the poly A tail can stabilize natural messengers and synthesize sense RNA. Therefore, in certain embodiments, a long poly A tail can be added to an mRNA molecule to make RNA more stable. A variety of techniques recognized in the art can be used to add a poly A tail. For example, a long poly A tail can be added to synthetic or in vitro transcribed RNA using poly A polymerase (Yokoe et al., Nature Biotechnology.1996; 14: 1252-1256). The transcription vector can also encode a long poly A tail. In addition, the poly A tail can be added by direct transcription from a PCR product. The poly A tail can also be connected to the 3' end of the sense RNA with RNA ligase (see, for example, Molecular Cloning A Laboratory Manual, 2nd edition, edited by Sambrook, Fritsch and Maniatis (Cold Spring Harbor Laboratory Press: 1991 edition)).
[0887] In some embodiments, mRNA includes a 3' poly (A) tail structure. Typically, the length of the poly A tail can be at least about 10, 50, 100, 200, 300, 400, or at least 500 nucleotides. In some embodiments, the poly A tail on the 3' end of the mRNA typically includes about 10 to 300 adenosine nucleotides (e.g., about 10 to 200 adenosine nucleotides, about 10 to 150 adenosine nucleotides, about 10 to 100 adenosine nucleotides, about 20 to 70 adenosine nucleotides, or about 20 to 60 adenosine nucleotides). In some embodiments, mRNA includes a 3' poly (C) tail structure. Suitable poly-C tails on the 3' end of the mRNA typically include about 10 to 200 cytosine nucleotides (e.g., about 10 to 150 cytosine nucleotides, about 10 to 100 cytosine nucleotides, about 20 to 70 cytosine nucleotides, about 20 to 60 cytosine nucleotides, or about 10 to 40 cytosine nucleotides). The poly-C tail can be added to the poly-A tail, or it can replace the poly-A tail.
[0888] In some embodiments, the length of the poly A tail or poly C tail is adjusted to control the stability of the modified sense mRNA molecules of the present invention, thereby controlling protein transcription. For example, because the length of the poly A tail can affect the half-life of the sense mRNA molecule, the length of the poly A tail can be adjusted to change the level of resistance of the mRNA to nucleases, thereby controlling the time course of polynucleotide expression and / or polypeptide production in the target cell.
[0889] 5' and 3' untranslated regions
[0890] In some embodiments, the mRNA includes a 5' and / or 3' untranslated region. In some embodiments, the 5' untranslated region includes one or more elements that affect the stability or translation of the mRNA, such as an iron response element. In some embodiments, the length of the 5' untranslated region can be between about 50 and 500 nucleotides.
[0891] In some embodiments, the 3' untranslated region includes one or more polyadenylation signals, protein binding sites that affect the localization and stability of the mRNA in the cell, or one or more miRNA binding sites. In some embodiments, the length of the 3' untranslated region can be between 50 and 500 nucleotides or longer.
[0892] Exemplary 3'UTR sequence and / or 5'UTR sequence can be derived from stable mRNA molecules (for example, globulin, actin, GAPDH, tubulin, histone or citric acid cycle enzyme), to increase the stability of sense mRNA molecules. For example, 5'UTR sequence can include a partial sequence of CMV immediate early 1 (IE1) gene or a fragment thereof, to improve nuclease resistance and / or improve the half-life of polynucleotides. It is also contemplated that the 3' end or non-translated region of a polynucleotide (for example, mRNA) comprises a sequence encoding human growth hormone (hGH) or a fragment thereof to further stabilize the polynucleotides. Generally speaking, these modifications improve the stability and / or pharmacokinetic properties (for example, half-life) of the polynucleotides relative to their unmodified counterparts, and include, for example, modifications carried out to improve the tolerance of such polynucleotides to nuclease digestion in vivo.
[0893] Cationic lipid and nucleic acid pharmaceutical preparations
[0894] In certain embodiments, the compounds described herein (e.g., Formula (A'), (A), (I), (Ia), (I-a'), (Ib), (I-b'), (Ic), (I-c'), (Ic-1), (I-c'-1), (Ic-2), (I-c'-2), (Id), (I-d'), (Id-1), (Id-2), (Ie), (I-e'), (Ie-1), (Ie-2), (If), (I-f'), (II), (II-a), (II-a'), (III), (III'), (III-a), (III-a'), (III-b), (III-b'), (III-c), (III-c-1), (III-c-2), (III-c-2), (III-d), (Id'), (Id-1), (Id-2), (Ie), (I-e'), (Ie-1), (Ie-2), (If), (I-f'), (II), (II-a), (II-a'), (III), (III'), (III-a), (III-a'), (III-b), (III-b'), (III-c), (III-c-1), (III-c-2), (III-d), (III-d), (III-d Compounds comprising: (III-c'-1), (III-c-2), (III-c'-2), (III-c'), (III-d), (III-d'), (III-d-1), (III-d-2), (III-e), (III-e'), (III-e-1), (III-e-2), (III-f), (III-f'), (IV), (IV-a), or (IV-a'), such as any of compounds 1-552), as well as pharmaceutical and liposome compositions comprising such lipids, can be used in formulations to facilitate delivery of encapsulated materials (e.g., one or more polynucleotides such as mRNA) to one or more target cells, and subsequent transfection of one or more target cells. For example, in certain embodiments, the cationic lipids described herein (and compositions comprising such lipids, such as liposome compositions) are characterized by causing one or more of receptor-mediated endocytosis, clathrin-mediated and caveolae-mediated endocytosis, phagocytosis and macropinocytosis, fusogenicity, endosomal or lysosomal disruption, and / or releasable properties, which provide advantages for such compounds over other similarly classified lipids.
[0895] According to the present invention, nucleic acids, such as mRNA encoding proteins (e.g., full length, fragments, or portions of proteins), can be synthesized by a method comprising a compound as described herein (e.g., Formula (A'), (A), (I), (Ia), (I-a'), (Ib), (I-b'), (Ic), (I-c'), (Ic-1), (I-c'-1), (Ic-2), (I-c'-2), (Id), (I-d'), (Id-1), (Id-2), (Ie), (I-e'), (Ie-1), (Ie-2), (If), (I-f'), (II), (II-a), (II-a'), (III), (III' ), (III-a), (III-a'), (III-b), (III-b'), (III-c), (III-c-1), (III-c'-1), (III-c-2), (III-c'-2), (III-c'), (III-d), (III-d'), (III-d-1), (III-d-2), (III-e), (III-e'), (III-e-1), (III-e-2), (III-f), (III-f'), (IV), (IV-a) or (IV-a'), such as any one of compounds 1-552) are delivered by a delivery vehicle.
[0896] As used herein, the terms "delivery vehicle," "transport vehicle," "nanoparticle," or grammatical equivalents are used interchangeably.
[0897] For example, the present invention provides a composition (e.g., a pharmaceutical composition) comprising a compound described herein (e.g., Formula (A'), (A), (I), (Ia), (I-a'), (Ib), (I-b'), (Ic), (I-c'), (Ic-1), (I-c'-1), (Ic-2), (I-c'-2), (Id), (I-d'), (Id-1), (Id-2), (Ie), (I-e'), (Ie-1), (Ie-2), (If), (I-f'), (II), (II-a), (II-a'), (III), (III'), (III-a), (III-a'), (III-b), (III-b'), (III-c), (III-c-1), (III-c'-1), (III-c-2), (III-c'-2), (III-c'), (III-d), (III-d'), (III-d-1), (III-d-2), (III-e), (III-e'), (III-e-1), (III-e-2), (III-f), (III-f'), (IV), (IV-a), or (IV-a'), such as any one of compounds 1-552, and one or more polynucleotides. The composition (e.g., a pharmaceutical composition) can also contain one or more cationic lipids, one or more non-cationic lipids, one or more cholesterol-based lipids, and / or one or more PEG-modified lipids.
[0898] In certain embodiments, the composition exhibits enhanced (e.g., improved) ability to transfect one or more target cells. Thus, methods of transfecting one or more target cells are also provided herein. Such methods generally comprise co-infecting one or more target cells with a cationic lipid and / or pharmaceutical composition disclosed herein (e.g., a compound comprising one or more polynucleotides encapsulated as described herein (e.g., Formula (A'), (A), (I), (Ia), (I-a'), (Ib), (I-b'), (Ic), (I-c'), (Ic-1), (I-c'-1), (Ic-2), (I-c'-2), (Id), (I-d'), (Id-1), (Id-2), (Ie), (I-e'), (Ie-1), (Ie-2), (If), (I-f'), (II), (II-a), (II-a'), (III), (III'), (III-a), (III- In some embodiments, the present invention relates to a step of contacting a liposomal formulation of a compound of any one of compounds I-552) with a liposomal formulation of (III-a'), (III-b), (III-b'), (III-c), (III-c-1), (III-c'-1), (III-c-2), (III-c'-2), (III-c'), (III-d), (III-d'), (III-d-1), (III-d-2), (III-e), (III-e'), (III-e-1), (III-e-2), (III-f), (III-f'), (IV), (IV-a), or (IV-a'), such as any one of compounds I-552), such that one or more target cells are transfected with the material (e.g., one or more polynucleotides) encapsulated therein. As used herein, the term "transfection" refers to the intracellular introduction of one or more encapsulating materials (e.g., nucleic acids and / or polynucleotides) into a cell, or preferably into a target cell. The introduced polynucleotide can be stably or transiently maintained in the target cell. The term "transfection efficiency" refers to the relative amount of such encapsulated material (e.g., polynucleotide) taken up, introduced and / or expressed by the target cells undergoing transfection. In practice, transfection efficiency can be estimated by the amount of reporter polynucleotide product produced by the target cells after transfection. In certain embodiments, the compounds and pharmaceutical compositions described herein exhibit high transfection efficiency, thereby increasing the likelihood that an appropriate dose of encapsulated material (e.g., one or more polynucleotides) will be delivered to the pathological site and subsequently expressed, while minimizing potential systemic side effects or toxicity associated with the compound or its encapsulated contents.
[0899] After transfection of one or more target cells by, for example, polynucleotides encapsulated in one or more lipid nanoparticles constituting a pharmaceutical composition or liposome composition disclosed herein, the production of a product (e.g., a polypeptide or protein) encoded by such polynucleotides can be preferably stimulated, and the ability of such target cells to express the polynucleotides and produce, for example, a polypeptide or protein of interest can be enhanced. For example, transfection of target cells by one or more compounds or pharmaceutical compositions encapsulating mRNA will enhance (i.e., increase) the production of a protein or enzyme encoded by such mRNA.
[0900] In addition, delivery vehicle as herein described (for example, liposome delivery vehicle) can be prepared to preferentially be distributed to other target tissues, cells or organs, such as heart, lung, kidney, spleen.In embodiments, lipid nanoparticle of the present invention can be prepared to realize the delivery of the enhancement to target cell and tissue.For example, the polynucleotide (for example, mRNA) encapsulated in one or more compounds as herein described or pharmaceutical composition and liposome composition can be delivered to and / or transfection target cell or target tissue.In some embodiments, the polynucleotide (for example, mRNA) of encapsulation can be expressed by target cell and produced (and in some cases secreted) functional polypeptide product by target cell, thus giving the characteristic that for example target cell or target tissue are useful.The polynucleotide (for example, mRNA) of this type of encapsulation can encode for example hormone, enzyme, receptor, polypeptide, peptide or other protein of interest.
[0901] Liposomal delivery vehicles
[0902] In some embodiments, the composition is a suitable delivery vehicle. In embodiments, the composition is a liposomal delivery vehicle, e.g., a lipid nanoparticle.
[0903] Any embodiment described herein (or any combination of any embodiments) applies to any compound described herein (e.g., Formula (A'), (A), (I), (Ia), (I-a'), (Ib), (I-b'), (Ic), (I-c'), (Ic-1), (I-c'-1), (Ic-2), (I-c'-2), (Id), (I-d'), (Id-1), (Id-2), (Ie), (I-e'), (Ie-1), (Ie-2), (If), (I-f'), (II), (II-a), (II-a'), (III), (III'), (I (III-a), (III-a'), (III-b), (III-b'), (III-c), (III-c-1), (III-c'-1), (III-c-2), (III-c'-2), (III-c'), (III-d), (III-d'), (III-d-1), (III-d-2), (III-e), (III-e'), (III-e-1), (III-e-2), (III-f), (III-f'), (IV), (IV-a) or (IV-a'), such as any one of compounds 1-552).
[0904] The terms "liposomal delivery vehicle" and "liposomal composition" are used interchangeably.
[0905] Enriching liposome compositions with one or more cationic lipids disclosed herein can be used as a means to improve (e.g., reduce) toxicity or otherwise impart one or more desired properties to such enriched liposome compositions (e.g., improving the delivery of encapsulated polynucleotides to one or more target cells and / or reducing the in vivo toxicity of the liposome composition). Thus, pharmaceutical compositions, particularly liposome compositions, comprising one or more cationic lipids disclosed herein are also contemplated.
[0906] Thus, in certain embodiments, the compounds described herein (e.g., Formula (A'), (A), (I), (Ia), (I-a'), (Ib), (I-b'), (Ic), (I-c'), (Ic-1), (I-c'-1), (Ic-2), (I-c'-2), (Id), (I-d'), (Id-1), (Id-2), (Ie), (I-e'), (Ie-1), (Ie-2), (If), (I-f'), (II), (II-a), (II-a'), (III), (III'), (III-a), (III-a'), (III-b), (III-b'), (III-c), (III-c-1), A compound of (III-c'-1), (III-c-2), (III-c'-2), (III-c'), (III-d), (III-d'), (III-d-1), (III-d-2), (III-e), (III-e'), (III-e-1), (III-e-2), (III-f), (III-f'), (IV), (IV-a), or (IV-a'), such as any of Compounds 1-552) can be used as a component of a liposome composition to facilitate or enhance the delivery and release of an encapsulated material (e.g., one or more therapeutic agents) to one or more target cells (e.g., by permeating or fusing with the lipid membrane of such target cells).
[0907] As used herein, liposome delivery vehicles (for example, lipid nanoparticles) are generally characterized as the microscopic vesicle with internal water space, and this internal water space is isolated from external medium by one or more double-layered films.The double-layer membrane of liposome is generally formed by amphipathic molecules, such as comprising the synthesis of spatially separated hydrophilic and hydrophobic domains or lipids of natural origin (Lasic, Trends Biotechnol., 16:307-321,1998).The double-layer membrane of liposome can also be formed by amphipathic polymers and surfactants (for example, polymer vesicles, noids etc.).In the context of the present invention, liposome delivery vehicles are generally used for desired nucleic acid (for example, mRNA or MCNA) transported to target cell or tissue.
[0908] In certain embodiments, such compositions (eg, liposome compositions) load or otherwise encapsulate a material, such as one or more biologically active polynucleotides (eg, mRNA).
[0909] In some embodiments, nanoparticle delivery vehicle is liposome.In some embodiments, liposome comprises one or more cationic lipids, one or more non-cationic lipids, one or more cholesterol-based lipids or one or more PEG-modified lipids.Typical liposomes for the present invention are made up of four lipid components: cationic lipids, non-cationic lipids (e.g., DOPE or DEPE), cholesterol-based lipids (e.g., cholesterol) and PEG-modified lipids (e.g., DMG-PEG2K).
[0910] In embodiments, the composition (e.g., a pharmaceutical composition) comprises an mRNA encoding a protein encapsulated within a liposome. In embodiments, the liposome comprises one or more cationic lipids, one or more non-cationic lipids, one or more cholesterol-based lipids, and one or more PEG-modified lipids, and wherein at least one cationic lipid is a compound described herein (e.g., Formula (A'), (A), (I), (Ia), (I-a'), (Ib), (I-b'), (Ic), (I-c'), (Ic-1), (I-c'-1), (Ic-2), (I-c'-2), (Id), (I-d'), (Id-1), (Id-2), (Ie), (I-e'), (Ie-1), (Ie-2), (If), (I-f'), (II), (II-a) In some embodiments, the composition comprises an mRNA encoding a protein (e.g., any protein described herein). In some embodiments, the composition comprises an mRNA encoding a cystic fibrosis transmembrane conductance regulator (CFTR) protein. In some embodiments, the composition comprises an mRNA encoding an ornithine transcarbamylase (OTC) protein.
[0911] In embodiments, a composition (e.g., a pharmaceutical composition) comprises a nucleic acid encapsulated within a liposome, wherein the liposome comprises any compound described herein (e.g., Formula (A'), (A), (I), (Ia), (I-a'), (Ib), (I-b'), (Ic), (I-c'), (Ic-1), (I-c'-1), (Ic-2), (I-c'-2), (Id), (I-d'), (Id-1), (Id-2), (Ie), (I-e'), (Ie-1), (Ie-2), (If), (I-f'), (II), (II-a), (II-a'), (III), (I (III-a), (III-a'), (III-b), (III-b'), (III-c), (III-c-1), (III-c'-1), (III-c-2), (III-c'-2), (III-c'), (III-d), (III-d'), (III-d-1), (III-d-2), (III-e), (III-e'), (III-e-1), (III-e-2), (III-f), (III-f'), (IV), (IV-a) or (IV-a'), such as any one of compounds 1-552).
[0912] In embodiments, nucleic acid is an mRNA encoding a peptide or protein. In embodiments, mRNA encoding is used to deliver to or treat a subject's lung or lung cells for a peptide or protein (e.g., mRNA encoding cystic fibrosis transmembrane conductance regulator (CFTR) protein). In embodiments, mRNA encoding is used to deliver to or treat a subject's liver or liver cells for a peptide or protein (e.g., mRNA encoding ornithine transcarbamylase (OTC) protein). Other exemplary mRNAs are also described herein.
[0913] In embodiments, the liposomal delivery vehicle (eg, lipid nanoparticle) may have a net positive charge.
[0914] In embodiments, the liposomal delivery vehicle (eg, lipid nanoparticle) can have a net negative charge.
[0915] In embodiments, the liposomal delivery vehicle (eg, lipid nanoparticle) can have a net neutral charge.
[0916] In embodiments, lipid nanoparticles encapsulating nucleic acids (e.g., mRNA encoding a peptide or protein) comprise one or more compounds described herein (e.g., Formula (A'), (A), (I), (Ia), (I-a'), (Ib), (I-b'), (Ic), (I-c'), (Ic-1), (I-c'-1), (Ic-2), (I-c'-2), (Id), (I-d'), (Id-1), (Id-2), (Ie), (I-e'), (Ie-1), (Ie-2), (If), (I-f'), (II), (II-a), (II-a'), (III), (II- I'), (III-a), (III-a'), (III-b), (III-b'), (III-c), (III-c-1), (III-c'-1), (III-c-2), (III-c'-2), (III-c'), (III-d), (III-d'), (III-d-1), (III-d-2), (III-e), (III-e'), (III-e-1), (III-e-2), (III-f), (III-f'), (IV), (IV-a) or (IV-a'), such as any one of compounds I-552).
[0917] For example, a compound as described herein (e.g., Formula (A'), (A), (I), (Ia), (I-a'), (Ib), (I-b'), (Ic), (I-c'), (Ic-1), (I-c'-1), (Ic-2), (I-c'-2), (Id), (I-d'), (Id-1), (Id-2), (Ie), (I-e'), (Ie-1), (Ie-2), (If), (I-f'), (II), (II-a), (II-a'), (III), (III'), (III-a), (III-a'), (III-b), (III-b'), (III-c'), (III-f'), (II), (II-a), (II-a'), (III-b), (III-b'), (III-c'), (III-f'), (II), (II-a), (II-a'), (III-b), (III-b'), (III-c'), (III-f'), (II), (II-a), (II-a'), (III-b), (III-b'), (III-c'), (III-f'), (II), (II- ), (III-c-1), (III-c'-1), (III-c-2), (III-c'-2), (III-c'), (III-d), (III-d'), (III-d-1), (III-d-2), (III-e), (III-e'), (III-e-1), (III-e-2), (III-f), (III-f'), (IV), (IV-a), or (IV-a'), such as any of Compounds 1-552) can be described as a percentage ("wt %") of the combined dry weight of all lipids of the composition (e.g., the combined dry weight of all lipids present in the liposome composition).
[0918] In embodiments of the pharmaceutical compositions described herein, a compound as described herein (e.g., Formula (A'), (A), (I), (Ia), (I-a'), (Ib), (I-b'), (Ic), (I-c'), (Ic-1), (I-c'-1), (Ic-2), (I-c'-2), (Id), (I-d'), (Id-1), (Id-2), (Ie), (I-e'), (Ie-1), (Ie-2), (If), (I-f'), (II), (II-a), (II-a'), (III), (III'), (III-a), (III-a'), (III-b), (III-b'), (III-c), (III-c- 1), (III-c'-1), (III-c-2), (III-c'-2), (III-c'), (III-d), (III-d'), (III-d-1), (III-d-2), (III-e), (III-e'), (III-e-1), (III-e-2), (III-f), (III-f'), (IV), (IV-a), or (IV-a'), such as any of Compounds 1-552) is present in an amount of about 0.5 wt % to about 30 wt % (e.g., about 0.5 wt % to about 50 wt %, e.g., about 0.5 wt % to about 20 wt %) of the combined dry weight of all lipids present in the composition (e.g., a liposome composition).
[0919] In embodiments, a compound as described herein (e.g., Formula (A'), (A), (I), (Ia), (I-a'), (Ib), (I-b'), (Ic), (I-c'), (Ic-1), (I-c'-1), (Ic-2), (I-c'-2), (Id), (I-d'), (Id-1), (Id-2), (Ie), (I-e'), (Ie-1), (Ie-2), (If), (I-f'), (II), (II-a), (II-a'), (III), (III'), (III-a), (III-a'), (III-b), (III-b'), (III-c), (III-c-1), (III-c'-1), (III-c'-2), (III-c'-2), (III-f'), (II- c'), (III-d), (III-d'), (III-d-1), (III-d-2), (III-e), (III-e'), (III-e-1), (III-e-2), (III-f), (III-f'), (IV), (IV-a), or (IV-a'), such as any of Compounds 1-552) is present in an amount of about 1 wt % to about 50 wt %, about 1 wt % to about 40 wt %, about 1 wt % to about 30 wt %, about 1 wt % to about 20 wt %, about 1 wt % to about 15 wt %, about 1 wt % to about 10 wt %, about 5 wt % to about 25 wt %, about 10 wt % to about 30 wt %, or about 20 wt % to about 40 wt % of the combined dry weight of all lipids present in the composition (e.g., a liposomal composition).In embodiments, a compound as described herein (e.g., Formula (A'), (A), (I), (Ia), (I-a'), (Ib), (I-b'), (Ic), (I-c'), (Ic-1), (I-c'-1), (Ic-2), (I-c'-2), (Id), (I-d'), (Id-1), (Id-2), (Ie), (I-e'), (Ie-1), (Ie-2), (If), (I-f'), (II), (II-a), (II-a'), (III), (III'), (III-a), (III-a'), (III-b), (III-b'), (III-c), (III-c-1), (III- c'-1), (III-c-2), (III-c'-2), (III-c'), (III-d), (III-d'), (III-d-1), (III-d-2), (III-e), (III-e'), (III-e-1), (III-e-2), (III-f), (III-f'), (IV), (IV-a), or (IV-a'), such as any of Compounds 1-552) is present in an amount of about 0.5% to about 5%, about 1% to about 10%, about 5% to about 20%, or about 10% to about 20% by weight of the combined molar amount of all lipids present in the composition, such as a liposomal delivery vehicle.
[0920] In embodiments, a compound as described herein (e.g., Formula (A'), (A), (I), (Ia), (I-a'), (Ib), (I-b'), (Ic), (I-c'), (Ic-1), (I-c'-1), (Ic-2), (I-c'-2), (Id), (I-d'), (Id-1), (Id-2), (Ie), (I-e'), (Ie-1), (Ie-2), (If), (I-f'), (II), (II-a), (II-a'), (III), (III'), (III-a), (III-a'), (III-b), (III-b'), (III-c), (III-c-1), (III-c'-1), (III-c-2), (III-c'-2), (III-c'), (III-d), (III-d') , (III-d-1), (III-d-2), (III-e), (III-e'), (III-e-1), (III-e-2), (III-f), (III-f'), (IV), (IV-a), or (IV-a'), such as any of Compounds 1-552) is present in an amount of at least about 5%, about 10%, about 15%, about 20%, about 25%, about 30%, about 35%, about 40%, about 45%, about 50%, about 55%, about 60%, about 65%, about 70%, about 75%, about 80%, about 85%, about 90%, about 95%, about 96%, about 97%, about 98%, or about 99% by weight of the combined dry weight of the total lipids in the composition (e.g., a liposomal composition).
[0921] In embodiments, a compound as described herein (e.g., Formula (A'), (A), (I), (Ia), (I-a'), (Ib), (I-b'), (Ic), (I-c'), (Ic-1), (I-c'-1), (Ic-2), (I-c'-2), (Id), (I-d'), (Id-1), (Id-2), (Ie), (I-e'), (Ie-1), (Ie-2), (If), (I-f'), (II), (II-a), (II-a'), (III), (III'), (III-a), (III-a'), (III-b), (III-b'), (III-c), (III-c-1), (III-c'-1), (III-c-2), (III-c'-2), (III-c'), (III-d), (III-d'), (III-d-1), (III-d-2), (III-e), (III-e'), (III-e-1), (III-e-2), (III-f), (III-f'), (IV), (IV-a), or (IV-a'), such as any of compounds 1-552) is present in an amount of no more than about 5%, about 10%, about 15%, about 20%, about 25%, about 30%, about 35%, about 40%, about 45%, about 50%, about 55%, about 60%, about 65%, about 70%, about 75%, about 80%, about 85%, about 90%, about 95%, about 96%, about 97%, about 98%, or about 99% by weight of the combined dry weight of the total lipids in the composition (e.g., a liposomal composition).
[0922] In embodiments, a composition (e.g., a liposomal delivery vehicle, such as a lipid nanoparticle) comprises from about 0.1% to about 20% by weight (e.g., from about 0.1% to about 15% by weight) of a compound described herein (e.g., Formula (A'), (A), (I), (Ia), (I-a'), (Ib), (I-b'), (Ic), (I-c'), (Ic-1), (Ic'-1), (Ic-2), (I-c'-2), (Id), (I-d'), (Id-1), (Id-2), (Ie), (I-e'), (Ie-1), (Ie-2), (If), (I-f'), (II), (II-a), (II- a'), (III), (III'), (III-a), (III-a'), (III-b), (III-b'), (III-c), (III-c-1), (III-c'-1), (III-c-2), (III-c'-2), (III-c'), (III-d), (III-d'), (III-d-1), (III-d-2), (III-e), (III-e'), (III-e-1), (III-e-2), (III-f), (III-f'), (IV), (IV-a), or (IV-a'), such as any one of compounds 1-552). In embodiments, the delivery vehicle (e.g., a liposomal delivery vehicle, such as a lipid nanoparticle) comprises about 0.5%, about 1%, about 3%, about 5%, or about 10% by weight of a compound described herein (e.g., Formula (A'), (A), (I), (Ia), (I-a'), (Ib), (I-b'), (Ic), (I-c'), (Ic-1), (I-c'-1), (Ic-2), (I-c'-2), (Id), (I-d'), (Id-1), (Id-2), (Ie), (I-e'), (Ie-1), (Ie-2), (If), (I-f'), (II), (II-a), (II- -a'), (III), (III'), (III-a), (III-a'), (III-b), (III-b'), (III-c), (III-c-1), (III-c'-1), (III-c-2), (III-c'-2), (III-c'), (III-d), (III-d'), (III-d-1), (III-d-2), (III-e), (III-e'), (III-e-1), (III-e-2), (III-f), (III-f'), (IV), (IV-a) or (IV-a'), such as any one of compounds 1-552).In embodiments, the delivery vehicle (e.g., a liposomal delivery vehicle, such as a lipid nanoparticle) comprises up to about 0.5%, about 1%, about 3%, about 5%, about 10%, about 15%, or about 20% by weight of a compound described herein (e.g., Formula (A'), (A), (I), (Ia), (I-a'), (Ib), (I-b'), (Ic), (I-c'), (Ic-1), (Ic'-1), (Ic-2), (I-c'-2), (Id), (I-d'), (Id-1), (Id-2), (Ie), (I-e'), (Ie-1), (Ie-2), (If), (I-f'), (II), (I (III-d), (III-d'), (III-d-1), (III-d-2), (III-e), (III-e'), (III-e-1), (III-e-2), (III-f), (III-f'), (IV), (IV-a), or (IV-a'), such as any one of compounds 1-552. In embodiments, the percentage results in an improvement in beneficial effect (e.g., improved delivery to a target tissue such as the liver or lung).
[0923] As described herein (e.g., compounds of Formula (A'), (A), (I), (Ia), (I-a'), (Ib), (I-b'), (Ic), (I-c'), (Ic-1), (I-c'-1), (Ic-2), (I-c'-2), (Id), (I-d'), (Id-1), (Id-2), (Ie), (I-e'), (Ie-1), (Ie-2), (If), (I-f'), (II), (II-a), (II-a'), (III), (III'), (III-a), (III-a'), (III-b), (III-b'), (III-c), (III- The amount of a compound such as any of Compounds 1-552) can also be described as a percentage ("mol %") of the combined molar amount of the total lipids of the composition (e.g., the combined molar amounts of all lipids present in the liposomal delivery vehicle).
[0924] In embodiments of the pharmaceutical compositions described herein, a compound as described herein (e.g., Formula (A'), (A), (I), (Ia), (I-a'), (Ib), (I-b'), (Ic), (I-c'), (Ic-1), (I-c'-1), (Ic-2), (I-c'-2), (Id), (I-d'), (Id-1), (Id-2), (Ie), (I-e'), (Ie-1), (Ie-2), (If), (I-f'), (II), (II-a), (II-a'), (III), (III'), (III-a), (III-a'), (III-b), (III-b'), (III-c), (III-f' ... A compound of any of Compounds 1-552) is present in an amount of about 0.5 mol% to about 50 mol% (e.g., about 0.5 mol% to about 30 mol%) of the combined molar amount of all lipids present in a composition, such as a liposomal delivery vehicle.
[0925] In embodiments, Formula (A'), (A), (I), (Ia), (I-a'), (Ib), (I-b'), (Ic), (I-c'), (Ic-1), (I-c'-1 ), (Ic-2), (I-c'-2), (Id), (I-d'), (Id-1), (Id-2), (Ie), (I-e'), (Ie-1), (Ie-2), ( If), (I-f'), (II), (II-a), (II-a'), (III), (III'), (III-a), (III-a'), (III-b), (III-b'), (III-c), (III-c-1), (III-c'-1), (III-c-2), (III-c'-2), (III-c'), (III- d), (III-d'), (III-d-1), (III-d-2), (III-e), (III-e'), (III-e-1), (III-e-2), (III-f), (III-f'), (IV), (IV-a), or (IV-a'), such as any of Compounds 1-552, is present in an amount of about 0.5 mol% to about 5 mol%, about 1 mol% to about 10 mol%, about 5 mol% to about 20 mol%, about 10 mol% to about 20 mol%, about 20 mol% to about 30 mol%, about 30 mol% to about 40 mol%, about 40 mol% to about 50 mol%, or about 50 mol% to about 60 mol% of the combined molar amount of all lipids present in the composition, such as a liposomal delivery vehicle.In embodiments, a compound as described herein (e.g., Formula (A'), (A), (I), (Ia), (I-a'), (Ib), (I-b'), (Ic), (I-c'), (Ic-1), (I-c'-1), (Ic-2), (I-c'-2), (Id), (I-d'), (Id-1), (Id-2), (Ie), (I-e'), (Ie-1), (Ie-2), (If), (I-f'), (II), (II-a), (II-a'), (III), (III'), (III-a), (III-a'), (III-b), (III-b'), (III-c), (III-c-1), (III-c'-1), (III-c'-2), (III-c'-2 ), (III-c'), (III-d), (III-d'), (III-d-1), (III-d-2), (III-e), (III-e'), (III-e-1), (III-e-2), (III-f), (III-f'), (IV), (IV-a), or (IV-a'), such as any of Compounds 1-552) is present in an amount of about 1 mol% to about 50 mol%, about 1 mol% to about 40 mol%, about 1 mol% to about 30 mol%, about 1 mol% to about 20 mol%, about 1 mol% to about 15 mol%, about 1 mol% to about 10 mol%, or about 5 mol% to about 25 mol% of the combined dry weight of all lipids present in a composition, such as a liposomal delivery vehicle.
[0926] In certain embodiments, as described herein (e.g., Formula (A'), (A), (I), (Ia), (I-a'), (Ib), (I-b'), (Ic), (I-c'), (Ic-1), (I-c'-1), (Ic-2), (I-c'-2), (Id), (I-d'), (Id-1), (Id-2), (Ie), (I-e'), (Ie-1), (Ie-2), (If), (I-f'), (II), (II-a), (II-a'), (III), (III'), (III-a), (III-a'), (III-b), (III-b'), (III-c), (III-c-1), (III- A compound of any of Compounds 1-552) such as (III-c'-1), (III-c-2), (III-c'-2), (III-c'), (III-d), (III-d'), (III-d-1), (III-d-2), (III-e), (III-e'), (III-e-1), (III-e-2), (III-f), (III-f'), (IV), (IV-a), or (IV-a'), such as any of Compounds 1-552) can comprise from about 0.1 mol% to about 50 mol%, or from 0.5 mol% to about 50 mol%, or from about 1 mol% to about 25 mol%, or from about 1 mol% to about 10 mol% of the total amount of lipid in the composition (e.g., a liposomal delivery vehicle).
[0927] In certain embodiments, as described herein (e.g., Formula (A'), (A), (I), (Ia), (I-a'), (Ib), (I-b'), (Ic), (I-c'), (Ic-1), (I-c'-1), (Ic-2), (I-c'-2), (Id), (I-d'), (Id-1), (Id-2), (Ie), (I-e'), (Ie-1), (Ie-2), (If), (I-f'), (II), (II-a), (II-a'), (III), (III'), (III-a), (III-a'), (III-b), (III-b'), (III-c), (III-c-1), (III-c'-1), (III-c'-2), (III-c'-2), (III-f'), (II- c'), (III-d), (III-d'), (III-d-1), (III-d-2), (III-e), (III-e'), (III-e-1), (III-e-2), (III-f), (III-f'), (IV), (IV-a), or (IV-a'), such as any of compounds 1-552) can comprise greater than about 0.1 mol%, or greater than about 0.5 mol%, or greater than about 1 mol%, or greater than about 5 mol%, or greater than about 10 mol%, or greater than about 15 mol%, or greater than about 20 mol%, or greater than about 25 mol%, or greater than about 30 mol%, or greater than about 35 mol%, or greater than about 40 mol%, or greater than about 45 mol%, or greater than about 50 mol% of the total lipid in the lipid nanoparticle.
[0928] In certain embodiments, the compounds (e.g., Formula (A'), (A), (I), (Ia), (I-a'), (Ib), (I-b'), (Ic), (I-c'), (Ic-1), (I-c'-1), (Ic-2), (I-c'-2), (Id), (I-d'), (Id-1), (Id-2), (Ie), (I-e'), (Ie-1), (Ie-2), (If), (I-f'), (II), (II-a), (II-a'), (III), (III'), (III-a), (III-a'), (III-b), (III-b'), (III-c), (III-c-1), (III-c'-1), (III-c-2), A compound of (III-c'-2), (III-c'), (III-d), (III-d'), (III-d-1), (III-d-2), (III-e), (III-e'), (III-e-1), (III-e-2), (III-f), (III-f'), (IV), (IV-a), or (IV-a'), such as any of Compounds 1-552) can comprise less than about 50 mol%, or less than about 45 mol%, or less than about 40 mol%, or less than about 30 mol%, or less than about 25 mol%, or less than about 20 mol%, or less than about 10 mol%, or less than about 5 mol%, or less than about 1 mol% of the total lipid in the composition (e.g., a liposomal delivery vehicle).
[0929] In embodiments, a compound as described herein (e.g., Formula (A'), (A), (I), (Ia), (I-a'), (Ib), (I-b'), (Ic), (I-c'), (Ic-1), (I-c'-1), (Ic-2), (I-c'-2), (Id), (I-d'), (Id-1), (Id-2), (Ie), (I-e'), (Ie-1), (Ie-2), (If), (I-f'), (II), (II-a), (II-a'), (III), (III'), (III-a), (III-a'), (III-b), (III-c), (III-c-1), (III-c'-1), (III-c-2), (III-c'), (III-d), (III-d'), (III-d-1), (III-c-2), (III-c'), (III-d), (III-d'), (III-d-1), (III-f'), (III-f'), (III-f'), (III-f'), (III-f'), (III-f'), (III-f'), (III-f'), (III-f'), (III-f'), (III-f'), (III-f'), (III-f'), (III-f'), (III-f'), (III-f'), (III-f'), (III-f'), (III-f'), (III-f'), (III-f'), (III-f'), (III-f'), (III-f %, about 70 mol%, about 75 mol%, about 80 mol%, about 85 mol%, about 90 mol%, about 95 mol%, about 96 mol%, about 97 mol%, about 98 mol% or about 99 mol% of the combined dry weight of the total lipids in the composition (e.g., a liposomal composition).
[0930] In embodiments, a compound as described herein (e.g., Formula (A'), (A), (I), (Ia), (I-a'), (Ib), (I-b'), (Ic), (I-c'), (Ic-1), (I-c'-1), (Ic-2), (I-c'-2), (Id), (I-d'), (Id-1), (Id-2), (Ie), (I-e'), (Ie-1), (Ie-2), (If), (I-f'), (II), (II-a), (II-a'), (III), (III'), (III-a), (III-a'), (III-b), (III-c), (III-c-1), (III-c'-1), (III-c-2), (III-c'), (III-d), (III-d'), (III-d-1), (III-c-2), (III-c'), (III-d), (III-d'), (III-d-1), (III-f'), (III-f'), (III-f'), (III-f'), (III-f'), (III-f'), (III-f'), (III-f'), (III-f'), (III-f'), (III-f'), (III-f'), (III-f'), (III-f'), (III-f'), (III-f'), (III-f'), (III-f'), (III-f'), (III-f'), (III-f'), (III-f'), (III-f'), (III-f %, about 70 mol%, about 75 mol%, about 80 mol%, about 85 mol%, about 90 mol%, about 95 mol%, about 96 mol%, about 97 mol%, about 98 mol% or about 99 mol% of the combined dry weight of the total lipids in the composition (e.g., a liposomal composition).
[0931] In embodiments, this percentage results in an improved beneficial effect (eg, improved delivery to a target tissue such as the liver or lung).
[0932] In embodiments, the composition further comprises one or more lipids (e.g., one or more lipids selected from the group consisting of one or more cationic lipids, one or more non-cationic lipids, one or more cholesterol-based lipids, and one or more PEG-modified lipids).
[0933] In certain embodiments, such pharmaceutical (e.g., liposome) compositions comprise one or more of PEG-modified lipids, non-cationic lipids, and cholesterol lipids. In embodiments, such pharmaceutical (e.g., liposome) compositions comprise: one or more PEG-modified lipids, one or more non-cationic lipids, and one or more cholesterol lipids. In embodiments, such pharmaceutical (e.g., liposome) compositions comprise: one or more PEG-modified lipids and one or more cholesterol lipids.
[0934] In embodiments, a composition (e.g., a lipid nanoparticle) that encapsulates a nucleic acid (e.g., an mRNA encoding a peptide or protein) comprises one or more compounds as described herein (e.g., Formula (A'), (A), (I), (Ia), (I-a'), (Ib), (I-b'), (Ic), (I-c'), (Ic-1), (I-c'-1), (Ic-2), (I-c'-2), (Id), (I-d'), (Id-1), (Id-2), (Ie), (I-e'), (Ie-1), (Ie-2), (If), (I-f'), (II), (II-a), (II-a'), (III), (III'), (III-a), (III-2), (III-3'), (III-4'), (III-5'), (III-6'), (III-7'), (III-8'), (III-9'), (III-10'), (III-11'), (III-12'), (III-13'), (III-14'), (III-15'), (III-16'), (III-17'), (III-18'), (III-19'), (III-20'), (III-21'), (III-22'), (III-33'), (III-34'), (III-35'), (III-36'), (III-37'), (III-38'), (III-39'), (III-40'), (III-5
[00155] In some embodiments, the present invention comprises a compound selected from the group consisting of: (III-a'), (III-b), (III-b'), (III-c), (III-c-1), (III-c'-1), (III-c-2), (III-c'-2), (III-c'), (III-d), (III-d'), (III-d-1), (III-d-2), (III-e), (III-e'), (III-e-1), (III-e-2), (III-f), (III-f'), (IV), (IV-a) or (IV-a'), such as any one of compounds 1-552, and one or more lipids selected from the group consisting of a cationic lipid, a non-cationic lipid and a PEGylated lipid.
[0935] In embodiments, a composition (e.g., a lipid nanoparticle) that encapsulates a nucleic acid (e.g., an mRNA encoding a peptide or protein) comprises one or more compounds as described herein (e.g., Formula (A'), (A), (I), (Ia), (I-a'), (Ib), (I-b'), (Ic), (I-c'), (Ic-1), (I-c'-1), (Ic-2), (I-c'-2), (Id), (I-d'), (Id-1), (Id-2), (Ie), (I-e'), (Ie-1), (Ie-2), (If), (I-f'), (II), (II-a), (II-a'), (III), (III'), (III-a), (III-a'), , (III-b), (III-b'), (III-c), (III-c-1), (III-c'-1), (III-c-2), (III-c'), (III-d), (III-d'), (III-d-1), (III-d-2), (III-e), (III-e'), (III-e-1), (III-e-2), (III-f), (III-f'), (IV), (IV-a) or (IV-a'), such as any one of compounds 1-552); one or more lipids selected from the group consisting of cationic lipids, non-cationic lipids and PEGylated lipids; and further comprising a cholesterol-based lipid.
[0936] In embodiments, lipid nanoparticles encapsulating nucleic acids (e.g., mRNA encoding a peptide or protein) comprise one or more compounds as described herein (e.g., Formula (A'), (A), (I), (Ia), (I-a'), (Ib), (I-b'), (Ic), (I-c'), (Ic-1), (I-c'-1), (Ic-2), (I-c'-2), (Id), (I-d'), (Id-1), (Id-2), (Ie), (I-e'), (Ie-1), (Ie-2), (If), (I-f'), (II), (II-a), (II-a'), (III), (III'), (III-a), (III-a'), (I II-b), (III-b'), (III-c), (III-c-1), (III-c'-1), (III-c-2), (III-c'-2), (III-c'), (III-d), (III-d'), (III-d-1), (III-d-2), (III-e), (III-e'), (III-e-1), (III-e-2), (III-f), (III-f'), (IV), (IV-a), or (IV-a'), such as any one of compounds 1-552), and one or more lipids selected from the group consisting of a cationic lipid, a non-cationic lipid, a PEGylated lipid, and a cholesterol-based lipid.
[0937] According to various embodiments, the selection of cationic lipids, non-cationic lipids and / or PEG-modified lipids comprising lipid nanoparticles, and the relative molar ratios of these lipids to each other are based on the characteristics of the selected lipid, the properties of the expected target cells, the characteristics of the mRNA to be delivered. Other considerations include, for example, the size, charge, pH, pKa, fusogenicity and toxicity of the alkyl chain saturation and the selected lipid. Therefore, the molar ratio can be adjusted accordingly.
[0938] Cationic lipids
[0939] In addition to the compounds described herein (e.g., Formula (A'), (A), (I), (Ia), (I-a'), (Ib), (I-b'), (Ic), (I-c'), (Ic-1), (I-c'-1), (Ic-2), (I-c'-2), (Id), (I-d'), (Id-1), (Id-2), (Ie), (I-e'), (Ie-1), (Ie-2), (If), (I-f'), (II), (II-a), (II-a'), (III), (III'), (III-a), (III-a'), (III-b), (III- In addition to any of the compounds of formula (b'), (III-c), (III-c-1), (III-c'-1), (III-c-2), (III-c'-2), (III-c'), (III-d), (III-d'), (III-d-1), (III-d-2), (III-e), (III-e'), (III-e-1), (III-e-2), (III-f), (III-f'), (IV), (IV-a), or (IV-a'), such as any of compounds 1-552), the composition may also contain one or more additional cationic lipids.
[0940] In some embodiments, liposomes may comprise one or more additional cationic lipids. As used herein, the phrase "cationic lipid" refers to any of a variety of lipid species having a net positive charge at a selected pH, such as physiological pH. Several cationic lipids have been described in the literature, many of which are commercially available.
[0941] Suitable cationic lipids for the compositions and methods of the present invention include cationic lipids as described in International Patent Publication WO 2010 / 144740, which is incorporated herein by reference. In certain embodiments, the compositions and methods of the present invention include cationic lipids, (6Z, 9Z, 28Z, 31Z)-heptatriacontac-6, 9, 28, 31-tetraene-19-base 4-(dimethylamino) butyric acid, and the cationic lipids have the following compound structure:
[0942]
[0943] and pharmaceutically acceptable salts thereof.
[0944] Other suitable cationic lipids for use in the compositions and methods of the present invention include ionizable cationic lipids as described in International Patent Publication WO2013 / 149140, which is incorporated herein by reference. In some embodiments, the compositions and methods of the present invention include a cationic lipid of one of the following formulas:
[0945]
[0946] or a pharmaceutically acceptable salt thereof, wherein R1 and R2 are each independently selected from the group consisting of hydrogen, optionally substituted different saturated or unsaturated C1-C 20 alkyl and optionally substituted different saturated or unsaturated C6-C 20 Acyl; wherein L1 and L2 are each independently selected from the group consisting of hydrogen, optionally substituted C1-C 30 Alkyl, optionally substituted different unsaturated C1-C 30 Alkenyl and optionally substituted C1-C 30 Alkynyl; wherein m and o are each independently selected from the group consisting of: zero and any positive integer (e.g., wherein m is three); and wherein n is zero or any positive integer (e.g., wherein n is one). In certain embodiments, the compositions and methods of the present invention include a cationic lipid (15Z, 18Z)-N, N-dimethyl-6-((9Z, 12Z)-octadeca-9,12-dien-1-yl)tetracosa-15,18-dien-1-amine ("HGT5000") having the following compound structure:
[0947]
[0948] and pharmaceutically acceptable salts thereof. In certain embodiments, the compositions and methods of the present invention include a cationic lipid (15Z,18Z)-N,N-dimethyl-6-((9Z,12Z)-octadeca-9,12-dien-1-yl)tetracosa-4,15,18-trien-1-amine ("HGT5001") having the following compound structure:
[0949]
[0950] and pharmaceutically acceptable salts thereof. In certain embodiments, the compositions and methods of the present invention include a cationic lipid and (15Z,18Z)-N,N-dimethyl-6-((9Z,12Z)-octadeca-9,12-dien-1-yl)tetracosa-5,15,18-trien-1-amine ("HGT5002"), wherein the cationic lipid has the following compound structure:
[0951]
[0952] and pharmaceutically acceptable salts thereof.
[0953] Other suitable cationic lipids for the compositions and methods of the present invention include cationic lipids described as amino alcohol lipids in International Patent Publication WO2010 / 053572, which is incorporated herein by reference. In certain embodiments, the compositions and methods of the present invention include cationic lipids having the following compound structure:
[0954]
[0955] and pharmaceutically acceptable salts thereof.
[0956] Other suitable cationic lipids for the compositions and methods of the present invention include cationic lipids as described in International Patent Publication WO2016 / 118725, which is incorporated herein by reference. In certain embodiments, the compositions and methods of the present invention include cationic lipids having the following compound structure:
[0957]
[0958] and pharmaceutically acceptable salts thereof.
[0959] Other suitable cationic lipids for the compositions and methods of the present invention include cationic lipids as described in International Patent Publication WO2016 / 118724, which is incorporated herein by reference. In certain embodiments, the compositions and methods of the present invention include cationic lipids having the following compound structure:
[0960]
[0961] and pharmaceutically acceptable salts thereof.
[0962] Other suitable cationic lipids for use in the compositions and methods of the present invention include cationic lipids having the general formula 14,25-di-tridecyl-15,18,21,24-tetraaza-octatriacontane and pharmaceutically acceptable salts thereof.
[0963] Other suitable cationic lipids for the compositions and methods of the present invention include cationic lipids as described in International Patent Publications WO 2013 / 063468 and WO 2016 / 205691, each of which is incorporated herein by reference. In some embodiments, the compositions and methods of the present invention include a cationic lipid having the formula:
[0964]
[0965] or a pharmaceutically acceptable salt thereof, wherein R L Each instance of is independently optionally substituted C6-C 40In certain embodiments, the compositions and methods of the present invention include a cationic lipid having the following compound structure:
[0966]
[0967] and pharmaceutically acceptable salts thereof. In certain embodiments, the compositions and methods of the present invention include a cationic lipid having the following compound structure:
[0968]
[0969] and pharmaceutically acceptable salts thereof. In certain embodiments, the compositions and methods of the present invention include a cationic lipid having the following compound structure:
[0970]
[0971] and pharmaceutically acceptable salts thereof. In certain embodiments, the compositions and methods of the present invention include a cationic lipid having the following compound structure:
[0972]
[0973] and pharmaceutically acceptable salts thereof.
[0974] Other suitable cationic lipids for use in the compositions and methods of the present invention include cationic lipids as described in International Patent Publication WO2015 / 184256, which is incorporated herein by reference. In some embodiments, the compositions and methods of the present invention include a cationic lipid having the formula:
[0975]
[0976] or a pharmaceutically acceptable salt thereof, wherein each X is independently O or S; each Y is independently O or S; each m is independently 0 to 20; each n is independently 1 to 6; each R A R is independently hydrogen, optionally substituted C1-50 alkyl, optionally substituted C2-50 alkenyl, optionally substituted C2-50 alkynyl, optionally substituted C3-10 carbocyclyl, optionally substituted 3-14 membered heterocyclyl, optionally substituted C6-14 aryl, optionally substituted 5-14 membered heteroaryl or halogen; and each R BIn certain embodiments, the compositions and methods of the present invention include a cationic lipid "target 23" having the following compound structure:
[0977]
[0978] (Target 23) and pharmaceutically acceptable salts thereof.
[0979] Other suitable cationic lipids for the compositions and methods of the present invention include cationic lipids as described in International Patent Publication WO2016 / 004202, which is incorporated herein by reference. In some embodiments, the compositions and methods of the present invention include cationic lipids having the following compound structure:
[0980]
[0981] Or a pharmaceutically acceptable salt thereof. In some embodiments, the compositions and methods of the present invention include a cationic lipid having the following compound structure:
[0982]
[0983] Or a pharmaceutically acceptable salt thereof. In some embodiments, the compositions and methods of the present invention include a cationic lipid having the following compound structure:
[0984]
[0985] or a pharmaceutically acceptable salt thereof.
[0986] Other suitable cationic lipids for the compositions and methods of the present invention include cationic lipids such as J.McClellan, MCKing, Cell 2010, 141, 210-217 and Whitehead et al., Nature Communications (2014) 5: 4277, which are incorporated herein by reference. In certain embodiments, the cationic lipids of the compositions and methods of the present invention include cationic lipids with the following compound structure:
[0987]
[0988] and pharmaceutically acceptable salts thereof.
[0989] Other suitable cationic lipids for the compositions and methods of the present invention include cationic lipids as described in International Patent Publication WO2015 / 199952, which is incorporated herein by reference. In some embodiments, the compositions and methods of the present invention include cationic lipids having the following compound structure:
[0990]
[0991] and pharmaceutically acceptable salts thereof. In some embodiments, the compositions and methods of the present invention include a cationic lipid having the following compound structure:
[0992]
[0993] and pharmaceutically acceptable salts thereof. In some embodiments, the compositions and methods of the present invention include a cationic lipid having the following compound structure:
[0994]
[0995] and pharmaceutically acceptable salts thereof. In some embodiments, the compositions and methods of the present invention include a cationic lipid having the following compound structure:
[0996]
[0997] and pharmaceutically acceptable salts thereof. In some embodiments, the compositions and methods of the present invention include a cationic lipid having the following compound structure:
[0998]
[0999] and pharmaceutically acceptable salts thereof. In some embodiments, the compositions and methods of the present invention include a cationic lipid having the following compound structure:
[1000]
[1001] and pharmaceutically acceptable salts thereof. In some embodiments, the compositions and methods of the present invention include a cationic lipid having the following compound structure:
[1002]
[1003] and pharmaceutically acceptable salts thereof. In some embodiments, the compositions and methods of the present invention include a cationic lipid having the following compound structure:
[1004]
[1005] and pharmaceutically acceptable salts thereof. In some embodiments, the compositions and methods of the present invention include a cationic lipid having the following compound structure:
[1006]
[1007] and pharmaceutically acceptable salts thereof. In some embodiments, the compositions and methods of the present invention include a cationic lipid having the following compound structure:
[1008]
[1009] and pharmaceutically acceptable salts thereof. In some embodiments, the compositions and methods of the present invention include a cationic lipid having the following compound structure:
[1010]
[1011] and pharmaceutically acceptable salts thereof. In some embodiments, the compositions and methods of the present invention include a cationic lipid having the following compound structure:
[1012]
[1013] and pharmaceutically acceptable salts thereof. In some embodiments, the compositions and methods of the present invention include a cationic lipid having the following compound structure:
[1014]
[1015] and pharmaceutically acceptable salts thereof.
[1016] Other suitable cationic lipids for the compositions and methods of the present invention include cationic lipids as described in International Patent Publication WO2017 / 004143, which is incorporated herein by reference. In some embodiments, the compositions and methods of the present invention include cationic lipids having the following compound structure:
[1017]
[1018] and pharmaceutically acceptable salts thereof. In some embodiments, the compositions and methods of the present invention include a cationic lipid having the following compound structure:
[1019]
[1020] and pharmaceutically acceptable salts thereof. In some embodiments, the compositions and methods of the present invention include a cationic lipid having the following compound structure:
[1021]
[1022] and pharmaceutically acceptable salts thereof. In some embodiments, the compositions and methods of the present invention include a cationic lipid having the following compound structure:
[1023]
[1024] and pharmaceutically acceptable salts thereof. In some embodiments, the compositions and methods of the present invention include a cationic lipid having the following compound structure:
[1025]
[1026] and pharmaceutically acceptable salts thereof. In some embodiments, the compositions and methods of the present invention include a cationic lipid having the following compound structure:
[1027]
[1028] and pharmaceutically acceptable salts thereof. In some embodiments, the compositions and methods of the present invention include a cationic lipid having the following compound structure:
[1029]
[1030] and pharmaceutically acceptable salts thereof. In some embodiments, the compositions and methods of the present invention include a cationic lipid having the following compound structure:
[1031]
[1032] and pharmaceutically acceptable salts thereof. In some embodiments, the compositions and methods of the present invention include a cationic lipid having the following compound structure:
[1033]
[1034] and pharmaceutically acceptable salts thereof. In some embodiments, the compositions and methods of the present invention include a cationic lipid having the following compound structure:
[1035]
[1036] and pharmaceutically acceptable salts thereof. In some embodiments, the compositions and methods of the present invention include a cationic lipid having the following compound structure:
[1037]
[1038] and pharmaceutically acceptable salts thereof. In some embodiments, the compositions and methods of the present invention include a cationic lipid having the following compound structure:
[1039]
[1040] and pharmaceutically acceptable salts thereof. In some embodiments, the compositions and methods of the present invention include a cationic lipid having the following compound structure:
[1041]
[1042] and pharmaceutically acceptable salts thereof. In some embodiments, the compositions and methods of the present invention include a cationic lipid having the following compound structure:
[1043]
[1044] and pharmaceutically acceptable salts thereof. In some embodiments, the compositions and methods of the present invention include a cationic lipid having the following compound structure:
[1045]
[1046] and pharmaceutically acceptable salts thereof. In some embodiments, the compositions and methods of the present invention include a cationic lipid having the following compound structure:
[1047]
[1048] and pharmaceutically acceptable salts thereof. In some embodiments, the compositions and methods of the present invention include a cationic lipid having the following compound structure:
[1049]
[1050] and pharmaceutically acceptable salts thereof.
[1051] Other suitable cationic lipids for use in the compositions and methods of the present invention include cationic lipids as described in International Patent Publication WO2017 / 075531, which is incorporated herein by reference. In some embodiments, the compositions and methods of the present invention include a cationic lipid having the formula:
[1052]
[1053] or a pharmaceutically acceptable salt thereof, wherein L 1 or L 2 One of them is -O(C=O)-, -(C=O)O-, -C(=O)-, -O-, -S(O) x , -SS-, -C(=O)S-, -SC(=O)-, -NR a C(=O)-, -C(=O)NR a -、NR a C(=O)NR a-、-OC(=O)NR a -or-NR a C(=O)O-; and L 1 or L 2 The other is -O(C=O)-, -(C=O)O-, -C(=O)-, -O-, -S(O) x , -SS-, -C(=O)S-, SC(=O)-, -NR a C(=O)-, -C(=O)NR a -、NR a C(=O)NR a -、-OC(=O)NR a -or-NR a C(=O)O- or direct bond; G 1 and G 2 Each independently is an unsubstituted C1-C 12 Alkylene or C1-C 12 Alkenylene; G 3 It is C1-C 24 Alkylene, C1-C 24 Alkenylene, C3-C8 cycloalkylene, C3-C8 cycloalkenylene; R a Is H or C1-C 12 Alkyl; R 1 and R 2 Each independently is C6-C 24 Alkyl or C6-C 24 Alkenyl; R 3 It is H, OR 5 、CN、-C(=O)OR 4 、-OC(=O)R 4 or -NR 5 C(=O)R 4 ; R 4 It is C1-C 12 Alkyl; R 5 is H or C1-C6 alkyl; and x is 0, 1 or 2.
[1054] Other suitable cationic lipids for the compositions and methods of the present invention include cationic lipids as described in International Patent Publication WO2017 / 117528, which is incorporated herein by reference. In some embodiments, the compositions and methods of the present invention include cationic lipids having the following compound structure:
[1055]
[1056] and pharmaceutically acceptable salts thereof. In some embodiments, the compositions and methods of the present invention include a cationic lipid having the following compound structure:
[1057]
[1058] and pharmaceutically acceptable salts thereof. In some embodiments, the compositions and methods of the present invention include a cationic lipid having the following compound structure:
[1059]
[1060] and pharmaceutically acceptable salts thereof.
[1061] Other suitable cationic lipids for use in the compositions and methods of the present invention include cationic lipids as described in International Patent Publication WO2017 / 049245, which is incorporated herein by reference. In some embodiments, the cationic lipids of the compositions and methods of the present invention include compounds having one of the following formulae:
[1062]
[1063]
[1064] and pharmaceutically acceptable salts thereof. For any of the four general formulae, R4 is independently selected from -(CH2) n Q and -(CH2) n CHQR; Q is selected from the group consisting of -OR, -OH, -O(CH2) n N(R)2, -OC(O)R, -CX3, -CN, -N(R)C(O)R, -N(H)C(O)R, -N(R)S(O)2R, -N(H)S(O)2R, -N(R)C(O)N(R)2, -N(H)C(O)N(R)2, -N(H)C(O)N(H)(R), -N(R)C(S)N(R)2, -N(H)C(S)N(R)2, -N(H)C(S)N(H)(R), and heterocycle; and n is 1, 2, or 3. In certain embodiments, the compositions and methods of the present invention include cationic lipids having the following compound structures:
[1065]
[1066] and pharmaceutically acceptable salts thereof. In certain embodiments, the compositions and methods of the present invention include a cationic lipid having the following compound structure:
[1067]
[1068] and pharmaceutically acceptable salts thereof. In certain embodiments, the compositions and methods of the present invention include a cationic lipid having the following compound structure:
[1069]
[1070] and pharmaceutically acceptable salts thereof. In certain embodiments, the compositions and methods of the present invention include a cationic lipid having the following compound structure:
[1071]
[1072] and pharmaceutically acceptable salts thereof.
[1073] Other suitable cationic lipids for the compositions and methods of the present invention include cationic lipids as described in International Patent Publications WO 2017 / 173054 and WO 2015 / 095340, each of which is incorporated herein by reference. In certain embodiments, the compositions and methods of the present invention include cationic lipids having the following compound structure:
[1074]
[1075] and pharmaceutically acceptable salts thereof. In certain embodiments, the compositions and methods of the present invention include a cationic lipid having the following compound structure:
[1076]
[1077] and pharmaceutically acceptable salts thereof. In certain embodiments, the compositions and methods of the present invention include a cationic lipid having the following compound structure:
[1078]
[1079] and pharmaceutically acceptable salts thereof. In certain embodiments, the compositions and methods of the present invention include a cationic lipid having the following compound structure:
[1080]
[1081] and pharmaceutically acceptable salts thereof.
[1082] Other suitable cationic lipids for use in the compositions and methods of the present invention include cleavable cationic lipids as described in International Patent Publication WO2012 / 170889, which is incorporated herein by reference. In some embodiments, the compositions and methods of the present invention include a cationic lipid having the formula:
[1083]
[1084] wherein R1 is selected from the group consisting of imidazole, guanidine, amino, imine, enamine, optionally substituted alkylamino (e.g., alkylamino such as dimethylamino), and pyridyl; wherein R2 is selected from the group consisting of one of the following two general formulae:
[1085]
[1086] and wherein R3 and R4 are each independently selected from the group consisting of: optionally substituted different saturated or unsaturated C6-C 20 alkyl and optionally substituted different saturated or unsaturated C6-C 20 Acyl; and wherein n is zero or any positive integer (e.g., one, two, three, four, five, six, seven, eight, nine, ten, eleven, twelve, thirteen, fourteen, fifteen, sixteen, seventeen, eighteen, nineteen, twenty or more). In certain embodiments, the compositions and methods of the present invention include a cationic lipid "HGT4001" having the following compound structure:
[1087]
[1088] and pharmaceutically acceptable salts thereof. In certain embodiments, the compositions and methods of the present invention include a cationic lipid having the following compound structure, "HGT4002":
[1089]
[1090]
[1091] and pharmaceutically acceptable salts thereof. In certain embodiments, the compositions and methods of the present invention include a cationic lipid having the following compound structure, "HGT4003":
[1092]
[1093] and pharmaceutically acceptable salts thereof. In certain embodiments, the compositions and methods of the present invention include a cationic lipid having the following compound structure, "HGT4004":
[1094]
[1095] and pharmaceutically acceptable salts thereof. In certain embodiments, the compositions and methods of the present invention include a cationic lipid "HGT4005" having the following compound structure:
[1096]
[1097] and pharmaceutically acceptable salts thereof.
[1098] In some embodiments, the compositions and methods of the present invention include the cationic lipid, N-[1-(2,3-dioleyloxy)propyl]-N,N,N-trimethylammonium chloride ("DOTMA") (Feigner et al., Proc. Nat'l Acad. Sci. 84, 7413 (1987); U.S. Pat. No. 4,897,355, which is incorporated herein by reference). Other cationic lipids suitable for the compositions and methods of the present invention include, for example, 5-carboxysperminylglycine dioctadecylamide ("DOGS"); 2,3-dioleyloxy-N-[2-(spermine-carboxamide)ethyl]-N,N-dimethyl-1-propylammonium ("DOSPA") (Behr et al. Proc. Nat. 'l Acad. Sci. 86, 6982 (1989), U.S. Pat. No. 5,171,678; U.S. Pat. No. 5,334,761); 1,2-dioleoyl-3-dimethylammonium-propane ("DODAP"); 1,2-dioleoyl-3-trimethylammonium-propane ("DOTAP").
[1099] Additional exemplary cationic lipids suitable for the compositions and methods of the present invention also include: 1,2-distearoyloxy-N,N-dimethyl-3-aminopropane ("DSDMA"), 1,2-dioleyloxy-N,N-dimethyl-3-aminopropane ("DODMA"), 1,2-dilinoleyloxy-N,N-dimethyl-3-aminopropane ("DLinDMA"), 1,2-dilinoleyloxy-N,N-dimethyl-3-aminopropane ("DLenDMA"), N-dioleyl-N,N-dimethylammonium chloride ("DODAC"), N,N-distearoyl-N,N-dimethylammonium bromide ("DDAB"), N-(1,2-dimyristyloxyprop-3-yl)-1,2-dioctyl ... )-N,N-dimethyl-N-hydroxyethylammonium bromide ("DMRIE"), 3-dimethylamino-2-(cholest-5-en-3-β-oxybutane-4-oxy)-1-(cis,cis-9,12-octadecadienyloxy)propane ("CLinDMA"), 2-[5'-(cholest-5-en-3-β-oxy)-3'-oxapentyloxy)-3-dimethyl-1-(cis,cis-9',1-2'-octadecadienyloxy)propane ("CpLinDMA"), N,N-dimethyl-3,4-dioleyloxybenzylamine ("DMOBA"), 1,2-N,N'-dioleylcarbamoyl-3-dimethylaminopropane ("DOcarbDAP"), 2,3 -dilinoleoyloxy-N,N-dimethylpropylamine ("DLinDAP"), 1,2-N,N'-dilinoleylcarbamoyl-3-dimethylaminopropane ("DLincarbDAP"), 1,2-dilinoleylcarbamoyl-3-dimethylaminopropane ("DLinCDAP"), 2,2-dilinoleyl-4-dimethylaminomethyl-[1,3]-dioxolane ("DLin-K-DMA"), 2-((8-[(3β)-cholest-5-en-3-yloxy]octyl)oxy)-N,N-dimethyl-3-[(9Z,12Z)-octadeca-9,12-dien-1-yloxy]propane-1-amine ("octyl-CLinDMA"), (2R) -2-((8-[(3β)-cholest-5-en-3-yloxy]octyl)oxy)-N,N-dimethyl-3-[(9Z,12Z)-octadeca-9,12-dien-1-yloxy]propan-1-amine (“octyl-CLinDMA(2R)”), (2S)-2-((8-[(3β)-cholest-5-en-3-yloxy]octyl)oxy)-N,N-dimethyl-3-[(9Z,12Z)-octadeca-9,12-dien-1-yloxy]propan-1-amine (“octyl-CLinDMA(2S)”), 2,2-dilinoleyl-4-dimethylaminoethyl-[1,3]-dioxolane (“DLin-K-XTC2-DMA”), and 2-(2,2-bis((9Z,12Z)-octadeca-9,12-dien-1-yl)-1,3-dioxolan-4-yl)-N,N-dimethylethylamine ("DLin-KC2-DMA") (see WO 2010 / 042877, incorporated herein by reference; Semple et al., Nature Biotech. 28:172-176 (2010)). (Heyes, J. et al., J Controlled Release 107:276-287 (2005); Morrissey, DV. et al., Nat. Biotechnol. 23(8):1003-1007 (2005); International Patent Publication No. WO 2005 / 121348). In some embodiments, the one or more cationic lipids comprise at least one of an imidazole, dialkylamino, or guanidinium moiety.
[1100] In some embodiments, one or more cationic lipids suitable for the compositions and methods of the present invention include 2,2-dilinoleyl-4-dimethylaminoethyl-[1,3]-dioxolane ("XTC"); (3aR,5s,6aS)-N,N-dimethyl-2,2-di((9Z,12Z)-octadeca-9,12-dienyl)tetrahydro-3aH-cyclopenta[d][1,3]dioxol-5-amine ("ALNY-100") and / or 4,7,13-tris(3-oxo-3-(undecylamino)propyl)-N1,N16-di-undecyl-4,7,10,13-tetraazahexadecane-1,16-diamide ("NC98-5").
[1101] In some embodiments, the compositions of the invention comprise one or more cationic lipids that comprise at least about 5%, 10%, 20%, 30%, 35%, 40%, 45%, 50%, 55%, 60%, 65%, or 70% by weight of the total lipid content in the composition (e.g., lipid nanoparticles). In some embodiments, the compositions of the invention comprise one or more cationic lipids that comprise at least about 5%, 10%, 20%, 30%, 35%, 40%, 45%, 50%, 55%, 60%, 65%, or 70% by mol% of the total lipid content in the composition (e.g., lipid nanoparticles). In some embodiments, a composition of the invention comprises one or more cationic lipids that comprise about 30%-70% (e.g., about 30%-65%, about 30%-60%, about 30%-55%, about 30%-50%, about 30%-45%, about 30%-40%, about 35%-50%, about 35%-45%, or about 35%-40%) of the total lipid content in the composition (e.g., lipid nanoparticle) by weight. In some embodiments, the compositions of the invention comprise one or more cationic lipids that comprise about 30%-70% (e.g., about 30%-65%, about 30%-60%, about 30%-55%, about 30%-50%, about 30%-45%, about 30%-40%, about 35%-50%, about 35%-45%, or about 35%-40%) of the total lipid content in the composition (e.g., lipid nanoparticle) on a mol% basis.
[1102] Non-cationic / helper lipids
[1103] In some embodiments, liposomes contain one or more non-cationic ("helper") lipids. As used herein, the phrase "non-cationic lipid" refers to any neutral, zwitterionic or anionic lipid. As used herein, the phrase "anionic lipid" refers to any of a variety of lipid substances that carry a net negative charge at a selected pH such as physiological pH. Non-cationic lipids include but are not limited to distearoylphosphatidylcholine (DSPC), dioleoylphosphatidylcholine (DOPC), dipalmitoylphosphatidylcholine (DPPC), dioleoylphosphatidylglycerol (DOPG), dipalmitoylphosphatidylglycerol (DPPG), dioleoylphosphatidylethanolamine (DOPE), palmitoyloleoylphosphatidylcholine (POPC), palmitoyloleoyl-phosphatidylethanolamine (POPE), 4-(N-maleimidomethyl)-cyclohexane-l-carboxylic acid dioleoyl-phosphatidylethanolamine ( In some embodiments, the liposomes suitable for use in the present invention include DOPE as a non-cationic lipid component. In other embodiments, the liposomes suitable for use in the present invention include DEPE as a non-cationic lipid component.
[1104] In some embodiments, the non-cationic lipid is a neutral lipid, ie, a lipid that carries no net charge under the conditions under which the composition is formulated and / or administered.
[1105] In some embodiments, such non-cationic lipids can be used alone, but are preferably used in combination with other lipids (eg, cationic lipids).
[1106] In some embodiments, the non-cationic lipid can exist at a mol ratio (mol%) of about 5% to about 90%, about 5% to about 70%, about 5% to about 50%, about 5% to about 40%, about 5% to about 30%, about 10% to about 70%, about 10% to about 50% or about 10% to about 40% of the total lipid present in the compositions. In some embodiments, the total non-cationic lipid can exist at a mol ratio (mol%) of about 5% to about 90%, about 5% to about 70%, about 5% to about 50%, about 5% to about 40%, about 5% to about 30%, about 10% to about 70%, about 10% to about 50% or about 10% to about 40% of the total lipid present in the compositions. In some embodiments, the percentage of non-cationic lipid in the liposome can be greater than about 5mol%, greater than about 10mol%, greater than about 20mol%, greater than about 30mol% or greater than about 40mol%. In some embodiments, the percentage of total non-cationic lipids in the liposome can be greater than about 5 mol%, greater than about 10 mol%, greater than about 20 mol%, greater than about 30 mol% or greater than about 40 mol%. In some embodiments, the percentage of non-cationic lipids in the liposome is no more than about 5 mol%, no more than about 10 mol%, no more than about 20 mol%, no more than about 30 mol% or no more than about 40 mol%. In some embodiments, the percentage of total non-cationic lipids in the liposome can be no more than about 5 mol%, no more than about 10 mol%, no more than about 20 mol%, no more than about 30 mol% or no more than about 40 mol%.
[1107] In some embodiments, the non-cationic lipid can exist at a weight ratio (wt %) of about 5% to about 90%, about 5% to about 70%, about 5% to about 50%, about 5% to about 40%, about 5% to about 30%, about 10% to about 70%, about 10% to about 50% or about 10% to about 40% of the TL present in the compositions. In some embodiments, the total non-cationic lipid can exist at a weight ratio (wt %) of about 5% to about 90%, about 5% to about 70%, about 5% to about 50%, about 5% to about 40%, about 5% to about 30%, about 10% to about 70%, about 10% to about 50% or about 10% to about 40% of the TL present in the compositions. In some embodiments, the per-cent of non-cationic lipid can be greater than about 5 wt %, greater than about 10 wt %, greater than about 20 wt %, greater than about 30 wt % or greater than about 40 wt %. In some embodiments, the percentage of total non-cationic lipid in the liposome can be greater than about 5 % by weight, greater than about 10 % by weight, greater than about 20 % by weight, greater than about 30 % by weight or greater than about 40 % by weight. In some embodiments, the percentage of non-cationic lipid in the liposome is no more than about 5 % by weight, no more than about 10 % by weight, no more than about 20 % by weight, no more than about 30 % by weight or no more than about 40 % by weight. In some embodiments, the percentage of total non-cationic lipid in the liposome can be no more than about 5 % by weight, no more than about 10 % by weight, no more than about 20 % by weight, no more than about 30 % by weight or no more than about 40 % by weight.
[1108] Cholesterol-based lipids
[1109] In some embodiments, the liposomes comprise one or more cholesterol-based lipids. For example, suitable cholesterol-based lipids include, for example, DC-Chol (N,N-dimethyl-N-ethylcarboxamide cholesterol), 1,4-bis(3-N-oleylamino-propyl)piperazine (Gao et al., Biochem.Biophys.Res.Comm.179,280 (1991); Wolf et al., BioTechniques 23,139 (1997); U.S. Patent No. 5,744,335) or imidazole cholesterol ester (ICE), which has the following structure,
[1110]
[1111] In embodiments, the cholesterol-based lipid is cholesterol.
[1112] In some embodiments, cholesterol-based lipids can account for a mol ratio (mol%) of about 1% to about 30% or about 5% to about 20% of the total lipids present in the liposome. In some embodiments, the percentage of cholesterol-based lipids in the lipid nanoparticles can be greater than about 5mol%, greater than about 10mol%, greater than about 20mol%, greater than about 30mol% or greater than about 40mol%. In some embodiments, the percentage of cholesterol-based lipids in the lipid nanoparticles can be no more than about 5mol%, no more than about 10mol%, no more than about 20mol%, no more than about 30mol% or no more than about 40mol%.
[1113] In some embodiments, the cholesterol-based lipid can exist with a weight ratio (wt %) of about 1% to about 30% or about 5% to about 20% of the total lipid present in the liposome. In some embodiments, the percentage ratio of the cholesterol-based lipid in the lipid nanoparticle can be greater than about 5 wt %, greater than about 10 wt %, greater than about 20 wt %, greater than about 30 wt % or greater than about 40 wt %. In some embodiments, the percentage ratio of the cholesterol-based lipid in the lipid nanoparticle can be no more than about 5 wt %, no more than about 10 wt %, no more than about 20 wt %, no more than about 30 wt % or no more than about 40 wt %.
[1114] PEGylated lipids
[1115] In some embodiments, the liposomes comprise one or more PEGylated lipids.
[1116] For example, the present invention also contemplates the use of polyethylene glycol (PEG)-modified phospholipids and derivatized lipids such as derivatized ceramides (PEG-CER), including N-octanoylsphingosine-1-[succinyl(methoxypolyethylene glycol)-2000] (C8PEG-2000ceramide), alone or, preferably, in combination with other lipid formulations comprising transfer vehicles (e.g., lipid nanoparticles).
[1117] Contemplated PEG-modified lipids include, but are not limited to, polyethylene glycol chains up to 5 kDa in length covalently linked to a lipid having one or more C6-C 20In some embodiments, the PEG-modified or PEGylated lipid is PEGylated cholesterol or PEG-2K. The addition of such components can prevent complex aggregation and can also provide a means of extending circulation life and increasing the delivery of lipid-nucleic acid compositions to target tissues (Klibanov et al. (1990) FEBS Letters, 268 (1): 235-237), or they can be selected to be rapidly exchanged from the formulation in vivo (see U.S. Patent No. 5,885,613). Particularly useful exchangeable lipids are those with shorter acyl chains (e.g., C 14 or C 18 ) PEG-ceramide. Liposomes suitable for use in the present invention typically include PEG-modified lipids, such as 1,2-dimyristoyl-rac-glycero-3-methoxypolyethylene glycol-2000 (DMG-PEG2K).
[1118] The phospholipids and derivatized lipids of the present invention can comprise about 0% to about 20%, about 0.5% to about 20%, about 1% to about 15%, about 4% to about 10% or about 2% of the total lipids present in the liposome transfer vehicle by molar ratio. In some embodiments, the lipids modified by one or more PEGs account for about 4% of the total lipids by molar ratio. In some embodiments, the lipids modified by one or more PEGs account for about 5% of the total lipids by molar ratio. In some embodiments, the lipids modified by one or more PEGs account for about 6% of the total lipids by molar ratio. In typical embodiments of the present invention, the lipids modified by PEG (e.g., DMG-PEG2K) exist in a molar ratio of about 2% to about 6% of the total lipids present in the liposome transfer vehicle. In specific embodiments, the lipids modified by PEG (e.g., DMG-PEG2K) exist in a molar ratio of about 3% to about 5% of the total lipids present in the liposome transfer vehicle. For some applications, such as pulmonary delivery, it has been found that the liposomes wherein the lipid component modified by PEG accounts for about 5% of the total lipids by molar ratio are particularly suitable. For other applications, such as intravenous delivery, liposomes in which the PEG-modified lipid component comprises less than about 5% by mole of total lipids (eg, 3% by mole of total lipids) may be particularly suitable.
[1119] Amphiphilic block copolymers
[1120] In some embodiments, suitable delivery vehicles contain amphiphilic block copolymers (eg, poloxamers).
[1121] A variety of amphiphilic block copolymers can be used to practice the present invention.In some embodiments, the amphiphilic block copolymer is also referred to as a surfactant or nonionic surfactant.
[1122] In some embodiments, the amphiphilic polymers suitable for the present invention are selected from poloxamers Poloxamine Polyoxyethylene glycol dehydrated alcohol alkyl esters (polysorbates) and polyvinyl pyrrolidone (PVP).
[1123] Poloxamer
[1124] In some embodiments, the suitable amphiphilic polymer is a poloxamer. For example, a suitable poloxamer has the following structure:
[1125]
[1126] wherein a is an integer between 10 and 150, and b is an integer between 20 and 60. For example, a is about 12 and b is about 20, or a is about 80 and b is about 27, or a is about 64 and b is about 37, or a is about 141 and b is about 44, or a is about 101 and b is about 56.
[1127] In some embodiments, poloxamers suitable for the present invention have from about 10 to about 150 ethylene oxide units. In some embodiments, poloxamers have from about 10 to about 100 ethylene oxide units.
[1128] In some embodiments, a suitable poloxamer is poloxamer 84. In some embodiments, a suitable poloxamer is poloxamer 101. In some embodiments, a suitable poloxamer is poloxamer 105. In some embodiments, a suitable poloxamer is poloxamer 108. In some embodiments, a suitable poloxamer is poloxamer 122. In some embodiments, a suitable poloxamer is poloxamer 123. In some embodiments, a suitable poloxamer is poloxamer 124. In some embodiments, a suitable poloxamer is poloxamer 181. In some embodiments, a suitable poloxamer is poloxamer 182. In some embodiments, a suitable poloxamer is poloxamer 183. In some embodiments, a suitable poloxamer is poloxamer 184. In some embodiments, a suitable poloxamer is poloxamer 185. In some embodiments, a suitable poloxamer is poloxamer 188. In some embodiments, a suitable poloxamer is poloxamer 212. In some embodiments, a suitable poloxamer is poloxamer 215. In some embodiments, a suitable poloxamer is poloxamer 217. In some embodiments, a suitable poloxamer is poloxamer 231. In some embodiments, a suitable poloxamer is poloxamer 234. In some embodiments, a suitable poloxamer is poloxamer 235. In some embodiments, a suitable poloxamer is poloxamer 237. In some embodiments, a suitable poloxamer is poloxamer 238. In some embodiments, a suitable poloxamer is poloxamer 282. In some embodiments, a suitable poloxamer is poloxamer 284. In some embodiments, a suitable poloxamer is poloxamer 288. In some embodiments, a suitable poloxamer is poloxamer 304. In some embodiments, a suitable poloxamer is poloxamer 331. In some embodiments, a suitable poloxamer is poloxamer 333. In some embodiments, a suitable poloxamer is poloxamer 334. In some embodiments, a suitable poloxamer is poloxamer 335. In some embodiments, a suitable poloxamer is poloxamer 338. In some embodiments, a suitable poloxamer is poloxamer 401. In some embodiments, a suitable poloxamer is poloxamer 402. In some embodiments, a suitable poloxamer is poloxamer 403. In some embodiments, a suitable poloxamer is poloxamer 407. In some embodiments, suitable poloxamers are combinations thereof.
[1129] In some embodiments, suitable poloxamers have an average molecular weight of about 4,000 g / mol to about 20,000 g / mol. In some embodiments, suitable poloxamers have an average molecular weight of about 1,000 g / mol to about 50,000 g / mol. In some embodiments, suitable poloxamers have an average molecular weight of about 1,000 g / mol. In some embodiments, suitable poloxamers have an average molecular weight of about 2,000 g / mol. In some embodiments, suitable poloxamers have an average molecular weight of about 3,000 g / mol. In some embodiments, suitable poloxamers have an average molecular weight of about 4,000 g / mol. In some embodiments, suitable poloxamers have an average molecular weight of about 5,000 g / mol. In some embodiments, suitable poloxamers have an average molecular weight of about 6,000 g / mol. In some embodiments, suitable poloxamers have an average molecular weight of about 7,000 g / mol. In some embodiments, suitable poloxamers have an average molecular weight of about 8,000 g / mol. In some embodiments, suitable poloxamers have an average molecular weight of about 9,000 g / mol. In some embodiments, suitable poloxamers have an average molecular weight of about 10,000 g / mol. In some embodiments, suitable poloxamers have an average molecular weight of about 20,000 g / mol. In some embodiments, suitable poloxamers have an average molecular weight of about 25,000 g / mol. In some embodiments, suitable poloxamers have an average molecular weight of about 30,000 g / mol. In some embodiments, suitable poloxamers have an average molecular weight of about 40,000 g / mol. In some embodiments, suitable poloxamers have an average molecular weight of about 50,000 g / mol.
[1130] Other amphiphilic polymers
[1131] In some embodiments, the amphiphilic polymer is a poloxamine, eg, Tetronic 304 or Tirtonic 904.
[1132] In some embodiments, the amphiphilic polymer is polyvinylpyrrolidone (PVP), such as PVP having a molecular weight of 3 kDa, 10 kDa, or 29 kDa.
[1133] In some embodiments, the amphiphilic polymer is polyethylene glycol ether (Brij), polysorbate, sorbitan, and their derivatives. In some embodiments, the amphiphilic polymer is a polysorbate, such as PS 20.
[1134] In some embodiments, the amphiphilic polymer is a polyethylene glycol ether (Brij), a poloxamer, a polysorbate, a sorbitan, or a derivative thereof.
[1135] In some embodiments, the amphiphilic polymer is a polyethylene glycol ether. In some embodiments, a suitable polyethylene glycol ether is a compound of formula (S1):
[1136]
[1137] or a salt or isomer thereof, wherein:
[1138] t is an integer between 1 and 100;
[1139] R 1BRIJ Independently C 10-40 Alkyl, C 10-40 Alkenyl or C 10-40 Alkynyl; and optionally, R 5PEG The one or more methylene groups are independently C 3-10 Carbocyclylene, 4- to 10-membered heterocyclylene, C 6-10 Arylene, 4- to 10-membered heteroarylene, -N(R N )-, -O-, -S-, -C(O)-, -C(O)N(R N )-、-NR N C(O)-, -NRC(O)N(R)-, -C(O)O-, -OC(O)-, -OC(O)O-, -OC(O)N(R N )-、-NR N C(O)O-, -C(O)S-, -SC(O)-, -C(=NR N )-, -C(=NR)N(R)-, -NRNC(=NR N )-、-NR N C(=NR N )N(R N )-、-C(S)-、-C(S)N(R N )-、-NR N C(S)-、-NR N C(S)N(R N )-, -S(O)-, -OS(O)-, -S(O)O-, -OS(O)O-, -OS(O)2-, -S(O)2O-, -OS(O)2O-, -N(R N )S(O)-、-S(O)N(R N )-、-N(R N )S(O)N(R N )-、-OS(O)N(R N )-、-N(RN )S(O)0-、-S(O)2-、-N(R N )S(O)2-、-S(O)2N(R N )-、-N(R N )S(O)2N(R N )-、-OS(O)2N(R N )-or-N(R N )S(O)2O-substituted; and
[1140] R N Each instance of is independently hydrogen, C 1-6 Alkyl or nitrogen protecting group.
[1141] In some embodiments, R 1BRIJ For example, the polyethylene glycol ether is a compound of formula (S-1a):
[1142]
[1143] or a salt or isomer thereof, wherein S is an integer between 1 and 100.
[1144] In some embodiments, R 1BRIJ For example, a suitable polyethylene glycol ether is a compound of formula (S-1b):
[1145]
[1146] or a salt or isomer thereof, wherein S is an integer between 1 and 100.
[1147] Typically, an amphiphilic polymer (e.g., poloxamer) is present in the formulation in an amount below its critical micelle concentration (CMC). In some embodiments, an amphiphilic polymer (e.g., poloxamer) is present in the mixture in an amount below about 1%, about 2%, about 3%, about 4%, about 5%, about 6%, about 7%, about 8%, about 9%, about 10%, about 15%, about 20%, about 25%, about 30%, about 35%, about 40%, about 45%, or about 50% of its CMC. In some embodiments, an amphiphilic polymer (e.g., poloxamer) is present in the mixture in an amount below about 0.9%, 0.8%, 0.7%, 0.6%, 0.5%, 0.4%, 0.3%, 0.2%, or 0.1% of its CMC. In some embodiments, the amphiphilic polymer (eg, poloxamer) is present in the mixture in an amount that is about 55%, 60%, 65%, 70%, 75%, 80%, 90%, or 95% below its CMC.
[1148] In some embodiments, less than about 0.1%, 0.09%, 0.08%, 0.07%, 0.06%, 0.05%, 0.04%, 0.03%, 0.02%, or 0.01% of the original amount of amphiphilic polymer (e.g., poloxamer) present in the formulation remains after removal. In some embodiments, a residual amount of amphiphilic polymer (e.g., poloxamer) remains in the formulation after removal. As used herein, residual amount means the amount remaining after substantially all of the material (amphiphilic silicon polymers such as poloxamer described herein) in the composition has been removed. The residual amount can be detected qualitatively or quantitatively using known techniques. The residual amount may not be detectable using known techniques.
[1149] In some embodiments, a suitable delivery vehicle comprises less than 5% of an amphiphilic block copolymer (e.g., poloxamer). In some embodiments, a suitable delivery vehicle comprises less than 3% of an amphiphilic block copolymer (e.g., poloxamer). In some embodiments, a suitable delivery vehicle comprises less than 2.5% of an amphiphilic block copolymer (e.g., poloxamer). In some embodiments, a suitable delivery vehicle comprises less than 2% of an amphiphilic block copolymer (e.g., poloxamer). In some embodiments, a suitable delivery vehicle comprises less than 1.5% of an amphiphilic block copolymer (e.g., poloxamer). In some embodiments, a suitable delivery vehicle comprises less than 1% of an amphiphilic block copolymer (e.g., poloxamer). In some embodiments, a suitable delivery vehicle comprises less than 0.5% (e.g., less than 0.4%, 0.3%, 0.2%, 0.1%) of an amphiphilic block copolymer (e.g., poloxamer). In some embodiments, suitable delivery vehicles include less than 0.09%, 0.08%, 0.07%, 0.06%, 0.05%, 0.04%, 0.03%, 0.02% or 0.01% of amphiphilic block copolymers (e.g., poloxamer). In some embodiments, suitable delivery vehicles include less than 0.01% of amphiphilic block copolymers (e.g., poloxamer). In some embodiments, suitable delivery vehicles contain a residual amount of amphiphilic polymers (e.g., poloxamer). As used herein, residual amount means the amount remaining after substantially all substances (amphiphilic silicon polymers such as poloxamer described herein) are removed from the composition. Residual amount can be detected qualitatively or quantitatively using known techniques. Residual amount may not be detected using known techniques.
[1150] polymer
[1151] In some embodiments, polymer is used as carrier, alone or in combination with other carriers comprising various lipids as described herein, suitable delivery vehicles are prepared.Therefore, in some embodiments, as used herein, liposome delivery vehicles also encompass the nanoparticle comprising polymer.Suitable polymer can include, for example, polyacrylate, polyalkyl cyanoacrylate, polylactide, polylactide-polyglycolide copolymer, polycaprolactone, dextran, albumin, gelatin, alginate, collagen, chitosan, cyclodextrin, protamine, PEGization protamine, PLL, PEGization PLL and polyethyleneimine (PEI).When there is PEI, it can be the branched PEI that molecular weight range is 10kDa to 40kDa, for example, the branched PEI (Sigma#408727) of 25kDa.
[1152] According to various embodiments, the selection of the relative molar ratio of the cationic lipid, non-cationic lipid, PEG-modified lipid, cholesterol-based lipid and / or amphipathic block copolymer and these components (lipid) to each other is based on the feature of selected lipid, the property of expected target cell, the feature of nucleic acid to be delivered. Other considerations include, for example, the size, electric charge, pH, pKa, fusogenicity and toxicity of the saturation degree of alkyl chain and selected lipid. Therefore, the mol ratio can be adjusted accordingly.
[1153] Liposome composition
[1154] Liposome compositions suitable for delivering mRNA to target cells in vivo may include a compound of the present invention as a cationic lipid component. In some embodiments, the ratio of one or more cationic lipids to one or more non-cationic lipids to one or more cholesterol-based lipids to one or more PEG-modified lipids can be between about 30-60:25-35:20-30:1-15 respectively. In some embodiments, the ratio of one or more cationic lipids to one or more non-cationic lipids to one or more cholesterol-based lipids to one or more PEG-modified lipids is about 40:30:20:10 respectively. In some embodiments, the ratio of one or more cationic lipids to one or more non-cationic lipids to one or more cholesterol-based lipids to one or more PEG-modified lipids is about 40:30:25:5 respectively. In some embodiments, the ratio of one or more cationic lipids to one or more non-cationic lipids to one or more cholesterol-based lipids to one or more PEG-modified lipids is about 40:32:25:3 respectively. In some embodiments, the ratio of one or more cationic lipids to one or more non-cationic lipids to one or more cholesterol-based lipids to one or more PEG-modified lipids is about 50:25:20:5. In some embodiments, the ratio of one or more sterol lipids to one or more non-cationic lipids to one or more PEG-modified lipids is 50:45:5. In some embodiments, the ratio of one or more sterol lipids to one or more non-cationic lipids to one or more PEG-modified lipids is 50:40:10. In some embodiments, the ratio of one or more sterol lipids to one or more non-cationic lipids to one or more PEG-modified lipids is 55:40:5. In some embodiments, the ratio of one or more sterol lipids to one or more non-cationic lipids to one or more PEG-modified lipids is 55:35:10. In some embodiments, the ratio of one or more sterol lipids to one or more non-cationic lipids to one or more PEG-modified lipids is 60:35:5. In some embodiments, the ratio of one or more sterol lipids to one or more non-cationic lipids to one or more PEG-modified lipids is 60:30:10.
[1155] Exemplary liposome compositions comprise a compound of the invention as the sole cationic lipid component. Suitable liposome compositions may also comprise cholesterol, non-cationic lipids (such as DOPE) and PEG-modified lipids (such as DMG-PEG2K).
[1156] Ratios of different lipid components
[1157] Suitable liposomes for use in the present invention can comprise one or more of any of the cationic lipids, non-cationic lipids, cholesterol lipids, PEG-modified lipids, amphiphilic block copolymers, and / or polymers described herein in various ratios. In some embodiments, the lipid nanoparticles comprise five and no more than five different components of the nanoparticles. In some embodiments, the lipid nanoparticles comprise four and no more than four different components of the nanoparticles. In some embodiments, the lipid nanoparticles comprise three and no more than three different components of the nanoparticles. As non-limiting examples, suitable liposome formulations may include combinations of the following lipid components: Formula (A'), (A), (I), (Ia), (I-a'), (Ib), (I-b'), (Ic), (I-c'), (Ic-1), (I-c'-1), (Ic-2), (I-c'-2), (Id), (I-d'), (Id-1), (Id-2), (Ie), (I-e'), (Ie-1), (Ie-2), (If), (I-f'), (II), (II-a), (II-a'), (III), (III'), (III-a), (III-a'), (III-b), (III-b'), (III- c), (III-c-1), (III-c'-1), (III-c-2), (III-c'-2), (III-c'), (III-d), (III-d'), (III-d-1), (III-d-2), (III-e), (III-e'), (III-e-1), (III-e-2), (III-f), (III-f'), (IV), (IV-a), or (IV-a'), such as any one of compounds 1-552, as the cationic lipid component; DOPE or DEPE as the non-cationic lipid component; cholesterol as the cholesterol-based lipid; DMG-PEG2K as the PEG-modified lipid.
[1158] In various embodiments, cationic lipids (e.g., Formula (A'), (A), (I), (Ia), (I-a'), (Ib), (I-b'), (Ic), (I-c'), (Ic-1), (I-c'-1), (Ic-2), (I-c'-2), (Id), (I-d'), (Id-1), (Id-2), (Ie), (I-e'), (Ie-1), (Ie-2), (If), (I-f'), (II), (II-a), (II-a'), (III), (III'), (III-a), (III-a'), (III-b), (III-b'), (III-c), (III-c-1), (III- -c'-1), (III-c-2), (III-c'-2), (III-c'), (III-d), (III-d'), (III-d-1), (III-d-2), (III-e), (III-e'), (III-e-1), (III-e-2), (III-f), (III-f'), (IV), (IV-a), or (IV-a'), such as any of Compounds 1-552) comprises about 30%-60% (e.g., about 30%-55%, about 30%-50%, about 30%-45%, about 30%-40%, about 35%-50%, about 35%-45%, or about 35%-40%) of the liposomes on a molar basis.In some embodiments, a cationic lipid (e.g., Formula (A'), (A), (I), (Ia), (I-a'), (Ib), (I-b'), (Ic), (I-c'), (Ic-1), (I-c'-1), (Ic-2), (I-c'-2), (Id), (I-d'), (Id-1), (Id-2), (Ie), (I-e'), (Ie-1), (Ie-2), (If), (I-f'), (II), (II-a), (II-a'), (III), (III'), (III-a), (III-a'), (III-b), (III-b'), (III-c ), (III-c-1), (III-c'-1), (III-c-2), (III-c'-2), (III-c'), (III-d), (III-d'), (III-d-1), (III-d-2), (III-e), (III-e'), (III-e-1), (III-e-2), (III-f), (III-f'), (IV), (IV-a) or (IV-a'), such as any of compounds 1-552) is equal to or greater than about 30%, about 35%, about 40%, about 45%, about 50%, about 55% or about 60% of the liposomes on a molar basis.
[1159] In some embodiments, the molar ratio of one or more cationic lipids to one or more non-cationic lipids to one or more cholesterol-based lipids to one or more PEG-modified lipids is about 30-60:25-35:20-30:1-15, respectively. In some embodiments, the ratio of one or more cationic lipids to one or more non-cationic lipids to one or more cholesterol-based lipids to one or more PEG-modified lipids is about 40:30:20:10, respectively. In some embodiments, the ratio of one or more cationic lipids to one or more non-cationic lipids to one or more cholesterol-based lipids to one or more PEG-modified lipids is about 40:30:25:5, respectively. In some embodiments, the ratio of one or more cationic lipids to one or more non-cationic lipids to one or more cholesterol-based lipids to one or more PEG-modified lipids is about 40:32:25:3, respectively. In some embodiments, the ratio of one or more cationic lipids to one or more non-cationic lipids to one or more cholesterol-based lipids to one or more PEG-modified lipids is about 50:25:20:5.
[1160] Formation of mRNA-encapsulated liposomes
[1161] The liposomal transfer vehicles used in the compositions of the present invention can be prepared by various techniques currently known in the art. For example, multilamellar vesicles (MLVs) can be prepared according to conventional techniques, for example, by dissolving the lipids in a suitable solvent, depositing the selected lipids on the inner wall of a suitable vessel or container, and then evaporating the solvent to leave a thin film on the interior of the container or spray drying. The aqueous phase can then be added to the vessel with a vortexing motion, which results in the formation of MLVs. Unilamellar vesicles (ULVs) can then be formed by homogenization, ultrasonication, or extrusion of the multilamellar vesicles. In addition, unilamellar vesicles can be formed by detergent removal techniques.
[1162] Various methods are described in disclosed U.S. Application No. US 2011 / 0244026, disclosed U.S. Application No. US 2016 / 0038432, disclosed U.S. Application No. US 2018 / 0153822, disclosed U.S. Application No. US 2018 / 0125989 and the U.S. Provisional Application No. 62 / 877,597 filed on July 23, 2019, and can be used to practice the present invention, all of which are incorporated herein by reference. As used herein, method A refers to a conventional method for encapsulating mRNA by mixing mRNA with a lipid mixture without first pre-forming lipid into lipid nanoparticles, as described in US 2016 / 0038432. As used herein, method B refers to a process for encapsulating messenger RNA (mRNA) by mixing pre-formed lipid nanoparticles with mRNA, as described in US 2018 / 0153822.
[1163] Briefly, the method for preparing mRNA-loaded lipid liposomes comprises the following steps: heating one or more solutions (i.e., applying heat to the solution from a heat source) to a temperature above ambient temperature (or maintaining at a temperature above ambient temperature), the one or more solutions being a solution comprising preformed lipid nanoparticles, a solution comprising mRNA, and a mixed solution comprising mRNA encapsulated by lipid nanoparticles. In some embodiments, the method comprises a step of heating one or both of the mRNA solution and the preformed lipid nanoparticle solution before the mixing step. In some embodiments, the method comprises heating one or more of the following during the mixing step: a solution comprising preformed lipid nanoparticles, a solution comprising mRNA, and a solution comprising mRNA encapsulated by lipid nanoparticles. In some embodiments, the method comprises a step of heating the mRNA encapsulated by lipid nanoparticles after the mixing step. In some embodiments, the temperature to which the one or more solutions are heated (or the temperature at which the one or more solutions are maintained) is or is greater than about 30°C, 37°C, 40°C, 45°C, 50°C, 55°C, 60°C, 65°C, or 70°C. In some embodiments, the temperature to which the one or more solutions are heated is in the range of about 25° C.-70° C., about 30° C.-70° C., about 35° C.-70° C., about 40° C.-70° C., about 45° C.-70° C., about 50° C.-70° C., or about 60° C.-70° C. In some embodiments, the temperature above ambient temperature to which the one or more solutions are heated is about 65° C.
[1164] Various methods can be used to prepare mRNA solutions suitable for the present invention. In some embodiments, mRNA can be directly dissolved in a buffer solution as described herein. In some embodiments, mRNA stock solution can be produced by mixing with a lipid solution before encapsulating with a buffer solution. In some embodiments, mRNA stock solution can be produced by mixing with a lipid solution before encapsulating with a buffer solution immediately. In some embodiments, suitable mRNA stock solution can contain an mRNA concentration of or greater than about 0.2 mg / ml, 0.4 mg / ml, 0.5 mg / ml, 0.6 mg / ml, 0.8 mg / ml, 1.0 mg / ml, 1.2 mg / ml, 1.4 mg / ml, 1.5 mg / ml, or 1.6 mg / ml, 2.0 mg / ml, 2.5 mg / ml, 3.0 mg / ml, 3.5 mg / ml, 4.0 mg / ml, 4.5 mg / ml, or 5.0 mg / ml in water.
[1165] In some embodiments, the mRNA stock solution is mixed with the buffer solution using a pump. Exemplary pumps include, but are not limited to, gear pumps, peristaltic pumps, and centrifugal pumps.
[1166] In some embodiments, the flow velocity of the mRNA stock solution is greater than that of the mRNA stock solution. Typically, the flow velocity of the mRNA stock solution is mixed with the buffer solution. For example, the flow velocity of the mRNA stock solution can be greater than at least 1 times, 2 times, 3 times, 4 times, 5 times, 6 times, 7 times, 8 times, 9 times, 10 times, 15 times or 20 times. In some embodiments, the flow velocity of the mRNA stock solution is mixed with the buffer solution at a range of about 100-6000ml / minute (for example, about 100-300ml / minute, 300-600ml / minute, 600-1200ml / minute, 1200-2400ml / minute, 2400-3600ml / minute, 3600-4800ml / minute, 4800-6000ml / minute or 60-420ml / minute). In some embodiments, the buffer solution is mixed at a flow rate of about 60 ml / min, 100 ml / min, 140 ml / min, 180 ml / min, 220 ml / min, 260 ml / min, 300 ml / min, 340 ml / min, 380 ml / min, 420 ml / min, 480 ml / min, 540 ml / min, 600 ml / min, 1200 ml / min, 2400 ml / min, 3600 ml / min, 4800 ml / min, or 6000 ml / min.
[1167] In some embodiments, the mRNA stock solution is mixed at a flow rate ranging between about 10-600 ml / min (e.g., about 5-50 ml / min, about 10-30 ml / min, about 30-60 ml / min, about 60-120 ml / min, about 120-240 ml / min, about 240-360 ml / min, about 360-480 ml / min, or about 480-600 ml / min). In some embodiments, the mRNA stock solution is mixed at a flow rate of about 5 ml / min, 10 ml / min, 15 ml / min, 20 ml / min, 25 ml / min, 30 ml / min, 35 ml / min, 40 ml / min, 45 ml / min, 50 ml / min, 60 ml / min, 80 ml / min, 100 ml / min, 200 ml / min, 300 ml / min, 400 ml / min, 500 ml / min, or 600 ml / min.
[1168] According to the present invention, lipid solution contains the lipid mixture that is suitable for forming lipid nanoparticles for encapsulating mRNA.In some embodiments, suitable lipid solution is based on ethanol.For example, suitable lipid solution can contain the mixture of the desired lipid dissolved in pure ethanol (that is, 100% ethanol).In another embodiment, suitable lipid solution is based on isopropanol.In another embodiment, suitable lipid solution is based on dimethyl sulfoxide.In another embodiment, suitable lipid solution is a mixture of suitable solvents (including but not limited to ethanol, isopropanol and dimethyl sulfoxide).
[1169] Suitable lipid solutions can contain the mixture of the expectation lipid of various concentrations.For example, suitable lipid solutions can contain the mixture of the expectation lipid of total concentration being equal to or greater than about 0.1mg / ml, 0.5mg / ml, 1.0mg / ml, 2.0mg / ml, 3.0mg / ml, 4.0mg / ml, 5.0mg / ml, 6.0mg / ml, 7.0mg / ml, 8.0mg / ml, 9.0mg / ml, 10mg / ml, 15mg / ml, 20mg / ml, 30mg / ml, 40mg / ml, 50mg / ml or 100mg / ml. In some embodiments, a suitable lipid solution can contain a mixture of desired lipids at a total concentration ranging from about 0.1 mg / ml to 100 mg / ml, 0.5 mg / ml to 90 mg / ml, 1.0 mg / ml to 80 mg / ml, 1.0 mg / ml to 70 mg / ml, 1.0 mg / ml to 60 mg / ml, 1.0 mg / ml to 50 mg / ml, 1.0 mg / ml to 40 mg / ml, 1.0 mg / ml to 30 mg / ml, 1.0 mg / ml to 20 mg / ml, 1.0 mg / ml to 15 mg / ml, 1.0 mg / ml to 10 mg / ml, 1.0 mg / ml to 9 mg / ml, 1.0 mg / ml to 8 mg / ml, 1.0 mg / ml to 7 mg / ml, 1.0 mg / ml to 6 mg / ml, or 1.0 mg / ml to 5 mg / ml. In some embodiments, a suitable lipid solution can contain a mixture of desired lipids at a total concentration of up to about 100 mg / ml, 90 mg / ml, 80 mg / ml, 70 mg / ml, 60 mg / ml, 50 mg / ml, 40 mg / ml, 30 mg / ml, 20 mg / ml, or 10 mg / ml.
[1170] In some embodiments, suitable lipid solution contains the mixture of expectation lipid, and this expectation lipid comprises the lipid of cationic lipid, helper lipid (for example, non-cationic lipid and / or cholesterol lipid), amphipathic block copolymer (for example, poloxamer) and / or PEGization.In some embodiments, suitable lipid solution contains the mixture of expectation lipid, and this expectation lipid comprises the lipid of one or more cationic lipid, one or more helper lipid (for example, non-cationic lipid and / or cholesterol lipid) and one or more PEGization.
[1171] In certain embodiments, provided compositions comprise liposomes, wherein mRNA is bound on both surfaces of the liposomes and encapsulated within the same liposomes. For example, during the preparation of the compositions of the present invention, cationic liposomes may bind to mRNA via electrostatic interactions.
[1172] In some embodiments, the compositions and methods of the present invention include mRNA encapsulated in liposomes. In some embodiments, one or more mRNA materials can be encapsulated in identical liposomes. In some embodiments, one or more mRNA materials can be encapsulated in different liposomes. In some embodiments, mRNA is encapsulated in one or more liposomes, and these liposomes are different in terms of the mol ratio, size, charge (zeta potential), targeting ligand and / or their combination of lipid composition, lipid components. In some embodiments, one or more liposomes can have the different compositions of cationic lipids based on sterol, neutral lipids, PEG-modified lipids and / or their combination. In some embodiments, one or more liposomes can have the cationic lipids based on cholesterol, neutral lipids and PEG-modified lipids for the production of liposomes with different mol ratios.
[1173] The process of incorporating a desired nucleic acid (e.g., mRNA) into a liposome is generally referred to as "loading". Exemplary methods are described in Lazorthes et al. FEBS Lett., 312: 255-258, 1992, which is incorporated herein by reference. The nucleic acid encapsulated in the liposome may be located completely or partially in the internal space of the liposome, within the bilayer membrane of the liposome, or bound to the outer surface of the liposome membrane. Incorporating nucleic acids into liposomes is also referred to herein as "encapsulation", wherein the nucleic acid is completely contained within the internal space of the liposome. The purpose of incorporating mRNA into a transfer vehicle (e.g., liposome) is often to protect the nucleic acid from environmental damage, which may contain enzymes or chemicals that degrade nucleic acids and / or systems or receptors that promote rapid excretion of nucleic acids. Therefore, in some embodiments, a suitable delivery vehicle can enhance the stability of the mRNA contained therein and / or promote the delivery of therapeutic agents (e.g., mRNA) to target cells or tissues.
[1174] Suitable liposomes according to the present invention can be prepared in various sizes. In some embodiments, the liposome provided can be prepared to be smaller than previously known liposomes. In some embodiments, the reduction in liposome size is relevant to the more effective delivery of therapeutic agents (e.g., mRNA). The selection of suitable liposome size can take into account the site of target cells or tissues, and to a certain extent prepare the application that liposomes are used for.
[1175] In some embodiments, liposomes are selected to be of an appropriate size to facilitate systemic distribution of the polypeptide encoded by the mRNA. In some embodiments, it may be desirable to limit transfection of the mRNA to certain cells or tissues. For example, to target hepatocytes, the liposomes may be sized so that they are smaller than the fenestrations in the endothelial layer lining the hepatic sinusoids in the liver; in this case, the liposomes can easily penetrate these endothelial fenestrations to reach the target hepatocytes.
[1176] Alternatively or additionally, the size of the liposomes can be tailored such that the liposomes are of a size sufficient in diameter to restrict or specifically avoid distribution into certain cells or tissues.
[1177] Various alternative methods known in the art can be used to determine the size of a liposome population. One such sizing method is described in U.S. Patent No. 4,737,323, which is incorporated herein by reference. Sonication of a liposome suspension by bath or probe sonication produces a gradual size reduction, down to small ULVs with a diameter of less than about 0.05 microns. Homogenization is another method that relies on shear energy to break large liposomes into smaller ones. In a typical homogenization procedure, MLVs are recirculated through a standard emulsion homogenizer until a selected liposome size is observed, typically between about 0.1 and 0.5 microns. The size of the liposomes can be determined by quasi-electroluminescent light scattering (QELS), as described in Bloomfield, Ann. Rev. Biophys. Bioeng., 10:421-450 (1981), which is incorporated herein by reference. The average liposome diameter can be reduced by sonication of the formed liposomes. Intermittent sonication cycles can be alternating with QELS evaluation to guide efficient liposome synthesis.
[1178] Provided mRNA-encapsulated nanoparticles
[1179] In some embodiments, a majority of the purified nanoparticles in the composition (i.e., greater than about 50%, 55%, 60%, 65%, 70%, 75%, 80%, 85%, 90%, 95%, 96%, 97%, 98%, or 99% of the nanoparticles) have a size of about 150 nm (e.g., about 145 nm, about 140 nm, about 135 nm, about 130 nm, about 125 nm, about 120 nm, about 115 nm, about 110 nm, about 105 nm, about 100 nm, about 95 nm, about 90 nm, about 85 nm, or about 80 nm). In some embodiments, substantially all of the purified nanoparticles have a size of about 150 nm (e.g., about 145 nm, about 140 nm, about 135 nm, about 130 nm, about 125 nm, about 120 nm, about 115 nm, about 110 nm, about 105 nm, about 100 nm, about 95 nm, about 90 nm, about 85 nm, or about 80 nm).
[1180] In some embodiments, the lipid nanoparticles have an average size of less than 150 nm. In some embodiments, the lipid nanoparticles have an average size of less than 120 nm. In some embodiments, the lipid nanoparticles have an average size of less than 100 nm. In some embodiments, the lipid nanoparticles have an average size of less than 90 nm. In some embodiments, the lipid nanoparticles have an average size of less than 80 nm. In some embodiments, the lipid nanoparticles have an average size of less than 70 nm. In some embodiments, the lipid nanoparticles have an average size of less than 60 nm. In some embodiments, the lipid nanoparticles have an average size of less than 50 nm. In some embodiments, the lipid nanoparticles have an average size of less than 30 nm. In some embodiments, the lipid nanoparticles have an average size of less than 20 nm.
[1181] In some embodiments, in the compositions provided by the invention, greater than about 70%, 75%, 80%, 85%, 90%, 95%, 96%, 97%, 98%, 99% of lipid nanoparticles (e.g., liposomes) have a size in the range of about 70nm-120nm (e.g., about 75nm-115nm, about 80nm-110nm, or about 85nm-105nm). In some embodiments, substantially all of the lipid nanoparticles (e.g., liposomes) have a size in the range of about 70nm-150nm (e.g., about 80nm-130nm or about 90nm-120nm). Compositions with lipid nanoparticles (e.g., liposomes) having an average size of about 90nm-130nm are particularly suitable for delivery to the liver via intravenous administration and for delivery to the lungs via aerosol administration (e.g., via nebulization).
[1182] In some embodiments, the dispersity or molecular size heterogeneity measure (PDI) of the nanoparticles in the compositions provided by the present invention is less than about 0.5. In some embodiments, the lipid nanoparticles have a PDI of less than about 0.5. In some embodiments, the lipid nanoparticles have a PDI of less than about 0.4. In some embodiments, the lipid nanoparticles have a PDI of less than about 0.3. In some embodiments, the lipid nanoparticles have a PDI of less than about 0.28. In some embodiments, the lipid nanoparticles have a PDI of less than about 0.25. In some embodiments, the lipid nanoparticles have a PDI of less than about 0.23. In some embodiments, the lipid nanoparticles have a PDI of less than about 0.20. In some embodiments, the lipid nanoparticles have a PDI of less than about 0.18. In some embodiments, the lipid nanoparticles have a PDI of less than about 0.16. In some embodiments, the lipid nanoparticles have a PDI of less than about 0.14. In some embodiments, the lipid nanoparticles have a PDI of less than about 0.12. In some embodiments, the lipid nanoparticles have a PDI of less than about 0.10. In some embodiments, the lipid nanoparticles have a PDI of less than about 0.08. Typical lipid nanoparticles for use in the present invention have a PDI of less than about 0.20.
[1183] In some embodiments, greater than about 75%, 80%, 85%, 90%, 95%, 96%, 97%, 98%, or 99% of the purified lipid nanoparticles in the compositions provided herein encapsulate mRNA within each individual particle. In some embodiments, substantially all of the purified lipid nanoparticles in the composition encapsulate mRNA within each individual particle. In some embodiments, the lipid nanoparticles have an encapsulation efficiency of 50% to 99%. In some embodiments, the lipid nanoparticles have an encapsulation efficiency of greater than about 60%. In some embodiments, the lipid nanoparticles have an encapsulation efficiency of greater than about 65%. In some embodiments, the lipid nanoparticles have an encapsulation efficiency of greater than about 70%. In some embodiments, the lipid nanoparticles have an encapsulation efficiency of greater than about 75%. In some embodiments, the lipid nanoparticles have an encapsulation efficiency of greater than about 80%. In some embodiments, the lipid nanoparticles have an encapsulation efficiency of greater than about 85%. In some embodiments, the lipid nanoparticles have an encapsulation efficiency of greater than about 90%. In some embodiments, the lipid nanoparticles have an encapsulation efficiency of greater than about 92%. In some embodiments, the lipid nanoparticles have an encapsulation efficiency greater than about 95%. In some embodiments, the lipid nanoparticles have an encapsulation efficiency greater than about 98%. In some embodiments, the lipid nanoparticles have an encapsulation efficiency greater than about 99%. Typically, the lipid nanoparticles used in the present invention have an encapsulation efficiency of at least 65%-97%. Lipid nanoparticles with an encapsulation efficiency greater than 80% (e.g., greater than 85% or greater than 90%) are particularly suitable for therapeutic applications.
[1184] In some embodiments, the lipid nanoparticles have an N / P ratio between 1 and 10. As used herein, the term "N / P ratio" refers to the molar ratio of positively charged molecular units in the cationic lipid in the lipid nanoparticle relative to the negatively charged molecular units in the mRNA encapsulated within the lipid nanoparticle. Therefore, the N / P ratio is generally calculated as the ratio of the molar number of amine groups in the cationic lipid in the lipid nanoparticle relative to the molar number of phosphate groups in the mRNA encapsulated within the lipid nanoparticle. In some embodiments, the lipid nanoparticles have an N / P ratio greater than 1. In some embodiments, the lipid nanoparticles have an N / P ratio of about 1. In some embodiments, the lipid nanoparticles have an N / P ratio of about 2. In some embodiments, the lipid nanoparticles have an N / P ratio of about 3. In some embodiments, the lipid nanoparticles have an N / P ratio of about 4. In some embodiments, the lipid nanoparticles have an N / P ratio of about 5. In some embodiments, the lipid nanoparticles have an N / P ratio of about 6. In some embodiments, the lipid nanoparticles have an N / P ratio of about 7. In some embodiments, the lipid nanoparticles have an N / P ratio of about 8. Typical lipid nanoparticles for use in the present invention have an N / P ratio of about 4.
[1185] In some embodiments, the compositions according to the present invention contain at least about 0.5 mg, 1 mg, 5 mg, 10 mg, 100 mg, 500 mg, or 1000 mg of encapsulated mRNA. In some embodiments, the compositions contain about 0.1 mg to 1000 mg of encapsulated mRNA. In some embodiments, the compositions contain at least about 0.5 mg of encapsulated mRNA. In some embodiments, the compositions contain at least about 0.8 mg of encapsulated mRNA. In some embodiments, the compositions contain at least about 1 mg of encapsulated mRNA. In some embodiments, the compositions contain at least about 5 mg of encapsulated mRNA. In some embodiments, the compositions contain at least about 8 mg of encapsulated mRNA. In some embodiments, the compositions contain at least about 10 mg of encapsulated mRNA. In some embodiments, the compositions contain at least about 50 mg of encapsulated mRNA. In some embodiments, the compositions contain at least about 100 mg of encapsulated mRNA. In some embodiments, the compositions contain at least about 500 mg of encapsulated mRNA. In some embodiments, the compositions contain at least about 1000 mg of encapsulated mRNA.
[1186] Pharmaceutical preparations and therapeutic uses
[1187] Compounds described herein (e.g., Formula (A'), (A), (I), (Ia), (I-a'), (Ib), (I-b'), (Ic), (I-c'), (I c-1), (I-c'-1), (Ic-2), (I-c'-2), (Id), (I-d'), (Id-1), (Id-2), (Ie), (I-e '), (Ie-1), (Ie-2), (If), (I-f'), (II), (II-a), (II-a'), (III), (III'), (III-a), (III-a'), (III-b), (III-b'), (III-c), (III-c-1), (III-c'-1), (III- Compounds of the invention (e.g., compounds I-552) can be used to prepare compositions (e.g., for constructing liposome compositions) that facilitate or enhance the delivery and release of encapsulated materials (e.g., one or more therapeutic polynucleotides) to one or more target cells (e.g., by permeating or fusing with the lipid membranes of such target cells).
[1188] For example, when a liposomal composition (e.g., lipid nanoparticle) contains or is otherwise enriched with one or more compounds disclosed herein, a phase transition in the lipid bilayer of one or more target cells can facilitate delivery of the encapsulated material (e.g., one or more therapeutic polynucleotides encapsulated in the lipid nanoparticle) to the one or more target cells.
[1189] Similarly, in certain embodiments, the compounds described herein (e.g., Formula (A'), (A), (I), (Ia), (I-a'), (Ib), (I-b'), (Ic), (I-c'), (Ic-1), (I-c'-1), (Ic-2), (I-c'-2), (Id), (I-d'), (Id-1), (Id-2), (Ie), (I-e'), (Ie-1), (Ie-2), (If), (I-f'), (II), (II-a), (II-a'), (III), (III'), (III-a), (III-a'), (III-b), (I Compounds of formula (III-1), (III-b'), (III-c), (III-c-1), (III-c'-1), (III-c-2), (III-c'-2), (III-c'), (III-d), (III-d'), (III-d-1), (III-d-2), (III-e), (III-e'), (III-e-1), (III-e-2), (III-f), (III-f'), (IV), (IV-a), or (IV-a'), such as any one of compounds 1-552) can be used to prepare liposome vehicles characterized by reduced in vivo toxicity. In certain embodiments, the reduced toxicity is a function of the high transfection efficiency associated with the compositions disclosed herein, such that reduced amounts of such compositions can be administered to a subject to achieve a desired therapeutic response or outcome.
[1190] Thus, compounds comprising the compounds (e.g., Formula (A'), (A), (I), (Ia), (I-a'), (Ib), (I-b'), (Ic), (I-c'), (Ic-1), (I-c'-1), (Ic-2), (I-c'-2), (Id), (I-d'), (Id-1), (Id-2), (Ie), (I-e'), (Ie-1), (Ie-2), (If), (I-f'), (II), (II-a), (II-a'), (III), (III'), (III-a), (III-a'), (III-b), (II Compounds of the invention comprising: (III-a), (III-b'), (III-c), (III-c-1), (III-c'-1), (III-c-2), (III-c'-2), (III-c'), (III-d), (III-d'), (III-d-1), (III-d-2), (III-e), (III-e'), (III-e-1), (III-e-2), (III-f), (III-f'), (IV), (IV-a) or (IV-a'), such as any one of compounds 1-552) and pharmaceutical preparations of the nucleic acids provided by the invention can be used for various therapeutic purposes. To facilitate in vivo delivery of nucleic acids, the compounds described herein (e.g., Formula (A'), (A), (I), (Ia), (I-a'), (Ib), (I-b'), (Ic), (I-c'), (Ic-1), (I-c'-1), (Ic-2), (I-c'-2), (Id), (I-d'), (Id-1), (Id-2), (Ie), (I-e'), (Ie-1), (Ie-2), (If), (I-f'), (II), (II-a), (II-a'), (III), (III'), (III-a), (III-a'), (III-b), ( A compound of any one of compounds 1-552) and a nucleic acid can be formulated in combination with one or more additional drug carriers, targeting ligands or stabilizers.In some embodiments, the compounds described herein (e.g., Formula (A'), (A), (I), (Ia), (I-a'), (Ib), (I-b'), (Ic), (I-c'), (Ic-1), (I-c'-1), (Ic-2), (I-c'-2), (Id), (I-d'), (Id-1), (Id-2), (Ie), (I-e'), (Ie-1), (Ie-2), (If), (I-f'), (II), (II-a), (II-a'), (III), (III'), (III-a), (III-a'), (II I-b), (III-b'), (III-c), (III-c-1), (III-c'-1), (III-c-2), (III-c'-2), (III-c'), (III-d), (III-d'), (III-d-1), (III-d-2), (III-e), (III-e'), (III-e-1), (III-e-2), (III-f), (III-f'), (IV), (IV-a) or (IV-a'), such as any of compounds 1-552) can be formulated via premixed lipid solutions. In other embodiments, the compositions comprising the compounds described herein (e.g., Formula (A'), (A), (I), (Ia), (I-a'), (Ib), (I-b'), (Ic), (I-c'), (Ic-1), (I-c'-1), (Ic-2), (I-c'-2), (Id), (I-d'), (Id-1), (Id-2), (Ie), (I-e'), (Ie-1), (Ie-2), (If), (I-f'), (II), (II-a), (II-a'), (III), (III'), (III-a), (III-a'), (III-b) , (III-b'), (III-c), (III-c-1), (III-c'-1), (III-c-2), (III-c'-2), (III-c'), (III-d), (III-d'), (III-d-1), (III-d-2), (III-e), (III-e'), (III-e-1), (III-e-2), (III-f), (III-f'), (IV), (IV-a) or (IV-a'), such as any one of compounds 1-552) can be formulated into the lipid membrane of the nanoparticle using a post-insertion technique.Techniques for formulating and administering drugs can be found in "Remington's Pharmaceutical Sciences," Mack Publishing Co., Easton, Pa., most recent edition.
[1191] Suitable routes of administration include, for example, oral, rectal, vaginal, transmucosal, pulmonary, including intratracheal or inhalation, or enteral administration; Parenteral delivery includes intradermal, transdermal (topical), intramuscular, subcutaneous, intramedullary injection; and intrathecal, directly intraventricular, intravenous, intraperitoneal or intranasal. In specific embodiments, intramuscular administration is to the muscle of the group selected from skeletal muscle, smooth muscle and cardiac muscle. In some embodiments, administration causes nucleic acid delivery to muscle cells. In some embodiments, administration causes nucleic acid delivery to hepatocytes (i.e., liver cells).
[1192] In some embodiments, the mRNA of the present invention can be delivered to the patient in the form of a lipid nanoparticle or a peptide. The selection of route of administration depends on target cells or tissues. The systemic delivery of proteins or peptides encoded by mRNA can be achieved, for example, by intravenous, intramuscular or pulmonary administration of the mRNA usually encapsulated in lipid nanoparticles (for example, liposomes). Intravenous delivery can be used for effectively targeting hepatocytes. Intramuscular administration is typically a method for selecting the mRNA (for example, as an antigen for use as a vaccine) for delivering an immunogenic protein or peptide encoding. Pulmonary delivery is generally used for targeting lung epithelium. In some embodiments, the lipid nanoparticles of load mRNA are administered by pulmonary delivery via atomization, generally related to a suitable atomizing device (for example, a mesh nebulizer).
[1193] Alternatively or in addition, the pharmaceutical formulations of the present invention can be administered in a local rather than systemic manner, for example, by injecting the pharmaceutical formulation directly into the target tissue, preferably in the form of a sustained-release formulation. Depending on the tissue to be targeted, local delivery can be affected in various ways. Exemplary tissues in which the delivered mRNA can be delivered and / or expressed include, but are not limited to, the liver, kidney, heart, spleen, serum, brain, skeletal muscle, lymph nodes, skin, and / or cerebrospinal fluid. In an embodiment, the tissue to be targeted is in the liver. For example, an aerosol containing the composition of the present invention can be inhaled (for nasal, tracheal, or bronchial delivery); for example, the composition of the present invention can be injected into the site of injury, disease manifestation, or pain; the composition can be provided in the form of a lozenge for oral, tracheal, or esophageal application; it can be supplied to the stomach or intestine in the form of a liquid, tablet, or capsule, or it can be supplied to the rectum or vagina in the form of a suppository; or it can even be delivered to the eye by using a cream, drops, or even an injection.
[1194] The compositions described herein may include mRNA encoding peptides, including those described herein (eg, polypeptides such as proteins).
[1195] In an embodiment, the mRNA encodes a polypeptide.
[1196] In an embodiment, the mRNA encodes a protein.
[1197] Exemplary peptides encoded by mRNA (eg, exemplary proteins encoded by mRNA) are described herein.
[1198] The present invention provides methods for delivering compositions having full-length mRNA molecules encoding a peptide or protein of interest for use in treating a subject, such as a human subject or cells of a human subject or cells treated and delivered to a human subject.
[1199] Therefore, in certain embodiments, the present invention provides a method for preparing a therapeutic composition comprising a full-length mRNA encoding a peptide or protein, the therapeutic composition being used to deliver to or treat a subject's lung or lung cells. In certain embodiments, the present invention provides a method for preparing a therapeutic composition with a full-length mRNA encoding a cystic fibrosis transmembrane conductance regulator (CFTR) protein. In certain embodiments, the present invention provides a method for preparing a therapeutic composition with a full-length mRNA encoding an ATP-binding cassette subfamily A member 3 protein. In certain embodiments, the present invention provides a method for preparing a therapeutic composition with a full-length mRNA encoding a dynamin axon intermediate chain 1 protein. In certain embodiments, the present invention provides a method for preparing a therapeutic composition with a full-length mRNA encoding a dynamin axon heavy chain 5 (DNAH5) protein. In certain embodiments, the present invention provides a method for preparing a therapeutic composition with a full-length mRNA encoding an alpha-1-antitrypsin protein. In certain embodiments, the present invention provides a method for preparing a therapeutic composition with a full-length mRNA encoding a forkhead box P3 (FOXP3) protein. In certain embodiments, the invention provides methods for producing therapeu...
Claims
1. A cationic lipid having the following structure: or a pharmaceutically acceptable salt thereof, wherein Each R 1 and R 2 are independently H or a C1-C6 aliphatic group; Each m is independently an integer having a value from 1 to 4; Each A is independently a covalent bond or an arylene group; Each L 1 are independently ester, thioester or disulfide groups; Each L 2 Independently for C2-C 10 aliphatic group; Each B site is -CHX 1 - or -CH2CO2-; Each X 1 are independently H or OH; and Each R 3 Independently C6-C 30 Aliphatic group.
2. cationic lipid according to claim 1, it has the following structure: or a pharmaceutically acceptable salt thereof, wherein Each R 1 and R 2 are independently H or a C1-C6 aliphatic group; Each m is independently an integer having a value from 1 to 4; Each A is independently a covalent bond or an arylene group; Each L 1 are independently ester, thioester or disulfide groups; Each L 2 Independently for C2-C 10 aliphatic group; Each X 1 are independently H or OH; and Each R 3 Independently C6-C 30 Aliphatic group.
3. The cationic lipid according to claim 1, wherein each A is independently a covalent bond or a phenylene group.
4. cationic lipid according to claim 1, it has the following structure, or a pharmaceutically acceptable salt thereof.
5. according to any one of claims 1-4 cationic lipids, wherein each R 1 For H.
6. according to any one of claims 1-4 cationic lipids, wherein each R 2 are independently H or C1-C6 alkyl.
7. according to any one of claims 1-4 cationic lipids, wherein each L 2 Independently for C2-C 10 Alkylene.
8. according to any one of claims 1-4 cationic lipids, wherein each R 3 Independently C6-C 20 Alkyl, C6-C 20 Alkenyl or C6-C 20 Alkynyl.
9. The cationic lipid according to claim 8, wherein R 3 Contains a substituent of -OC(O)R' or -C(O)-OR', wherein R' is C1-C 16 alkyl.
10. according to any one of claims 1-4 cationic lipids, wherein each X 1 For OH.
11. The cationic lipid according to any one of claims 1-4, wherein each m is 1.
12. The cationic lipid according to any one of claims 1-4, wherein each m is 2.
13. The cationic lipid according to any one of claims 1-4, wherein each m is 3.
14. The cationic lipid according to any one of claims 1-4, wherein each m is 4.
15. The cationic lipid according to claim 1, having the following structure: or a pharmaceutically acceptable salt thereof, wherein each n is independently an integer having a value of 1 to 9.
16. The cationic lipid according to claim 15, having the following structure: or a pharmaceutically acceptable salt thereof.
17. The cationic lipid of claim 15 or 16, wherein (i) each n is 1; (ii) each n is 2; or (iii) each n is 3.
18. The cationic lipid according to claim 1, having the following structure: or a pharmaceutically acceptable salt thereof, wherein each n is an integer having a value of 1 to 9.
19. The cationic lipid according to claim 18, having the following structure: or a pharmaceutically acceptable salt thereof.
20. The cationic lipid of claim 18 or 19, wherein (i) each n is 1; (ii) each n is 2; or (iii) each n is 3.
21. The cationic lipid according to claim 1, having the following structure: or a pharmaceutically acceptable salt thereof, wherein each n is an integer having a value from 1 to 9; and each R 2 are independently H or CH3.
22. according to the cationic lipid of claim 21, it has the following structure: or a pharmaceutically acceptable salt thereof.
23. according to the cationic lipid described in claim 21 or 22, wherein each R 2 For H.
24. The cationic lipid of claim 21, having the following structure: or a pharmaceutically acceptable salt thereof.
25. according to the cationic lipid of claim 24, it has the following structure: or a pharmaceutically acceptable salt thereof.
26. according to the cationic lipid described in claim 21 or 22, wherein each R 2 For CH3.
27. according to the cationic lipid of claim 21, it has the following structure: or a pharmaceutically acceptable salt thereof, optionally wherein the cationic lipid has the following structure: or a pharmaceutically acceptable salt thereof.
28. The cationic lipid of any one of claims 21, 22, 24, 25 and 27, wherein (i) each n is 1; (ii) each n is 2; or (iii) each n is 3.
29. The cationic lipid of claim 1, having the following structure: or a pharmaceutically acceptable salt thereof, wherein each n is independently an integer having a value from 1 to 9; and each X 2 are independently O or S.
30. according to the cationic lipid of claim 29, it has the following structure: or a pharmaceutically acceptable salt thereof.
31. The cationic lipid of claim 29 or 30, wherein each n is 1.
32. The cationic lipid of claim 29 or 30, wherein each n is 2.
33. The cationic lipid of claim 29 or 30, wherein each n is 3.
34. according to any one of claims 29 or 30 cationic lipids, wherein each X 2 For S.
35. according to the cationic lipid described in claim 29, it has following structure, or a pharmaceutically acceptable salt thereof.
36. according to the cationic lipid of claim 29, wherein each X 2 is O.
37. according to the cationic lipid described in claim 36, it has the following structure, or a pharmaceutically acceptable salt thereof.
38. The cationic lipid of claim 1, having the following structure: or a pharmaceutically acceptable salt thereof, wherein each n is independently an integer having a value from 2 to 10; and each X 2 are independently O or S.
39. according to the cationic lipid described in claim 38, it has the following structure: or a pharmaceutically acceptable salt thereof.
40. The cationic lipid of claim 38 or 39, wherein each n is 2.
41. according to the cationic lipid described in claim 38 or 39, wherein each n is 3.
42. The cationic lipid of claim 38 or 39, wherein each n is 4.
43. according to the cationic lipid described in claim 38 or 39, wherein each X 2 For S.
44. according to the cationic lipid described in claim 38, it has following structure, or a pharmaceutically acceptable salt thereof.
45. according to the cationic lipid described in claim 38 or 39, wherein each X 2 is O.
46. according to the cationic lipid described in claim 38, it has following structure, or a pharmaceutically acceptable salt thereof.
47. The cationic lipid of claim 1, having the structure: or a pharmaceutically acceptable salt thereof, wherein each n is independently an integer having a value from 2 to 10.
48. according to the cationic lipid described in claim 47, it has the following structure: or a pharmaceutically acceptable salt thereof.
49. according to the cationic lipid described in claim 47 or 48, wherein each n is 2.
50. The cationic lipid of claim 47 or 48, wherein each n is 3.
51. according to the cationic lipid described in claim 47 or 48, wherein each n is 4.
52. according to any one of claims 1-4, 15, 16, 18, 19, 21, 22, 24, 25, 27, 29, 30, 35, 37, 38, 39, 44, 46, 47 and 48, wherein each R 3 Independently C6-C 20 Aliphatic group.
53. according to the cationic lipid of claim 1, it has the following structure: or a pharmaceutically acceptable salt thereof, wherein Each R 1 are independently H or a C1-C6 aliphatic group; Each L 1 are independently ester, thioester or disulfide groups; Each L 2 Independently for C2-C 10 aliphatic group; Each X 1 are independently H or OH; and Each R 3 Independently C6-C 30 Aliphatic group.
54. according to the cationic lipid described in claim 53, wherein each R 1 are independently H or C1-C6 alkyl.
55. according to the cationic lipid described in claim 53 or 54, wherein each R 1 For H.
56. according to the cationic lipid described in claim 53 or 54, wherein each X 1 For OH.
57. according to the cationic lipid described in claim 53, it has the following structure: or a pharmaceutically acceptable salt thereof, wherein each n is an integer having a value of 1 to 9.
58. according to the cationic lipid described in claim 57, it has the following structure: or a pharmaceutically acceptable salt thereof.
59. according to the cationic lipid described in claim 57 or 58, wherein each n is 2.
60. according to the cationic lipid described in claim 53,54,57 or 58, wherein each R 3 Independently for C8-C 20 Aliphatic group.
61. according to the cationic lipid of claim 1, it has the following structure: or a pharmaceutically acceptable salt thereof, wherein Each R 1 and R 2 are independently H or a C1-C6 aliphatic group; Each m is independently an integer having a value from 1 to 4; Each A is independently a covalent bond or an arylene group; Each L 1 are independently ester, thioester or disulfide groups; Each L 2 Independently for C2-C 10 aliphatic group; Each R 3 Independently C6-C 30 Aliphatic group.
62. The cationic lipid of claim 61, wherein each A is independently a covalent bond or a phenylene group.
63. according to the cationic lipid described in claim 61, it has following structure, or a pharmaceutically acceptable salt thereof.
64. according to the cationic lipid described in any one of claim 61-63, wherein each R 1 For H.
65. according to the cationic lipid described in any one of claim 61-63, wherein each R 2 are independently H or C1-C6 alkyl.
66. according to the cationic lipid described in any one of claim 61-63, wherein each L 2 Independently for C2-C 10 Alkylene.
67. according to the cationic lipid described in any one of claim 61-63, wherein each R 3 Independently C6-C 20 Alkyl, C6-C 20 Alkenyl or C6-C 20 Alkynyl.
68. according to the cationic lipid described in claim 67, wherein said R 3 Contains a substituent of -OC(O)R' or -C(O)-OR', wherein R' is C1-C 16 alkyl.
69. The cationic lipid of any one of claims 61-63, wherein each m is 1.
70. A cationic lipid according to any one of claims 61-63, wherein each m is 2.
71. according to the cationic lipid described in any one of claim 61-63, wherein each m is 3.
72. according to the cationic lipid described in any one of claim 61-63, wherein each m is 4.
73. according to the cationic lipid described in claim 61, it has the following structure: or a pharmaceutically acceptable salt thereof, wherein each n is independently an integer having a value of 1 to 9.
74. according to the cationic lipid described in claim 73, it has the following structure: or a pharmaceutically acceptable salt thereof.
75. The cationic lipid of claim 73 or 74, wherein (i) each n is 1; (ii) each n is 2; or (iii) each n is 3.
76. according to the cationic lipid described in claim 61, it has the following structure: or a pharmaceutically acceptable salt thereof, wherein each n is an integer having a value of 1 to 9.
77. according to the cationic lipid described in claim 76, it has the following structure: or a pharmaceutically acceptable salt thereof.
78. The cationic lipid of claim 76 or 77, wherein (i) each n is 1; (ii) each n is 2; or (iii) each n is 3.
79. according to the cationic lipid described in claim 61, it has the following structure: or a pharmaceutically acceptable salt thereof, wherein each n is an integer having a value from 1 to 9; and each R 2 are independently H or CH3.
80. according to the cationic lipid described in claim 79, it has the following structure: or a pharmaceutically acceptable salt thereof.
81. according to the cationic lipid described in claim 79 or 80, wherein each R 2 For H.
82. according to the cationic lipid described in claim 79, it has the following structure: or a pharmaceutically acceptable salt thereof.
83. according to the cationic lipid described in claim 82, it has the following structure: or a pharmaceutically acceptable salt thereof.
84. according to the cationic lipid described in claim 79 or 80, wherein each R 2 For CH3.
85. according to the cationic lipid described in claim 79, it has the following structure: or a pharmaceutically acceptable salt thereof.
86. according to the cationic lipid described in claim 85, it has the following structure: or a pharmaceutically acceptable salt thereof.
87. A cationic lipid according to any one of claims 79, 80, 82, 83 and 85, wherein (i) each n is 1; (ii) each n is 2; or (iii) each n is 3.
88. according to the cationic lipid described in claim 61, it has the following structure: or a pharmaceutically acceptable salt thereof, wherein each n is independently an integer having a value from 1 to 9; and each X 2 are independently O or S.
89. according to the cationic lipid described in claim 88, it has the following structure: or a pharmaceutically acceptable salt thereof.
90. according to the cationic lipid described in claim 88 or 89, wherein each n is 1.
91. according to the cationic lipid described in claim 88 or 89, wherein each n is 2.
92. according to the cationic lipid described in claim 88 or 89, wherein each n is 3.
93. according to the cationic lipid described in claim 88 or 89, wherein each X 2 For S.
94. according to the cationic lipid described in claim 88, it has following structure, or a pharmaceutically acceptable salt thereof.
95. according to the cationic lipid described in claim 88 or 89, wherein each X 2 is O.
96. according to the cationic lipid described in claim 88, it has following structure, or a pharmaceutically acceptable salt thereof.
97. according to the cationic lipid described in claim 61, it has the following structure: or a pharmaceutically acceptable salt thereof, wherein each n is independently an integer having a value from 2 to 10; and each X 2 are independently O or S.
98. according to the cationic lipid described in claim 97, it has the following structure: or a pharmaceutically acceptable salt thereof.
99. according to the cationic lipid described in claim 97 or 98, wherein each n is 2.
100. The cationic lipid of claim 97 or 98, wherein each n is 3.
101. according to the cationic lipid described in claim 97 or 98, wherein each n is 4.
102. according to the cationic lipid described in claim 97 or 98, wherein each X 2 For S.
103. according to the cationic lipid described in claim 97, it has following structure, or a pharmaceutically acceptable salt thereof.
104. according to the cationic lipid described in claim 97 or 98, wherein each X 2 is O.
105. according to the cationic lipid described in claim 97, it has following structure, or a pharmaceutically acceptable salt thereof.
106. according to the cationic lipid described in claim 61, it has the following structure: or a pharmaceutically acceptable salt thereof, wherein each n is independently an integer having a value from 2 to 10.
107. according to the cationic lipid described in claim 106, it has the following structure: or a pharmaceutically acceptable salt thereof.
108. according to the cationic lipid described in claim 106 or 107, wherein each n is 2.
109. according to the cationic lipid described in claim 106 or 107, wherein each n is 3.
110. The cationic lipid of claim 106 or 107, wherein each n is 4.
111. according to any one of claims 61-63, 73, 74, 76, 77, 79, 80, 82, 83, 85, 86, 88, 89, 94, 96-98, 103 and 105-107, wherein each R 3 Independently selected from C6-C 20 Aliphatic group.
112. according to the cationic lipid described in claim 61, it has the following structure: or a pharmaceutically acceptable salt thereof, wherein Each R 1 are independently H or a C1-C6 aliphatic group; Each L 1 are independently ester, thioester or disulfide groups; Each L 2 Independently for C2-C 10 aliphatic group; Each R 3 Independently C6-C 30 Aliphatic group.
113. according to the cationic lipid described in claim 112, wherein each R 1 are independently H or C1-C6 alkyl.
114. according to the cationic lipid described in claim 112 or 113, wherein each R 1 For H.
115. according to the cationic lipid described in claim 112, it has the following structure: or a pharmaceutically acceptable salt thereof, wherein each n is an integer having a value of 1 to 9.
116. according to the cationic lipid described in claim 115, it has the following structure: or a pharmaceutically acceptable salt thereof.
117. The cationic lipid of claim 115 or 116, wherein (i) each n is 1; (ii) each n is 2; or (iii) each n is 3.
118. according to the cationic lipid described in any one of claim 112,115 and 116, wherein each R 3 Independently selected from C8-C 20 Aliphatic group.
119. according to any one of claims 1-4, 15, 16, 18, 19, 21, 22, 24, 25, 27, 29, 30, 35, 36, 37, 38, 39, 44, 46-48, 53, 54, 57, 58, 61-63, 73, 74, 76, 77, 79, 80, 82, 83, 85, 86, 88, 89, 94, 96-98, 103, 105-107, 112, 113, 115 and 116, wherein each R 3 For unsubstituted C6-C 20 alkyl.
120. according to the cationic lipid described in claim 119, wherein each R 3 C6H 13 、C8H 17 , C 10 H 21 , C 12 H 25 , C 14 H 29 , C 16 H 33 or C 18 H 37 .
121. according to the cationic lipid described in claim 119, wherein each R 3 C 10 H 21 .
122. according to claim 1-4,15,16,18,19,21,22,24,25,27,29,30,35,36,37,38,39,44,46-48,53,54,57,58,61-63,73,74,76,77,79,80,82,83,85,86,88,89,94,96-98,103,105-107,112,113,115 and 116 any one of the cationic lipids, wherein each R 3 To replace C6-C 20 alkyl.
123. according to the cationic lipid described in claim 122, wherein R 3 Contains a substituent of -OC(O)R' or -C(O)-OR', wherein R' is C1-C 16 alkyl.
124. according to the cationic lipid described in claim 123, wherein R 3 For -OC(O)C7H 15 or -C(O)-O-(CH2)2CH(C5H 11 )2 substituted C6-C 10 alkyl.
125. according to the cationic lipid described in claim 123, wherein each R 3 -(CH2)9-OC(O)C7H 15 or -(CH2)8C(O)-O-(CH2)2CH(C5H 11 )2.
126. according to claim 1-4,15,16,18,19,21,22,24,25,27,29,30,35,36,37,38,39,44,46-48,53,54,57,58,61-63,73,74,76,77,79,80,82,83,85,86,88,89,94,96-98,103,105-107,112,113,115 and 116 any one of the cationic lipids, wherein each R 3 For unsubstituted C6-C 20 Alkenyl.
127. according to the cationic lipid described in claim 126, wherein each R 3 is an unsubstituted monoalkenyl, an unsubstituted dienyl or an unsubstituted trienyl.
128. according to the cationic lipid described in claim 126, wherein each R 3 -(CH2) o R', wherein o is 6, 7, 8, 9 or 10, and R' is 129. according to the cationic lipid described in claim 126, wherein each R 3 C 16 H 31 or C 16 H 29 .
130. according to any one of claims 1-4, 15, 16, 18, 19, 21, 22, 24, 25, 27, 29, 30, 35, 36, 37, 38, 39, 44, 46-48, 53, 54, 57, 58, 61-63, 73, 74, 76, 77, 79, 80, 82, 83, 85, 86, 88, 89, 94, 96-98, 103, 105-107, 112, 113, 115 and 116, wherein each R 3 For unsubstituted C6-C 20 Alkynyl.
131. A cationic lipid, which is any one of compounds 1-552: or a pharmaceutically acceptable salt thereof.
132. according to the cationic lipid described in claim 131, it has the following structure: or a pharmaceutically acceptable salt thereof.
133. A composition comprising mRNA encoding a protein encapsulated in a liposome, wherein the liposome comprises a cationic lipid according to any one of claims 1-132.
134. The composition of claim 133, comprising mRNA encoding the cystic fibrosis transmembrane conductance regulator (CFTR) protein.
135. The composition of claim 133, comprising mRNA encoding ornithine transcarbamylase (OTC) protein.
136. A composition comprising a nucleic acid encapsulated within a liposome, wherein the liposome comprises a cationic lipid according to any one of claims 1-132.
137. The composition of claim 136, wherein the nucleic acid is an mRNA encoding a peptide or protein.
138. The composition of claim 137, wherein the mRNA encodes a peptide or protein for delivery to or treatment of the lungs or lung cells of a subject.
139. The composition of claim 138, wherein the mRNA encodes the cystic fibrosis transmembrane conductance regulator (CFTR) protein.
140. The composition of claim 137, wherein the mRNA encodes a peptide or protein for delivery to or treatment of the liver or hepatocytes of a subject.
141. The composition of claim 140, wherein the mRNA encodes ornithine transcarbamylase (OTC) protein.
142. The composition of claim 137, wherein the mRNA encodes a peptide or protein for a vaccine.
143. The composition of claim 142, wherein the mRNA encodes an antigen.
144. A composition according to any one of claims 133-143, comprising one or more cationic lipids, one or more PEG-modified lipids and / or one or more helper lipids.
145. The composition of claim 144, wherein the one or more helper lipids is 1,2-dierucoyl-sn-glycero-3-phosphoethanolamine (DEPE).
146. The composition of claim 145, wherein the one or more helper lipids is dioleoylphosphatidylethanolamine (DOPE).
147. Use of a composition as described in any one of claims 133-146 in the preparation of a medicament for treating a disease in a subject in need thereof.
Citation Information
Patent Citations
Delivery of mRNA for the augmentation of proteins and enzymes in human genetic diseases
US20110244026A1
RIBONUCLEIC ACIDs WITH 4'-THIO-MODIFIED NUCLEOTIDES AND RELATED METHODS
US20160031928A1
Encapsulation of messenger RNA
US20160038432A1
Ice-based lipid nanoparticle formulation for delivery of mRNA
US20180125989A1
Process of Preparing mRNA-Loaded Lipid Nanoparticles
US20180153822A1
